<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC2802127/results/search/country/results.xml">
   <result pre="encephalitis is the most common form of fatal encephalitis in" exact="the US." post="Reports of prevalance of HSV encephalitis2,3 suggest that it"/>
   <result pre="it occurs from 1–2 per 100,000 persons per year in" exact="the US." post="A detailed survey by the Centers of Disease Control4"/>
   <result pre="and diagnostic considerationsClin Infect Dis1995204144207742450 4KhetsurianiNHolmanRCAndersonLJBurden of encephalitis-associated hospitalizations in" exact="the United States," post="1988–1997Clin Infect Dis20023517518212087524 5LipsitchMDavisGCoreyLPotential benefits of a serodiagnostic test"/>
   <result pre="diagnostic considerationsClin Infect Dis1995204144207742450 4KhetsurianiNHolmanRCAndersonLJBurden of encephalitis-associated hospitalizations in the" exact="United States," post="1988–1997Clin Infect Dis20023517518212087524 5LipsitchMDavisGCoreyLPotential benefits of a serodiagnostic test"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC2857246/results/search/country/results.xml">
   <result pre="emergence of influenza A pandemic (H1N1) 2009 virus in North" exact="America" post="and associated illness and death suggest that humanity faces"/>
   <result pre="been observed in recent cases in Europe, Asia, and North" exact="America" post="(1). More recently, pandemic (H1N1) 2009 virus resistance to"/>
   <result pre="to oseltamivir emerged during treatment of 2 immunosuppressed patients in" exact="the United States." post="Such cases demonstrate that oseltamivir resistance can emerge in"/>
   <result pre="oseltamivir emerged during treatment of 2 immunosuppressed patients in the" exact="United States." post="Such cases demonstrate that oseltamivir resistance can emerge in"/>
   <result pre="oseltamivir-resistant human influenza viruses (H1N1) emerged and became prevalent in" exact="the United States" post="and Europe in the 2007–08 influenza season, and prevalence"/>
   <result pre="human influenza viruses (H1N1) emerged and became prevalent in the" exact="United States" post="and Europe in the 2007–08 influenza season, and prevalence"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC2972676/results/search/country/results.xml">
   <result pre="are available in only a few locations in the U.S.:" exact="the United States" post="Army Medical Research Institute for Infectious Diseases (USAMRIID), University"/>
   <result pre="available in only a few locations in the U.S.: the" exact="United States" post="Army Medical Research Institute for Infectious Diseases (USAMRIID), University"/>
   <result pre="least. Since most of these pathogens are not endemic in" exact="the United States" post="and may be rare even in endemic areas, it"/>
   <result pre="Since most of these pathogens are not endemic in the" exact="United States" post="and may be rare even in endemic areas, it"/>
   <result pre="smallpox, there are numerous surrogate animal models being studied across" exact="the United States," post="and elsewhere, and we have availed ourselves of as"/>
   <result pre="there are numerous surrogate animal models being studied across the" exact="United States," post="and elsewhere, and we have availed ourselves of as"/>
   <result pre="viral disease can impact mankind. HIV was first reported in" exact="the United States" post="in 1981, and now there are almost a million"/>
   <result pre="disease can impact mankind. HIV was first reported in the" exact="United States" post="in 1981, and now there are almost a million"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3058091/results/search/country/results.xml">
   <result pre="Noyce (Accession no. AF083069) strain, which was originally identified in" exact="the USA" post="in 1954, and the nucleotide sequence of which was"/>
   <result pre="an intramural research fund from the National Institute of Health," exact="South Korea." post="References HuttunenPSanttiJPulliTHyypiäTThe major echovirus group is genetically coherent and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3136400/results/search/country/results.xml">
   <result pre="million individuals (6% of the population) have been spotted in" exact="Pakistan" post="[2]. HCV was firstly recognized in 1989 [3], comprising"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3184032/results/search/country/results.xml">
   <result pre="further prolonged in immunocompromised patients.8 Acyclovir is also approved by" exact="the US" post="Food and Drug Administration (FDA) for the treatment of"/>
   <result pre="However, concerns about its toxicity halted its clinical development in" exact="the United States." post="Its metabolite, bromovinyluracil, irreversibly inhibits dihydropyridine dehydrogenase, which regulates"/>
   <result pre="concerns about its toxicity halted its clinical development in the" exact="United States." post="Its metabolite, bromovinyluracil, irreversibly inhibits dihydropyridine dehydrogenase, which regulates"/>
   <result pre="CMV donor-positive/recipient-negative recipients of kidney, heart, or kidney-pancreas transplants.61,84 In" exact="the United States," post="valganciclovir is not approved for preventing CMV disease in"/>
   <result pre="donor-positive/recipient-negative recipients of kidney, heart, or kidney-pancreas transplants.61,84 In the" exact="United States," post="valganciclovir is not approved for preventing CMV disease in"/>
   <result pre="Nature. 2005;437:110816228009 104.DharanNJGubarevaLVMeyerJJet al.Infections with oseltamivir-resistant influenza A(H1N1) virus in" exact="the United States." post="JAMA. 2009;301:1034-104119255110 105.HatakeyamaSSugayaNItoMet al.Emergence of influenza B viruses with"/>
   <result pre="2005;437:110816228009 104.DharanNJGubarevaLVMeyerJJet al.Infections with oseltamivir-resistant influenza A(H1N1) virus in the" exact="United States." post="JAMA. 2009;301:1034-104119255110 105.HatakeyamaSSugayaNItoMet al.Emergence of influenza B viruses with"/>
   <result pre="176.DienstagJLSchiffERWrightTLet al.Lamivudine as initial treatment for chronic hepatitis B in" exact="the United States." post="N Engl J Med. 1999;341:1256-126310528035 177.LaiCLChienRNLeungNWet al.; collab: Asia"/>
   <result pre="al.Lamivudine as initial treatment for chronic hepatitis B in the" exact="United States." post="N Engl J Med. 1999;341:1256-126310528035 177.LaiCLChienRNLeungNWet al.; collab: Asia"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3185584/results/search/country/results.xml">
   <result pre="most prevalent in the Western World (Western Europe, the Americas," exact="Japan" post="and Australia), whilst non-B subtypes predominate in the rest"/>
   <result pre="addition, the proportion of non-B subtypes in North and South" exact="America" post="and Western Europe is increasing [4–7]. Combination antiretroviral therapy"/>
   <result pre="also not observed in patients with subtype C in India," exact="South Africa," post="or Malawi [24–27]. Another study from Botswana reported a"/>
   <result pre="in patients with subtype C in India, South Africa, or" exact="Malawi" post="[24–27]. Another study from Botswana reported a high incidence"/>
   <result pre="in India, South Africa, or Malawi [24–27]. Another study from" exact="Botswana" post="reported a high incidence of K65R (30%) in subtype"/>
   <result pre="or EFV [28]. In a much larger study, results from" exact="Malawi" post="detected K65R or K70E in 23% of patients failing"/>
   <result pre="K65R was detected in 7% and 15% of patients in" exact="South Africa" post="failing first or second line regimens, respectively, whose nucleoside"/>
   <result pre="included d4T/3TC or ddI/ZDV [29–30]. In addition, a study from" exact="Israel" post="reported a high frequency of K65R in subtype C"/>
   <result pre="viruses from Ethiopian immigrants [31]. Finally, a recent report from" exact="India" post="has shown that K65R was present in about 10–12%"/>
   <result pre="disease stage [24–27]. Access to viral load testing lead in" exact="India" post="was associated with early detection of NNRTI-treatment failure, preventing"/>
   <result pre="studies support regional differences among subtype C sub-epidemics from Ethiopia," exact="Brazil" post="and sub Saharan Africa, that impact on the RT"/>
   <result pre="CRF_06 (AGK recombinants) as compared to patients carrying CRF02_AG from" exact="Burkina Faso" post="[44]. In conclusion, the differential selection of K65R pathways"/>
   <result pre="frequent among subtype C infected patients failing NNRTI-based therapy in" exact="Israel" post="and India. In the Israeli but not the Indian"/>
   <result pre="was seen in subtype C isolates from Ethiopian immigrants to" exact="Israel" post="after NFV usage versus a higher frequency in subtype"/>
   <result pre="usage versus a higher frequency in subtype C viruses from" exact="Botswana" post="[55–56], suggesting that subtype C viruses from Ethiopia (the"/>
   <result pre="viruses from Botswana [55–56], suggesting that subtype C viruses from" exact="Ethiopia" post="(the origin of the samples identified in Israel) and"/>
   <result pre="rare in subtype F but common in subtype B from" exact="Brazil" post="[58]. A recent paper suggests that polymorphisms at position"/>
   <result pre="B compared to C [64]. An observational study from southern" exact="Brazil" post="also showed a lower relative frequency of primary resistance"/>
   <result pre="underestimated. The TAM pathway 67N/70R/215Y found in subtype C in" exact="Botswana" post="will probably be adequately detected by most resistance algorithms,"/>
   <result pre="as 40% of patients after two years [73] and in" exact="India" post="where resistance rates of 80% to two drug classes"/>
   <result pre="in approximately 70% of patients failing ddI-containing nucleoside backbones in" exact="Botswana" post="[28]. However, K65R does not appear to emerge frequently"/>
   <result pre="virus type 1 subtype C isolates from infected patients in" exact="Botswana" post="treated with didanosine-based regimensAntimicrob Agents Chemother2006504182418517015626 29.OrrellCWalenskyRPLosinaEPittJFreedbergKAWoodRHIV type-1 clade"/>
   <result pre="1 subtype C on drug resistance mutations in patients from" exact="Botswana" post="failing a nelfinavir-containing regimenAntimicrob Agents Chemother2006502210221316723586 57.DumansATSoaresMAMachadoESHueSBrindeiroRMPillayDTanuriASynonymous genetic polymorphisms"/>
   <result pre="antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in" exact="Mali" post="and Burkina FasoAntivir Ther20081314114818389909 70.KinomotoMAppiah-OpongRBrandfulJAYokoyamaMNii-TrebiNUgly-KwameESatoHOfori-AdjeiDKurataTBarre-SinoussiFet al.HIV-1 proteases from drug-naive"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3207218/results/search/country/results.xml">
   <result pre="they not be used during the 2010/2011 influenza season in" exact="the USA." post="The drugs that are recommended for clinical use are"/>
   <result pre="to replication. Proceedings of the National Academy of Sciences of" exact="the United States" post="of America2010; 107: 11525–11530.20534471 12O'NeillRE, TalonJ, PaleseP. The influenza"/>
   <result pre="replication. Proceedings of the National Academy of Sciences of the" exact="United States" post="of America2010; 107: 11525–11530.20534471 12O'NeillRE, TalonJ, PaleseP. The influenza"/>
   <result pre="2009 influenza a (H1N1) under an emergency IND program in" exact="the United States." post="Clinical Infectious Diseases2011; 52: 695–706.21367722 29IvesJA, CarrJA, MendelDBet alThe"/>
   <result pre="influenza a (H1N1) under an emergency IND program in the" exact="United States." post="Clinical Infectious Diseases2011; 52: 695–706.21367722 29IvesJA, CarrJA, MendelDBet alThe"/>
   <result pre="GubarevaL, KamimotoLet alCharacteristics of patients with oseltamivir‐resistant pandemic (H1N1) 2009," exact="United States." post="Emerging Infectious Diseases2011; 17: 255–257.21291599 33SeibertCW, KaminskiM, PhilippJet alOseltamivir‐resistant"/>
   <result pre="pore complex. Proceedings of the National Academy of Sciences of" exact="the United States" post="of America2007; 104: 1853–1858.17267598"/>
   <result pre="complex. Proceedings of the National Academy of Sciences of the" exact="United States" post="of America2007; 104: 1853–1858.17267598"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3262966/results/search/country/results.xml">
   <result pre="to poultry and other livestock in China, Southeast Asia and" exact="Russia" post="[7, 18, 19]. To prevent excessive use of antiviral"/>
   <result pre="use of antiviral drugs in food production are established. Within" exact="the USA," post="the FDA prohibited extra-label use of antiviral drugs [20]."/>
   <result pre="of amantadine-resistant variants among avian influenza viruses isolated in North" exact="America" post="and AsiaVirology200534110210616081121 14.WeinstockDMZuccottiGAdamantane resistance in influenza AJ Am Med"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3291404/results/search/country/results.xml">
   <result pre="A0 H1N1 1947 A prime H1N1 1957 Asian H2N2 1968" exact="Hong Kong" post="H3N2 1976 Swine H1N1† 1977 Russian H1N1 *Unknown N"/>
   <result pre="pathogenic avian strains, including A (H7N7), which infected humans in" exact="the Netherlands," post="and A (H7N3), which spread extensively in western Canada,"/>
   <result pre="A (H5N1) virus. The virus has evolved since the 1997" exact="Hong Kong" post="outbreak, and some evidence of a systemic infection involving"/>
   <result pre="to evaluate dosage and duration of therapy, particularly against the" exact="Vietnam" post="strain of the A (H5N1) virus. These studies would"/>
   <result pre="given for 5 days as it was against the 1997" exact="Hong Kong" post="variant of A (H5N1) influenza (36). This finding indicates"/>
   <result pre="the neuraminidase inhibitors in therapy of influenza, and working with" exact="the United States" post="and international organizations on pandemic preparedness. References References 1."/>
   <result pre="neuraminidase inhibitors in therapy of influenza, and working with the" exact="United States" post="and international organizations on pandemic preparedness. References References 1."/>
   <result pre="et al.Correlation of laboratory studies with clinical responses to A/New" exact="Jersey" post="influenza vaccines.J Infect Dis. 1977;136(Suppl):S397–40610.1093/infdis/136.Supplement_3.S397606763 4. BoyerKM, CherryJD, WrightPF,"/>
   <result pre="virus.J Exp Med. 1953;98:641–5610.1084/jem.98.6.64113109114 6. MasurelN, MarineWMRecycling of Asian and" exact="Hong Kong" post="influenza A virus hemagglutinins in man.Am J Epidemiol. 1973;97:44–94684066"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3322031/results/search/country/results.xml">
   <result pre="A virus H3N2 subtype zanamivir amantadine antiviral drug resistance viruses" exact="Myanmar" post="expedited dispatch Adamantanes and neuraminidase inhibitors (NAIs) are the"/>
   <result pre="253 and 802 rapid test kit–positive samples were collected in" exact="Myanmar" post="in 2007 and 2008, respectively. Of these, 64 isolates"/>
   <result pre="neuraminidase (B) genes of influenza virus A (H3N2) isolates in" exact="Myanmar" post="in 2007 and 2008. Trees were generated by using"/>
   <result pre="Q136K viruses were isolated at a low frequency (&amp;lt;1.5%) in" exact="Myanmar" post="in 2007 and 2008. Phylogenetic analysis showed that these"/>
   <result pre="been the predominant circulating strains among subtype H3N2 viruses in" exact="Myanmar" post="since 2005 (8). The Q136K substitution in NA was"/>
   <result pre="and 1 sequence from swine influenza, which was isolated in" exact="Japan" post="in 1997, contained the Q136K substitution. Sequences from Q136K"/>
   <result pre="introduction of zanamivir into clinical practice in 1999 in Australia," exact="New Zealand," post="United States, and Europe (9,13). In addition, Myanmar patients"/>
   <result pre="zanamivir into clinical practice in 1999 in Australia, New Zealand," exact="United States," post="and Europe (9,13). In addition, Myanmar patients who shed"/>
   <result pre="Australia, New Zealand, United States, and Europe (9,13). In addition," exact="Myanmar" post="patients who shed these Q136K viruses did not receive"/>
   <result pre="TomasovC, DeedN, KomadinaNIncreased adamantane resistance in influenza A(H3) viruses in" exact="Australia" post="and neighbouring countries in 2005.Antiviral Res. 2007;73:112–710.1016/j.antiviral.2006.08.00216963130 2. SaitoR,"/>
   <result pre="et al.Epidemiology of human influenza A and B viruses in" exact="Myanmar" post="from 2005 to 2007.Intervirology. 2009;52:310–2010.1159/00023773819776616 9. HurtAC, BarrI, HartelG,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3323435/results/search/country/results.xml">
   <result pre="Public health systems research Influenza Background On April 26, 2009," exact="the United States" post="Government declared a public health emergency in response to"/>
   <result pre="health systems research Influenza Background On April 26, 2009, the" exact="United States" post="Government declared a public health emergency in response to"/>
   <result pre="for Infectious Diseases and Emergency Readiness under cooperative agreements with" exact="the US" post="Centers for Disease Control and Prevention (CDC) grant number"/>
   <result pre="and administrative regionshttp://www.oes.ca.gov/WebPage/oeswebsite.nsf/PDF/Cal%20E.M.A.%20Mutual%20Aid%20Regions/$file/emaMutaid.pdf JainSKamimotoLBramleyAMSchmitzAMBenoitSRLouieJSugermanDEDruckenmillerJKRitgerKAChughRJasujaSDeutscherMChenSWalkerJDDuchinJSLettSSolivaSWellsEVSwerdlowDUyekiTMFioreAEOlsenSJFryAMBridgesCBFinelliLHospitalized patients with 2009 H1N1 influenza in" exact="the United States," post="April-June 2009N Engl J Med20093611935194410.1056/NEJMoa090669519815859 AtkinsCYPatelATaylorTHJrBiggerstaffMMerlinTLDulinSMEricksonBABorseRHHunklerRMeltzerMIEstimating effect of antiviral"/>
   <result pre="administrative regionshttp://www.oes.ca.gov/WebPage/oeswebsite.nsf/PDF/Cal%20E.M.A.%20Mutual%20Aid%20Regions/$file/emaMutaid.pdf JainSKamimotoLBramleyAMSchmitzAMBenoitSRLouieJSugermanDEDruckenmillerJKRitgerKAChughRJasujaSDeutscherMChenSWalkerJDDuchinJSLettSSolivaSWellsEVSwerdlowDUyekiTMFioreAEOlsenSJFryAMBridgesCBFinelliLHospitalized patients with 2009 H1N1 influenza in the" exact="United States," post="April-June 2009N Engl J Med20093611935194410.1056/NEJMoa090669519815859 AtkinsCYPatelATaylorTHJrBiggerstaffMMerlinTLDulinSMEricksonBABorseRHHunklerRMeltzerMIEstimating effect of antiviral"/>
   <result pre="adults hospitalized with influenza before and during the 2009 pandemic:" exact="United States," post="2005-2009J Infect Dis2011204121848185610.1093/infdis/jir64822013219 collab: National Association of County and"/>
   <result pre="A national studyJ Homeland Security Emergen Manage20096144 ListerSAAn Overview of" exact="the US" post="Public Health System in the Context of Emergency Preparedness2005Washington"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3358196/results/search/country/results.xml">
   <result pre="and prophylaxis of household contacts provides effective protection. Abstract The" exact="United Kingdom" post="implemented a containment strategy for pandemic (H1N1) 2009 through"/>
   <result pre="pandemic prophylaxis pandemic (H1N1) 2009 H1N1 household contacts antimicrobial drugs" exact="United Kingdom" post="research Following emergence of pandemic influenza A (H1N1) 2009"/>
   <result pre="Following emergence of pandemic influenza A (H1N1) 2009 in North" exact="America" post="in spring 2009 (1,2), global spread of the virus"/>
   <result pre="global spread of the virus was rapid (3,4). In the" exact="United Kingdom," post="the first confirmed cases were detected in travelers returning"/>
   <result pre="the first confirmed cases were detected in travelers returning from" exact="Mexico" post="(5). The United Kingdom implemented a containment strategy until"/>
   <result pre="cases were detected in travelers returning from Mexico (5). The" exact="United Kingdom" post="implemented a containment strategy until July 2009 that involved"/>
   <result pre="case-patients and their close contacts (13) was undertaken across the" exact="United Kingdom" post="beginning in April 2009 to gain an early understanding"/>
   <result pre="Initially, all patients with virologically confirmed cases detected in the" exact="United Kingdom" post="were included in the FF100 dataset, and their households"/>
   <result pre="trivalent influenza vaccines from various manufacturers are used in the" exact="United Kingdom" post="with composition determined by World Health Organization recommendations. Case-patients"/>
   <result pre="contacts from whom swab specimens were collected, and PCR result," exact="United Kingdom," post="2009. *Symptom onset date &amp;lt;2 weeks after index case-patient"/>
   <result pre="Household size of case-patients with pandemic (H1N1) 2009 virus infection," exact="United Kingdom," post="2009 No. persons in household No. households No. primary"/>
   <result pre="infection and household contacts, by sex, age, and prophylaxis status," exact="United Kingdom," post="2009* Variable No. (%) primary and co-primary case-patients No."/>
   <result pre="plus timing of secondary cases after onset of primary case," exact="United Kingdom," post="2009* Timing No. contacts No. secondary case-patients at 14"/>
   <result pre="2009 virus infection until antiviral prophylaxis started, N = 352," exact="United Kingdom," post="2009. Household Secondary Attack Rates Household contacts in whom"/>
   <result pre="(H1N1) 2009 virus infection, by gender, age group, and prophylaxis," exact="United Kingdom," post="2009* Variable No. contacts† No. secondary case-patients Univariate analysis Multivariate"/>
   <result pre="SAR, by age of patient with virologically confirmed primary case," exact="United Kingdom," post="2009* Transmission† No. contacts No. secondary case-patients SAR, % (95% CI)"/>
   <result pre="cases of influenza-like illness, by gender, age group, and prophylaxis," exact="United Kingdom," post="2009* Variable No. contacts† No. secondary case-patients Univariate analysis Multivariate"/>
   <result pre="for acute respiratory infection, by gender, age group and prophylaxis," exact="United Kingdom," post="2009* Variable No. contacts† No. secondary case-patients Univariate analysis Multivariate"/>
   <result pre="in index case-patient until onset of symptoms in secondary case-patients," exact="United Kingdom," post="2009. A) Virologically confirmed pandemic (H1N1) 2009; B) clinical"/>
   <result pre="acute respiratory infection endpoints, by gender, age group, and prophylaxis," exact="United Kingdom," post="2009* Variable Hazard ratio (95% confidence interval) Virologic Influenza-like"/>
   <result pre="not receive AVs compare to results of a study in" exact="Kenya" post="which reported a confirmed household SAR of 26% (10)"/>
   <result pre="population without widespread use of AV prophylaxis. Another study in" exact="Japan" post="(7), where &amp;gt;90% of contacts had received AV prophylaxis,"/>
   <result pre="5%. Other studies have used clinical endpoints, such as in" exact="the United States" post="(8), where a clinical SAR of 10% was reported"/>
   <result pre="Other studies have used clinical endpoints, such as in the" exact="United States" post="(8), where a clinical SAR of 10% was reported"/>
   <result pre="that AVs are effective for all endpoints. Other studies in" exact="Japan" post="(7), the United States (9,12), Hong Kong, China (23),"/>
   <result pre="are effective for all endpoints. Other studies in Japan (7)," exact="the United States" post="(9,12), Hong Kong, China (23), and Germany (24) have"/>
   <result pre="effective for all endpoints. Other studies in Japan (7), the" exact="United States" post="(9,12), Hong Kong, China (23), and Germany (24) have"/>
   <result pre="endpoints. Other studies in Japan (7), the United States (9,12)," exact="Hong Kong," post="China (23), and Germany (24) have attempted to determine"/>
   <result pre="studies in Japan (7), the United States (9,12), Hong Kong," exact="China" post="(23), and Germany (24) have attempted to determine the"/>
   <result pre="(7), the United States (9,12), Hong Kong, China (23), and" exact="Germany" post="(24) have attempted to determine the effectiveness of postexposure"/>
   <result pre="transmission of pandemic influenza in the household setting in the" exact="United Kingdom" post="during the containment phase. Household SARs were generally higher"/>
   <result pre="antiviral drugs to reduce household transmission of pandemic (H1N1) 2009," exact="United Kingdom." post="Emerg Infect Dis [serial on the Internet]. 2011 Jun"/>
   <result pre="Microbiology Network, Health Protection Scotland, and Public Health Agency Northern" exact="Ireland" post="who assisted in data collection, sample collection, and testing."/>
   <result pre="A(H1N1) Investigation Teams. Epidemiology of new influenza A(H1N1) in the" exact="United Kingdom," post="April–May 2009. Euro Surveill. 2009;14:pii:19213. 6. van BovenM, KoopmansM,"/>
   <result pre="al. The early transmission dynamics of H1N1pdm influenza in the" exact="United Kingdom." post="PLoS Curr Influenza. 2009;RRN1130. 12. MorganOW, ParksS, ShimT, BlevinsPA,"/>
   <result pre="for comprehensive assessment of early swine influenza cases in the" exact="United Kingdom." post="2009 May 28 [cited 2011 Mar 22]. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1257260453727 17."/>
   <result pre="large school outbreak of influenza A(H1N1)v in the West Midlands," exact="United Kingdom," post="May 2009. Euro Surveill. 2009;14:pii:19264. 28. CalatayudL, KurkelaS, NeavePE,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3764029/results/search/country/results.xml">
   <result pre="Products, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland," exact="United States" post="of AmericaHottaHakEditor[], Kobe University, Japan * E-mail: dino.feigelstock@fda.hhs.gov Competing"/>
   <result pre="Research, FDA, Bethesda, Maryland, United States of AmericaHottaHakEditor[], Kobe University," exact="Japan" post="* E-mail: dino.feigelstock@fda.hhs.gov Competing Interests: The authors have declared"/>
   <result pre="of Hepatocellular-Carcinoma. Proceedings of the National Academy of Sciences of" exact="the United States" post="of America87: 6547–6549.2168552 3Alter H, Seeff LB (1997) Zuckermanm"/>
   <result pre="Hepatocellular-Carcinoma. Proceedings of the National Academy of Sciences of the" exact="United States" post="of America87: 6547–6549.2168552 3Alter H, Seeff LB (1997) Zuckermanm"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3854647/results/search/country/results.xml">
   <result pre="observational study using electronic medical files of general practitioners in" exact="the Netherlands" post="HooiveldMariëtte1m.hooiveld@nivel.nlvan de GroepTine2tinevandegroep@hotmail.comVerheijTheo JM2T.J.M.Verheij@umcutrecht.nlvan der SandeMarianne AB23marianne.van.der.sande@rivm.nlVerheijRobert A1r.verheij@nivel.nlTackenMargot AJB4M.Tacken@iq.umcn.nlvan"/>
   <result pre="study using electronic medical files of general practitioners in the" exact="Netherlands" post="HooiveldMariëtte1m.hooiveld@nivel.nlvan de GroepTine2tinevandegroep@hotmail.comVerheijTheo JM2T.J.M.Verheij@umcutrecht.nlvan der SandeMarianne AB23marianne.van.der.sande@rivm.nlVerheijRobert A1r.verheij@nivel.nlTackenMargot AJB4M.Tacken@iq.umcn.nlvan"/>
   <result pre="data from routine electronic medical records of practices participating in" exact="the Netherlands" post="Information Network of General Practice LINH in the period"/>
   <result pre="from routine electronic medical records of practices participating in the" exact="Netherlands" post="Information Network of General Practice LINH in the period"/>
   <result pre="presentation of patients was not available. Conclusions General practitioners in" exact="the Netherlands" post="have been restrictive in prescribing antiviral drugs during the"/>
   <result pre="of patients was not available. Conclusions General practitioners in the" exact="Netherlands" post="have been restrictive in prescribing antiviral drugs during the"/>
   <result pre="2009, the first case of influenza A(H1N1)pdm09 was identified in" exact="the Netherlands," post="while it eventually caused an epidemic with influenza activity"/>
   <result pre="In the beginning of August 2009, the Health Council of" exact="the Netherlands" post="and the National Institute for Public Health and the"/>
   <result pre="the beginning of August 2009, the Health Council of the" exact="Netherlands" post="and the National Institute for Public Health and the"/>
   <result pre="be unusually severe or with complications were considered [5]. In" exact="the Netherlands," post="oseltamivir was the drug of first choice for treatment"/>
   <result pre="whether the prescription of oseltamivir by general practitioners (GPs) in" exact="the Netherlands" post="was in accordance with the national guidelines described above."/>
   <result pre="the prescription of oseltamivir by general practitioners (GPs) in the" exact="Netherlands" post="was in accordance with the national guidelines described above."/>
   <result pre="routine electronic medical records of GP practices that participate in" exact="the Netherlands" post="Information Network of General Practice (LINH), a national network"/>
   <result pre="electronic medical records of GP practices that participate in the" exact="Netherlands" post="Information Network of General Practice (LINH), a national network"/>
   <result pre="oseltamivir prescriptions. Discussion This study showed that general practitioners in" exact="the Netherlands" post="have been restrained in prescribing oseltamivir during the influenza"/>
   <result pre="prescriptions. Discussion This study showed that general practitioners in the" exact="Netherlands" post="have been restrained in prescribing oseltamivir during the influenza"/>
   <result pre="it can therefore be said that when general practitioners in" exact="the Netherlands" post="prescribed oseltamivir, they followed the recommendations on the prescribing"/>
   <result pre="can therefore be said that when general practitioners in the" exact="Netherlands" post="prescribed oseltamivir, they followed the recommendations on the prescribing"/>
   <result pre="Conclusions In conclusion, this study showed that general practitioners in" exact="the Netherlands" post="have been very restrained in prescribing antiviral drugs during"/>
   <result pre="In conclusion, this study showed that general practitioners in the" exact="Netherlands" post="have been very restrained in prescribing antiviral drugs during"/>
   <result pre="GP: General practitioner; ICPC: International Classification of Primary Care; LINH:" exact="Netherlands" post="Information Network of General Practice; OR: Odds ratio. Competing"/>
   <result pre="in analysing the data. Funding This work was supported by" exact="the Netherlands" post="Organisation for Health Research and Development ZonMW (grant number"/>
   <result pre="analysing the data. Funding This work was supported by the" exact="Netherlands" post="Organisation for Health Research and Development ZonMW (grant number"/>
   <result pre="der HoekWSurveillance of hospitalisations for 2009 pandemic influenza A(H1N1) in" exact="the Netherlands," post="5 June – 31 December 2009Euro Surveill201015pii:19461 collab: World"/>
   <result pre="of the indication. Publication no. 2007/092007The Hague: Health Council of" exact="the Netherlands" post="Stirbu-WagnerIDorsmanSAVisscherSDavidsRGravesteinJVAbrahamseHvan AlthuisTJansenBSchliefATiersmaWWalkCWentinkEWennekesLBraspenningJKorevaarJCThe Netherlands Information Network of General Practice. Facts"/>
   <result pre="the indication. Publication no. 2007/092007The Hague: Health Council of the" exact="Netherlands" post="Stirbu-WagnerIDorsmanSAVisscherSDavidsRGravesteinJVAbrahamseHvan AlthuisTJansenBSchliefATiersmaWWalkCWentinkEWennekesLBraspenningJKorevaarJCThe Netherlands Information Network of General Practice. Facts"/>
   <result pre="no. 2007/092007The Hague: Health Council of the Netherlands Stirbu-WagnerIDorsmanSAVisscherSDavidsRGravesteinJVAbrahamseHvan AlthuisTJansenBSchliefATiersmaWWalkCWentinkEWennekesLBraspenningJKorevaarJCThe" exact="Netherlands" post="Information Network of General Practice. Facts and numbers in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC3898391/results/search/country/results.xml">
   <result pre="epidemiology has been described in countries with temperate climates like" exact="South Africa" post="and Morocco [3,4] but there are now data that"/>
   <result pre="described in countries with temperate climates like South Africa and" exact="Morocco" post="[3,4] but there are now data that comprehensively describe"/>
   <result pre="data that comprehensively describe influenza viruses in tropical countries like" exact="Kenya" post="and Zambia [5,6]. In Africa, influenza causes severe illness"/>
   <result pre="comprehensively describe influenza viruses in tropical countries like Kenya and" exact="Zambia" post="[5,6]. In Africa, influenza causes severe illness and deaths"/>
   <result pre="the globe, have caused unusually high case fatality ratios in" exact="Madagascar" post="and the Democratic Republic of Congo [9,10]. In addition,"/>
   <result pre="caused unusually high case fatality ratios in Madagascar and the" exact="Democratic Republic of Congo" post="[9,10]. In addition, the elderly in South Africa are"/>
   <result pre="unusually high case fatality ratios in Madagascar and the Democratic" exact="Republic of" post="Congo [9,10]. In addition, the elderly in South Africa"/>
   <result pre="case fatality ratios in Madagascar and the Democratic Republic of" exact="Congo" post="[9,10]. In addition, the elderly in South Africa are"/>
   <result pre="Democratic Republic of Congo [9,10]. In addition, the elderly in" exact="South Africa" post="are four times more likely to die from an"/>
   <result pre="to die from an influenza infection than their counterparts in" exact="the United States" post="[11]. The high prevalence of comorbidities including human immunodeficiency"/>
   <result pre="die from an influenza infection than their counterparts in the" exact="United States" post="[11]. The high prevalence of comorbidities including human immunodeficiency"/>
   <result pre="experts in Africa who could answer the survey. In addition," exact="La Réunion," post="a French territory in the Indian Ocean east of"/>
   <result pre="Indian Ocean east of Madagascar, was asked to participate. Since" exact="La Réunion" post="is not a country, their data were excluded from"/>
   <result pre="Ocean east of Madagascar, was asked to participate. Since La" exact="Réunion" post="is not a country, their data were excluded from"/>
   <result pre="24 countries attending the Third Annual ANISE Meeting in Nairobi," exact="Kenya" post="[16], via email and in person. Data were entered"/>
   <result pre="for 12/31 (39%) of the countries represented. A representative from" exact="La Réunion" post="also completed the survey. Of the 31 countries surveyed,"/>
   <result pre="12/31 (39%) of the countries represented. A representative from La" exact="Réunion" post="also completed the survey. Of the 31 countries surveyed,"/>
   <result pre="vaccine (Figure 1); six in the private sector only (Democratic" exact="Republic of" post="Congo, Senegal, Togo, Uganda, Zambia, and Zimbabwe) and eight"/>
   <result pre="Zimbabwe) and eight in both private and public sectors (Cameroon," exact="Côte d’Ivoire," post="Egypt, Kenya, Madagascar, Mauritius, Morocco, and South Africa) (Table"/>
   <result pre="in Algeria, WHO reports influenza vaccine is available there [14]." exact="La Réunion" post="also reported availability of vaccine in both the private"/>
   <result pre="Algeria, WHO reports influenza vaccine is available there [14]. La" exact="Réunion" post="also reported availability of vaccine in both the private"/>
   <result pre="Type of vaccine Antiviral drugs available Sector (Public vs private)" exact="Angola" post="South Upper middle No -- -- No -- Burkina"/>
   <result pre="private) Angola South Upper middle No -- -- No --" exact="Burkina Faso" post="West Low No -- -- No -- Cameroon Central"/>
   <result pre="-- Burkina Faso West Low No -- -- No --" exact="Cameroon" post="Central Lower-middle Yes Both Southern Yes Public Cape Verde"/>
   <result pre="No -- Cameroon Central Lower-middle Yes Both Southern Yes Public" exact="Cape Verde" post="West Lower-middle No -- -- No -- Comoros Indian"/>
   <result pre="Public Cape Verde West Lower-middle No -- -- No --" exact="Comoros" post="Indian Ocean Low No -- -- No -- Côte"/>
   <result pre="-- Comoros Indian Ocean Low No -- -- No --" exact="Côte d’Ivoire" post="West Lower-middle Yes Both Northern Yes Public Democratic Republic"/>
   <result pre="-- Côte d’Ivoire West Lower-middle Yes Both Northern Yes Public" exact="Democratic Republic of Congo" post="Central Low Yes Private Northern No -- Djibouti East"/>
   <result pre="Côte d’Ivoire West Lower-middle Yes Both Northern Yes Public Democratic" exact="Republic of" post="Congo Central Low Yes Private Northern No -- Djibouti"/>
   <result pre="West Lower-middle Yes Both Northern Yes Public Democratic Republic of" exact="Congo" post="Central Low Yes Private Northern No -- Djibouti East"/>
   <result pre="Republic of Congo Central Low Yes Private Northern No --" exact="Djibouti" post="East Lower-middle No -- -- Yes Public Egypt North"/>
   <result pre="No -- Djibouti East Lower-middle No -- -- Yes Public" exact="Egypt" post="North Lower-middle Yes Both Unknown Yes Both Ethiopia East"/>
   <result pre="Yes Public Egypt North Lower-middle Yes Both Unknown Yes Both" exact="Ethiopia" post="East Low No -- -- No -- Ghana West"/>
   <result pre="Yes Both Ethiopia East Low No -- -- No --" exact="Ghana" post="West Lower-middle No -- -- Yes Public Kenya East"/>
   <result pre="No -- Ghana West Lower-middle No -- -- Yes Public" exact="Kenya" post="East Low Yes Both Southern Yes Private Madagascar Indian"/>
   <result pre="Yes Public Kenya East Low Yes Both Southern Yes Private" exact="Madagascar" post="Indian Ocean Low Yes Both Southern Yes Both Malawi"/>
   <result pre="Private Madagascar Indian Ocean Low Yes Both Southern Yes Both" exact="Malawi" post="South Low No -- -- No -- Mali Central"/>
   <result pre="Yes Both Malawi South Low No -- -- No --" exact="Mali" post="Central Low No -- -- No -- Mauritius Indian"/>
   <result pre="No -- Mali Central Low No -- -- No --" exact="Mauritius" post="Indian Ocean Upper-middle Yes Both Southern Yes Both Morocco"/>
   <result pre="-- Mauritius Indian Ocean Upper-middle Yes Both Southern Yes Both" exact="Morocco" post="North Lower-middle Yes Both Northern Yes Both Mozambique South"/>
   <result pre="Yes Both Morocco North Lower-middle Yes Both Northern Yes Both" exact="Mozambique" post="South Low No -- -- Yes Private Namibia South"/>
   <result pre="Yes Both Mozambique South Low No -- -- Yes Private" exact="Namibia" post="South Upper-middle No -- -- No -- Niger Central"/>
   <result pre="Yes Private Namibia South Upper-middle No -- -- No --" exact="Niger" post="Central Low No -- -- No -- Nigeria West"/>
   <result pre="No -- Niger Central Low No -- -- No --" exact="Nigeria" post="West Lower-middle No -- -- Yes Public Republic of"/>
   <result pre="No -- Nigeria West Lower-middle No -- -- Yes Public" exact="Republic of" post="Congo Central Lower-middle No -- -- Yes Both Réunion"/>
   <result pre="Nigeria West Lower-middle No -- -- Yes Public Republic of" exact="Congo" post="Central Lower-middle No -- -- Yes Both Réunion (France)"/>
   <result pre="Republic of Congo Central Lower-middle No -- -- Yes Both" exact="Réunion" post="(France) Indian Ocean NA Yes Both Southern Yes Both"/>
   <result pre="Réunion (France) Indian Ocean NA Yes Both Southern Yes Both" exact="Senegal" post="West Lower-middle Yes Private Northern No -- Seychelles Indian"/>
   <result pre="Yes Both Senegal West Lower-middle Yes Private Northern No --" exact="Seychelles" post="Indian Ocean Upper-middle No -- -- Yes Public Sierra"/>
   <result pre="-- Seychelles Indian Ocean Upper-middle No -- -- Yes Public" exact="Sierra Leone" post="West Low No -- -- No -- South Africa"/>
   <result pre="Public Sierra Leone West Low No -- -- No --" exact="South Africa" post="South Upper-middle Yes Both Southern Yes Both Tanzania East"/>
   <result pre="-- South Africa South Upper-middle Yes Both Southern Yes Both" exact="Tanzania" post="East Low No -- -- Yes Both Togo West"/>
   <result pre="Yes Both Tanzania East Low No -- -- Yes Both" exact="Togo" post="West Low Yes Private Unknown Yes Both Uganda East"/>
   <result pre="Yes Both Togo West Low Yes Private Unknown Yes Both" exact="Uganda" post="East Low Yes Private Southern Yes Private Zambia South"/>
   <result pre="Yes Both Uganda East Low Yes Private Southern Yes Private" exact="Zambia" post="South Lower-middle Yes Private Unknown Yes Private Zimbabwe South"/>
   <result pre="Yes Private Zambia South Lower-middle Yes Private Unknown Yes Private" exact="Zimbabwe" post="South Low Yes Private Unknown Yes Both *This table"/>
   <result pre="South Low Yes Private Unknown Yes Both *This table includes" exact="La Réunion" post="(a French territory in the Indian Ocean) in addition"/>
   <result pre="Low Yes Private Unknown Yes Both *This table includes La" exact="Réunion" post="(a French territory in the Indian Ocean) in addition"/>
   <result pre="Hemisphere vaccine, four the Northern Hemisphere, and four were unknown." exact="La Réunion" post="reported using Southern Hemisphere vaccine as well (Table 1)."/>
   <result pre="vaccine, four the Northern Hemisphere, and four were unknown. La" exact="Réunion" post="reported using Southern Hemisphere vaccine as well (Table 1)."/>
   <result pre="Three target pregnant women and one pilgrims going to Hajj." exact="South Africa" post="has standing guidelines for the prevention and treatment of"/>
   <result pre="of these reported using these vaccines. Four countries (Kenya, Mali," exact="Senegal" post="and South Africa) and La Réunion reported conducting influenza"/>
   <result pre="vaccines. Four countries (Kenya, Mali, Senegal and South Africa) and" exact="La Réunion" post="reported conducting influenza vaccine research in the years 2012"/>
   <result pre="Four countries (Kenya, Mali, Senegal and South Africa) and La" exact="Réunion" post="reported conducting influenza vaccine research in the years 2012"/>
   <result pre="only and four in the private sector only (Table 1)." exact="La Réunion" post="also reported availability of antiviral drugs in both the"/>
   <result pre="and four in the private sector only (Table 1). La" exact="Réunion" post="also reported availability of antiviral drugs in both the"/>
   <result pre="drugs in both the private and public sectors. Cameroon, Egypt," exact="Ghana" post="and South Africa reported having national guidelines for the"/>
   <result pre="both the private and public sectors. Cameroon, Egypt, Ghana and" exact="South Africa" post="reported having national guidelines for the use of these"/>
   <result pre="Infect Dis2012206Suppl 1S14S2110.1093/infdis/jis60623169960 McAnerneyJMCohenCMoyesJBesselaarTGBuysASchoubBDBlumbergLTwenty-five years of outpatient influenza surveillance in" exact="South Africa," post="1984–2008J Infect Dis2012206Suppl 1S153S15810.1093/infdis/jis57523169963 BarakatAIhazmadHBenkaroumSCherkaouiIBenmamounAYoubiMEl AouadRInfluenza surveillance among outpatients"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4066892/results/search/country/results.xml">
   <result pre="in the minimal OriS duplex) (Aslani et al., 2001, 2002;" exact="Macao" post="et al., 2004; Olsson et al., 2009). In solution,"/>
   <result pre="+ T-rich segment and flanked regions (Aslani et al., 2002;" exact="Macao" post="et al., 2004). In the present studies, we used"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4195804/results/search/country/results.xml">
   <result pre="and Greece), North Africa (Tunisia and Egypt), Asia (Malaysia) and" exact="the United States" post="of America (http://www.who.int/csr/don/2014_05_16_mers/en/, http://www.cdc.gov/coronavirus/mers/). This CoV is closely related"/>
   <result pre="Greece), North Africa (Tunisia and Egypt), Asia (Malaysia) and the" exact="United States of America" post="(http://www.who.int/csr/don/2014_05_16_mers/en/, http://www.cdc.gov/coronavirus/mers/). This CoV is closely related to severe"/>
   <result pre="(Tunisia and Egypt), Asia (Malaysia) and the United States of" exact="America" post="(http://www.who.int/csr/don/2014_05_16_mers/en/, http://www.cdc.gov/coronavirus/mers/). This CoV is closely related to severe"/>
   <result pre="and speculationsArch Virol2014 12AnnanA.BaldwinH.J.CormanV.M.KloseS.M.OwusuM.NkrumahE.E.BaduE.K.AntiP.AgbenyegaO.MeyerB.Human betacoronavirus 2c EMC/2012-related viruses in bats," exact="Ghana" post="and EuropeEmerg Infect Dis19201345645923622767 13AnthonyS.J.Ojeda-FloresR.Rico-ChavezO.Navarrete-MaciasI.Zambrana-TorrelioC.M.RostalM.K.EpsteinJ.H.TippsT.LiangE.Sanchez-LeonM.Coronaviruses in bats from MexicoJ"/>
   <result pre="Ministry of Knowledge and Economy, Bilateral International Collaborative R&amp;amp;D Program," exact="Republic of" post="Korea."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4247767/results/search/country/results.xml">
   <result pre="a Grants-in-Aid for Young Scientists B25800092 (to S.I.) from the" exact="Japan" post="Society for the Promotion of Science (JSPS); the Kyushu"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4313645/results/search/country/results.xml">
   <result pre="1997 ( 5 ); the first human case in North" exact="America" post="was reported in January 2014 ( 6 ). Since"/>
   <result pre="reported in January 2014 ( 6 ). Since March 2013," exact="China" post="has been trying to contain an ongoing outbreak of"/>
   <result pre="16 , 17 ). In preparation for future influenza pandemics," exact="the US" post="Department of Health and Human Services therefore maintains a"/>
   <result pre="detection of the new influenza A(H1N1)pdm09 virus in April 2009," exact="the US" post="government declared a public health emergency, and the World"/>
   <result pre="( 23 ). In the early weeks of the pandemic," exact="the US" post="Department of Health and Human Services distributed 11 million"/>
   <result pre="easily extended to other states by using data available through" exact="the US" post="Census Bureau and state pharmacy associations ( 29 ,"/>
   <result pre="Jan 23]. http://www.cdc.gov/flu/avianflu/h7n9-virus.htm 8.SchnirringL . Pace of H7N9 cases in" exact="China" post="continues unabated, 2014 [2014 Jan 23]. http://www.cidrap.umn.edu/news-perspective/2014/01/pace-h7n9-cases-china-continues-unabated 9.CouchRB ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4353273/results/search/country/results.xml">
   <result pre="Diseases &amp;amp; Medical Microbiology1712-95321918-1493Pulsus Group Inc pmcid: 4353273idmm-26-e1 : AMMI" exact="Canada" post="Guidelines Guidance for practitioners on the use of antiviral"/>
   <result pre="to noncommercial purposes. For commercial reuse, contact support@pulsus.com The AMMI" exact="Canada" post="Guidelines document ‘The use of antiviral drugs for influenza:"/>
   <result pre="2014 from information provided by the Public Health Agency of" exact="Canada" post="regarding early data indicating a mismatch of the influenza"/>
   <result pre="approved the document before a further review from the AMMI" exact="Canada" post="Guidelines Committee and the Infectious Diseases and Immunization Committee"/>
   <result pre="Diseases and Immunization Committee of the Canadian Paediatric Society. AMMI" exact="Canada" post="approved the final document before submission to the Journal"/>
   <result pre="MESSAGES The current guidance document supplements recommendations in the AMMI" exact="Canada" post="Guideline ‘The use of antiviral drugs for influenza: A"/>
   <result pre="outbreaks this season compared with usual in several parts of" exact="Canada" post="(4). These viruses remain susceptible to the neuraminidase inhibitor"/>
   <result pre="majority of influenza A(H3N2) viruses (&amp;gt;95%) characterized thus far in" exact="Canada" post="this season show genetic and antigenic evidence of mismatch"/>
   <result pre="the 2014–2015 season To date during the 2014–2015 season in" exact="Canada" post="(current as of week 50, ending December 13, 2014),"/>
   <result pre="A(H3N2) viruses. Of the 2011 influenza A viruses detected in" exact="Canada" post="thus far with subtype information available to December 13,"/>
   <result pre="Evidence for antigenic drift/vaccine mismatch among H3N2 viruses detected in" exact="Canada" post="Of 61 influenza A(H3N2) viruses characterized so far this"/>
   <result pre="sequenced by investigators during the fall 2014 in British Columbia," exact="Canada" post="(verbal communication, D. Skowronski, BC Centre for Disease Control)."/>
   <result pre="been associated with VE of approximately 40% or less in" exact="Canada" post="and elsewhere (13–17). One of the particular combinations of"/>
   <result pre="157) was associated with VE of 30% or less in" exact="Spain" post="with use of the same A/Texas/50/2012(H3N2) vaccine component in"/>
   <result pre="are referred to provincial guidelines and an interim guideline from" exact="the United States" post="Centers for Disease Control and Prevention (22). For control"/>
   <result pre="referred to provincial guidelines and an interim guideline from the" exact="United States" post="Centers for Disease Control and Prevention (22). For control"/>
   <result pre="of the present document by the Public Health Agency of" exact="Canada" post="and the Infectious Diseases and Immunization Committee of the"/>
   <result pre="Paediatric Society and its review and endorsement by the AMMI" exact="Canada" post="Guidelines Committee. AMMI Canada would like to acknowledge the"/>
   <result pre="review and endorsement by the AMMI Canada Guidelines Committee. AMMI" exact="Canada" post="would like to acknowledge the Public Health Agency of"/>
   <result pre="Canada would like to acknowledge the Public Health Agency of" exact="Canada" post="who contributed by funding the translation of the guidelines."/>
   <result pre="platform to evaluate influenza vaccine effectiveness and new variant circulation," exact="Canada" post="2010–11 seasonClin Infect Dis2012553324222539661 14.OhmitSEPetrieJGMaloshREet al.Influenza vaccine effectiveness in"/>
   <result pre="end of season resultsEuro Surveillance20141951325033051 17.McLeanHQThompsonMGSundaramMEet al.Influenza vaccine effectiveness in" exact="the United States" post="during 2012–13: Variable protection by age and virus typeJ"/>
   <result pre="of season resultsEuro Surveillance20141951325033051 17.McLeanHQThompsonMGSundaramMEet al.Influenza vaccine effectiveness in the" exact="United States" post="during 2012–13: Variable protection by age and virus typeJ"/>
   <result pre="on Immunization (NACI)Statement on seasonal influenza vaccine for 2014–2015 22.collab:" exact="United States" post="Centers for Disease Control &amp;amp; PreventionInterim guidance for influenza"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4353274/results/search/country/results.xml">
   <result pre="Diseases &amp;amp; Medical Microbiology1712-95321918-1493Pulsus Group Inc pmcid: 4353274idmm-26-e5 : AMMI" exact="Canada" post="Guidelines Guidance on the use of antiviral drugs for"/>
   <result pre="support@pulsus.com This article represents the second update to the AMMI" exact="Canada" post="Guidelines document on the use of antiviral drugs for"/>
   <result pre="the acute care setting infected with influenza viruses circulating in" exact="Canada" post="during the 2014–2015 influenza season. A. PROCESS STATEMENT The"/>
   <result pre="2014 from information provided by the Public Health Agency of" exact="Canada" post="regarding early data indicating a mismatch of the influenza"/>
   <result pre="approved the document before a further review from the AMMI" exact="Canada" post="Guidelines Committee and the Infectious Diseases and Immunization Committee"/>
   <result pre="Diseases and Immunization Committee of the Canadian Paediatric Society. AMMI" exact="Canada" post="approved the final document before submission to the Journal"/>
   <result pre="it can be obtained by request to the Government of" exact="Canada" post="Health Protection Branch, Special Access Program, Ottawa. (Web access"/>
   <result pre="who have received influenza vaccineClin Infect Dis2003361697412522748 12.BisnoALGriffinJPVan EppsKANiellHBRytelMWPneumonia and" exact="Hong Kong" post="influenza: A prospective study of the 1968–1969 epidemicAm J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4531042/results/search/country/results.xml">
   <result pre="drug-induced immunosuppression. The three antiviral drugs that are approved by" exact="the US" post="Food and Drug Administration for CMV treatment are the"/>
   <result pre="of CMV disease by the European Commission. In August 2011," exact="the US" post="Food and Drug Administration granted it a fast track"/>
   <result pre="the chemical structure of letermovir, the antivirals currently approved by" exact="the US" post="Food and Drug Administration, and other investigational drugs with"/>
   <result pre="matched related or unrelated donors from 19 transplant centers in" exact="Germany" post="and the USA. In this trial, different doses (60,"/>
   <result pre="or unrelated donors from 19 transplant centers in Germany and" exact="the USA." post="In this trial, different doses (60, 120, or 240"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4539848/results/search/country/results.xml">
   <result pre="therapeutic effects, including hepatoprotective, antioxidant, and anti-lipogenic properties (12). In" exact="the United States" post="and Europe, about 65% of patients with liver disease"/>
   <result pre="effects, including hepatoprotective, antioxidant, and anti-lipogenic properties (12). In the" exact="United States" post="and Europe, about 65% of patients with liver disease"/>
   <result pre="bile acid (UDCA)&quot;, the study retrieved papers indexed in the" exact="China" post="national knowledge internet (CNKI) (2000 - 2012), Pubmed (19832013),"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4574619/results/search/country/results.xml">
   <result pre="asymptomatic circulation of serotype 1 WPV (WPV1) in parts of" exact="Israel" post="despite very high IPV routine immunization coverage strongly suggests"/>
   <result pre="development of symptoms and diagnosis. A study of VAPP in" exact="the US" post="assumed an incidence of approximately 1 PID patient per"/>
   <result pre="incidence of approximately 1 PID patient per 10,000 births in" exact="the US" post="[42]. Intravenous immunoglobulin (IVIG) therapy reduces morbidity and probably"/>
   <result pre="total PID patients (0.1 %) (Table 1). Another child in" exact="Sri Lanka" post="with SCID died while infected and appeared as a"/>
   <result pre="PID patients (0.1 %) (Table 1). Another child in Sri" exact="Lanka" post="with SCID died while infected and appeared as a"/>
   <result pre="excretors iVDPV excretors Patients with &amp;gt; 6 months of documented excretion Source(s)" exact="Bangladesh" post="13 0 1 0 0 [52] Brazil 95 70"/>
   <result pre="documented excretion Source(s) Bangladesh 13 0 1 0 0 [52]" exact="Brazil" post="95 70 3 0 0 [16] China 167 22"/>
   <result pre="0 0 [52] Brazil 95 70 3 0 0 [16]" exact="China" post="167 22 3 0 0 [52] Egypta 15 3"/>
   <result pre="0 0 [52] Egypta 15 3 2 0 0 [21]" exact="Iran" post="43 16 1 0 0 [52] Italy 38 0"/>
   <result pre="0 0 [21] Iran 43 16 1 0 0 [52]" exact="Italy" post="38 0 0 0 0 [17] Mexico 33 5"/>
   <result pre="0 0 [52] Italy 38 0 0 0 0 [17]" exact="Mexico" post="33 5 1 0 0 [16] Philippines 70 6"/>
   <result pre="0 0 [17] Mexico 33 5 1 0 0 [16]" exact="Philippines" post="70 6 1 0 0 [52, 60] Russia 136"/>
   <result pre="0 [16] Philippines 70 6 1 0 0 [52, 60]" exact="Russia" post="136 27 0 0 0 [52] Sri Lanka 51"/>
   <result pre="0 [52, 60] Russia 136 27 0 0 0 [52]" exact="Sri Lanka" post="51 13 5 2 1b [20, 52] Tunisia 16"/>
   <result pre="[52, 60] Russia 136 27 0 0 0 [52] Sri" exact="Lanka" post="51 13 5 2 1b [20, 52] Tunisia 16"/>
   <result pre="[52] Sri Lanka 51 13 5 2 1b [20, 52]" exact="Tunisia" post="16 2 4 0 0 [61] Tunisia 82 14"/>
   <result pre="1b [20, 52] Tunisia 16 2 4 0 0 [61]" exact="Tunisia" post="82 14 6 0 [19, 52] United Kingdom 125"/>
   <result pre="0 0 [61] Tunisia 82 14 6 0 [19, 52]" exact="United Kingdom" post="125 65 0 0 0 [16] United States 94"/>
   <result pre="[19, 52] United Kingdom 125 65 0 0 0 [16]" exact="United States" post="94 75 0 0 0 [16] Total 978 318"/>
   <result pre="retrospective analysis of all 37 immunodeficient VAPP cases reported in" exact="the United States" post="between 1975 and 1997 found 6 months of excretion"/>
   <result pre="analysis of all 37 immunodeficient VAPP cases reported in the" exact="United States" post="between 1975 and 1997 found 6 months of excretion"/>
   <result pre="[62] and approximately 50 % secondarily infected from SIAs in" exact="Oman" post="and Cuba [63, 64], assuming 1 SIA per year"/>
   <result pre="approximately 50 % secondarily infected from SIAs in Oman and" exact="Cuba" post="[63, 64], assuming 1 SIA per year on average"/>
   <result pre="Based on case-fatality rates among 6 immunodeficient VAPP patients in" exact="Iran" post="and 36 immunodeficient VAPP cases in the US; for"/>
   <result pre="VAPP patients in Iran and 36 immunodeficient VAPP cases in" exact="the US;" post="for the latter, we assume that a death within"/>
   <result pre="4 CVID and 33 oPID patients reported with VAPP in" exact="the US" post="during the 23-year period 1975–1997 [53]. Assuming approximately 400"/>
   <result pre="1975–1997 [53]. Assuming approximately 400 annual PID births [42] in" exact="the US" post="and that 20 % of PID patients represent CVIDs"/>
   <result pre="manuscript. RJDT and KMT acknowledge support for this work from" exact="the US" post="Centers for Disease Control and Prevention under Contract U66IP000519."/>
   <result pre="the authors and do not represent the official views of" exact="the US" post="Centers for Disease Control and Prevention. References References 1.World"/>
   <result pre="TebbensRJGrottoIShulmanLMAnisEWassilakSGFPallanschMAThompsonKMModeling options to manage type 1 wild poliovirus imported into" exact="Israel" post="in 2013J Infect Dis20152111118001210.1093/infdis/jiu67425505296 13.Duintjer TebbensRJThompsonKMModeling the potential role"/>
   <result pre="virus carriers among people with primary immune deficiency diseases in" exact="the United States," post="Mexico, Brazil and the United KingdomBull World Health Organ20048213815106294"/>
   <result pre="carriers among people with primary immune deficiency diseases in the" exact="United States," post="Mexico, Brazil and the United KingdomBull World Health Organ20048213815106294"/>
   <result pre="with primary immune deficiency diseases in the United States, Mexico," exact="Brazil" post="and the United KingdomBull World Health Organ20048213815106294 17.FioreLPlebaniAButtinelliGFioreSDonatiVMarturanoJSoresinaAMartireBAzzariCNigroGet al.Search"/>
   <result pre="review of the literatureJ Infect Dis1997175Suppl. 1S1768210.1093/infdis/175.Supplement_1.S1769203713 26.MacCallumFOHypogammaglobulinaemia in the" exact="United Kingdom." post="VII. The role of humoral antibodies in protection against"/>
   <result pre="and inactivated poliovirus vaccines: results of a randomized trial in" exact="The Gambia," post="Oman, and Thailand. WHO Collaborative Study Group on Oral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4623666/results/search/country/results.xml">
   <result pre="we assume individuals know the age of the individual making" exact="the US" post="offer, and ρi is the vaccine coverage in the"/>
   <result pre="Math. Biosci.92, 119–199 (1988). NagelkerkeN. J.et al.Modelling HIV/AIDS epidemics in" exact="Botswana" post="and India: impact of interventions to prevent transmission. Bull."/>
   <result pre="Comput Appl Math.184, 10–49 (2005). PrejeanJ.et al.Estimated HIV incidence in" exact="the United States" post="2006–2009. PLoS One6, 10.1371/journal.pone.0017502 (2011). International AIDS vaccine initiative."/>
   <result pre="Appl Math.184, 10–49 (2005). PrejeanJ.et al.Estimated HIV incidence in the" exact="United States" post="2006–2009. PLoS One6, 10.1371/journal.pone.0017502 (2011). International AIDS vaccine initiative."/>
   <result pre="and Prevention Estimated HIV incidence among adults and adolescents in" exact="the United States," post="2007–2010. HIV Surveillance Supplemental Report17, 1–26 (2012). Available at:"/>
   <result pre="Prevention Estimated HIV incidence among adults and adolescents in the" exact="United States," post="2007–2010. HIV Surveillance Supplemental Report17, 1–26 (2012). Available at:"/>
   <result pre="SanchezT.et al.Human Immunodeficiency Virus (HIV) Risk, Prevention, and Testing Behaviors:" exact="United States," post="National HIV Behavioral Surveillance System: Men who Have Sex"/>
   <result pre="for HIV/AIDS, viral hepatitis, STD and TB prevention HIV in" exact="the United States" post="at a glance, (2012) Available at: http://www.cdc.gov/hiv/resources/factsheets/PDF/HIV_at_a_glance.pdf (Accessed: 1st"/>
   <result pre="HIV/AIDS, viral hepatitis, STD and TB prevention HIV in the" exact="United States" post="at a glance, (2012) Available at: http://www.cdc.gov/hiv/resources/factsheets/PDF/HIV_at_a_glance.pdf (Accessed: 1st"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC4654359/results/search/country/results.xml">
   <result pre="timeframes is lacking. Viral infection Drug development timeframes Drug licensing" exact="United Kingdom" post="Strengths and limitations of this study This is the"/>
   <result pre="the Investigational New Drug (IND) Application (a step required by" exact="the US" post="Food and Drug Administration (FDA) prior to testing in"/>
   <result pre="the regulatory review process). For all new drugs approved in" exact="the USA" post="from 1992 to 2001, the authors found no increase"/>
   <result pre="filing (increasing from a mean 5.7 years for drugs approved in" exact="the USA" post="1980–1984, to 6.4 years for those approved 2005–2009) and concluded"/>
   <result pre="found by Kaitin and DiMasi for all drugs approved in" exact="the USA" post="between 1980 and 2009 (from 5.7 years in the period"/>
   <result pre="date of IND application, a process which only applies to" exact="the USA" post="and not to Europe. This point in the development"/>
   <result pre="decades the majority of new drugs have been launched in" exact="the USA" post="at an earlier or similar time to Europe.18 The"/>
   <result pre="and waiting periods21–24 and introduced a range of initiatives in" exact="the USA" post="and Europe to provide a more rapid pathway to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC5065164/results/search/country/results.xml">
   <result pre="D.123SmithSuzanne1GideonClare1BonomoRobert A.1234Falck-YtterYngve1234*[1], Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio," exact="United States" post="of America[2], University Hospitals Case Medical Center, Cleveland, Ohio,"/>
   <result pre="States of America[2], University Hospitals Case Medical Center, Cleveland, Ohio," exact="United States" post="of America[3], Case Western Reserve University, Cleveland, Ohio, United"/>
   <result pre="United States of America[3], Case Western Reserve University, Cleveland, Ohio," exact="United States" post="of America[4], Geriatric Research Education and Clinical Center (GRECC),"/>
   <result pre="Center (GRECC), Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio," exact="United States" post="of AmericaKimDo YoungEditor[], Yonsei University College of Medicine, REPUBLIC"/>
   <result pre="are infected with the Hepatitis C virus (HCV).[1, 2] In" exact="the United States," post="between 2.7 and 3.5 million people are believed to"/>
   <result pre="infected with the Hepatitis C virus (HCV).[1, 2] In the" exact="United States," post="between 2.7 and 3.5 million people are believed to"/>
   <result pre="be infected with HCV.[3, 4] Approximately 5.4% of veterans in" exact="the United States" post="have chronic HCV, which is more than double the"/>
   <result pre="infected with HCV.[3, 4] Approximately 5.4% of veterans in the" exact="United States" post="have chronic HCV, which is more than double the"/>
   <result pre="nonstructural 3/4A protease inhibitors, boceprevir and telaprevir, were approved by" exact="the United States" post="Food and Drug Administration (FDA) in 2011 for the"/>
   <result pre="3/4A protease inhibitors, boceprevir and telaprevir, were approved by the" exact="United States" post="Food and Drug Administration (FDA) in 2011 for the"/>
   <result pre="KuhnertWL, AlterMJ. The prevalence of hepatitis C virus infection in" exact="the United States," post="1999 through 2002. Annals of internal medicine. 2006;144(10):705–14. .16702586"/>
   <result pre="AlterMJ. The prevalence of hepatitis C virus infection in the" exact="United States," post="1999 through 2002. Annals of internal medicine. 2006;144(10):705–14. .16702586"/>
   <result pre="KlevensRM, WardJW, McQuillanGM, et al.Chronic hepatitis C virus infection in" exact="the United States," post="National Health and Nutrition Examination Survey 2003 to 2010."/>
   <result pre="WardJW, McQuillanGM, et al.Chronic hepatitis C virus infection in the" exact="United States," post="National Health and Nutrition Examination Survey 2003 to 2010."/>
   <result pre="et al.Elevated prevalence of hepatitis C infection in users of" exact="United States" post="veterans medical centers. Hepatology. 2005;41(1):88–96. 10.1002/hep.20502 .15619249 6PradatP, VoirinN,"/>
   <result pre="hepatocellular carcinoma. Proceedings of the National Academy of Sciences of" exact="the United States" post="of America. 1990;87(17):6547–9. 2168552 8SmithBD, MorganRL, BeckettGA, Falck-YtterY, HoltzmanD,"/>
   <result pre="carcinoma. Proceedings of the National Academy of Sciences of the" exact="United States of America." post="1990;87(17):6547–9. 2168552 8SmithBD, MorganRL, BeckettGA, Falck-YtterY, HoltzmanD, TeoCG, et"/>
   <result pre="of hepatitis C virus treatment with sofosbuvir and ledipasvir in" exact="the United States." post="Ann Intern Med. 2015;162(6):397–406. 10.7326/M14-133625775312 32BackusLI, BelperioPS, ShahoumianTA, LoomisTP,"/>
   <result pre="hepatitis C virus treatment with sofosbuvir and ledipasvir in the" exact="United States." post="Ann Intern Med. 2015;162(6):397–406. 10.7326/M14-133625775312 32BackusLI, BelperioPS, ShahoumianTA, LoomisTP,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC5228644/results/search/country/results.xml">
   <result pre="Inha University School of Medicine, 27 Inhang-ro, Jung-gu, Incheon 400-711," exact="South Korea" post="(e-mail: jyj412@hanmail.net). collection: 2017-1epub: 2017-1-1961e5321received: 2016-6-7rev-recd: 2016-10-12accepted: 2016-10-12(C) ,"/>
   <result pre="by the Institutional Review Board of Inha University Hospital, Incheon," exact="South Korea" post="(approval number: INHAUH 2015-11-018). 2.2 Recruitment of clinical database"/>
   <result pre="3 or more groups were analyzed by ANOVA test with" exact="Turkey" post="multiple comparison test. Multivariate analysis was conducted using the"/>
   <result pre="study on the outcomes of hepatitis C virus-related cirrhosis in" exact="South Korea." post="J Gastroenterol Hepatol2015;30:1281–7.25778783 [19]OgawaEFurusyoNKajiwaraEet al.Efficacy of pegylated interferon alpha-2b"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC5549007/results/search/country/results.xml">
   <result pre="Transplant MedIjotmInternational Journal of Organ Transplantation Medicine2008-64822008-6490Avicenna Organ Transplantation InstituteShiraz," exact="Iran" post="pmcid: 5549007ijotm-8-104 : Original Article HCV-infected Renal Transplant Recipients:"/>
   <result pre="Raquel Fernandes, MD, Department of Nephrology, Hospital São Bernardo, Setúbal," exact="Portugal" post="Tel: +35-193-951-7668, E-mail: anar.fernandes@sapo.pt ppub: 2017epub: 2017-5-582104109(C) , This"/>
   <result pre="C virus infection and kidney transplantation: a review for clinicians" exact="Iran" post="J Kidney Dis201041820081297 6PereiraBJLeveyASHepatitis C virus infection in dialysis"/>
   <result pre="diabetes mellitus among persons with hepatitis C virus infection in" exact="the United States" post="Ann Intern Med2000133592911033586 32ZeinCOLevyCBasuAZeinNNChronic hepatitis C and type II"/>
   <result pre="mellitus among persons with hepatitis C virus infection in the" exact="United States" post="Ann Intern Med2000133592911033586 32ZeinCOLevyCBasuAZeinNNChronic hepatitis C and type II"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC5644647/results/search/country/results.xml">
   <result pre="shown to be active against HIV in 1986 [37]. In" exact="the United States," post="it was the second drug to be approved for"/>
   <result pre="to be active against HIV in 1986 [37]. In the" exact="United States," post="it was the second drug to be approved for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC5753465/results/search/country/results.xml">
   <result pre="Natural Science Foundation of China81373892 National Natural Science Foundation of" exact="China" post="31540008 Background Dengue fever disease (DF)is a mosquito-borne disease"/>
   <result pre="We evaluated outpatients referred to Centre for Tropical Diseases, Guangzhou," exact="China" post="during March–December 2015. It was approved by the ethical"/>
   <result pre="Loratadine (LRD, batch LRD/0909180) produced by Vasudna Pharma. Chem. Ltd.," exact="China" post="were used in the research for their potential activities"/>
   <result pre="Northwest A &amp;amp; F University, National Natural Science Foundation of" exact="China" post="(31170796 and 81373892). It also was supported in part"/>
   <result pre="in part by Grants from, National Natural Science Foundation of" exact="China" post="(31540008). Availability of data and materials All data generated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6027266/results/search/country/results.xml">
   <result pre="no conflict of interest. References References 1.CalisherC.H.Medically important arboviruses of" exact="the United States" post="and CanadaClin. Microbiol. Rev.199478911610.1128/CMR.7.1.898118792 2.HuneycuttB.S.BiZ.AokiC.J.ReissC.S.Central neuropathogenesis of vesicular stomatitis"/>
   <result pre="conflict of interest. References References 1.CalisherC.H.Medically important arboviruses of the" exact="United States" post="and CanadaClin. Microbiol. Rev.199478911610.1128/CMR.7.1.898118792 2.HuneycuttB.S.BiZ.AokiC.J.ReissC.S.Central neuropathogenesis of vesicular stomatitis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6439212/results/search/country/results.xml">
   <result pre="of Pharmacy, King Saud University, P.O. Box. 2457, Riyadh 11451," exact="Saudi Arabia." post="mohkhalid@ksu.edu.saaperwez@ksu.edu.sa pmc-release: 2018-12-12ppub: 2019-3epub: 2018-12-12273389400received: 2018-8-30accepted: 2018-12-23(C) , 2018This"/>
   <result pre="endemic regions in Asia, sub-Sharan Africa, Eastern Europe and Latin" exact="America" post="(WHO, 2017). HBV is the smallest known DNA virus"/>
   <result pre="2017). Interestingly therefore, approximately 80% of the CHB patients in" exact="China" post="rely on traditional herbal medicines. The HBV-reporter cell line,"/>
   <result pre="HBV Pol structure as reported previously (Huang et al., 1998)." exact="Swiss" post="model server was used for the prediction of three-dimensional"/>
   <result pre="The homology model of HBV Pol was generated using the" exact="Swiss" post="model server (Fig. 6B), and validated by Ramachandran plot."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6444013/results/search/country/results.xml">
   <result pre="screening of antiviral drugs, are discussed. Funding Independent Research Fund" exact="Denmark" post="(Technology and Production Sciences, DFF-FTP),application number 6111-00104B. Funding https://doi.org/10.13039/501100003329Ministerio"/>
   <result pre="and microcephaly has been associated with outbreaks of ZIKV in" exact="Micronesia" post="(2007), French Polynesia (2013), and Brazil (2015)8–10. Accordingly, the"/>
   <result pre="has been associated with outbreaks of ZIKV in Micronesia (2007)," exact="French Polynesia" post="(2013), and Brazil (2015)8–10. Accordingly, the World Health Organization"/>
   <result pre="outbreaks of ZIKV in Micronesia (2007), French Polynesia (2013), and" exact="Brazil" post="(2015)8–10. Accordingly, the World Health Organization Public Health Emergency"/>
   <result pre="recipient of a Research project-1 grant from Independent Research Fund" exact="Denmark" post="(Technology and Production Sciences, DFF-FTP), application number 6111-00104B. Author"/>
   <result pre="&amp;amp; Musso, D. Evidence of perinatal transmission of Zika virus," exact="French Polynesia," post="December 2013 and February 2014. Euro Surveill19, 10.2807/1560-7917.ES2014.19.13.20751 (2014)."/>
   <result pre="virus transmission through blood transfusion demonstrated during an outbreak in" exact="French Polynesia," post="November 2013 to February 2014. Euro Surveill19, 10.2807/1560-7917.ES2014.19.14.20761 (2014)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6702965/results/search/country/results.xml">
   <result pre="(CSIC-UAM), Universidad Autónoma de MadridMadridSpain Edited by: Douglas Paul Gladue," exact="United States" post="Department of Agriculture, United States Reviewed by: Covadonga Alonso,"/>
   <result pre="Edited by: Douglas Paul Gladue, United States Department of Agriculture," exact="United States" post="Reviewed by: Covadonga Alonso, Instituto Nacional de Investigación y"/>
   <result pre="Agraria y Alimentaria (INIA), Spain; Raymond Rowland, Kansas State University," exact="United States" post="*Correspondence: Francisco Sobrino, fsobrino@cbm.csic.es This article was submitted to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6724046/results/search/country/results.xml">
   <result pre="2.ZhaoZ.LiuH.DingK.PengC.XueQ.YuZ.XueY.Occurrence of canine parvovirus in dogs from Henan province of" exact="China" post="in 2009–2014BMC Veter. Res.20161213810.1186/s12917-016-0753-127377264 3.GoddardA.LeisewitzA.L.Canine parvovirusVet. Clin. N. Am."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6755163/results/search/country/results.xml">
   <result pre="rabbit hepatocytes (PRHs) were isolated from the liver tissues of" exact="New Zealand" post="rabbits (n=4; estimated age, 4 weeks) provided by Guangdong"/>
   <result pre="work was supported by the National Natural Science Foundation of" exact="China" post="(grant. no. 81601760), the General Financial Grant from the"/>
   <result pre="China (grant. no. 81601760), the General Financial Grant from the" exact="China" post="Postdoctoral Science Foundation (grant. no. 2016M602587), the Shenzhen Foundation"/>
   <result pre="the Health and Family Planning Commission of Shaoxing, Zhejiang Province," exact="China" post="(grant. no. 2017QN001), the Science Technology Bureau of Shaoxing,"/>
   <result pre="no. 2017QN001), the Science Technology Bureau of Shaoxing, Zhejiang Province," exact="China" post="(grant. no. 2017B70022 to BQ), the Sanming Project of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6780377/results/search/country/results.xml">
   <result pre="were reported in Philadelphia, Zanzibar, Calcutta, the West Indies, and" exact="Hong Kong." post="Where the relevant factors considered for all these epidemics"/>
   <result pre="[14,15,16]. From 1922 to 1945, many outbreaks were recorded in" exact="the United States," post="Australia, Greece, and Japan. In 1922, it was estimated"/>
   <result pre="From 1922 to 1945, many outbreaks were recorded in the" exact="United States," post="Australia, Greece, and Japan. In 1922, it was estimated"/>
   <result pre="estimated that 1 to 2 million individuals in the southern" exact="United States" post="were affected. In the three decades after World War"/>
   <result pre="after World War II, dengue epidemics occurred sporadically in Central" exact="America" post="and the Caribbean basin [17]. Socio-economic conditions after the"/>
   <result pre="and DENV-4 strains were first isolated from infected individuals in" exact="the Philippines" post="and Thailand [20]. 1.2. Vector and Non-Vector Transmission of"/>
   <result pre="DENV-4 strains were first isolated from infected individuals in the" exact="Philippines" post="and Thailand [20]. 1.2. Vector and Non-Vector Transmission of"/>
   <result pre="were first isolated from infected individuals in the Philippines and" exact="Thailand" post="[20]. 1.2. Vector and Non-Vector Transmission of Dengue In"/>
   <result pre="infants born to a DHF-diagnosed mother [30]. A child from" exact="Puerto Rico" post="attained DENV-4 via bone marrow transplant and subsequently died"/>
   <result pre="the rainforests of western Africa and Southeast Asia, including Peninsular" exact="Malaysia" post="and eastern Senegal [6,33]. Aedes luteocephalus, A. furcifer, and"/>
   <result pre="western Africa and Southeast Asia, including Peninsular Malaysia and eastern" exact="Senegal" post="[6,33]. Aedes luteocephalus, A. furcifer, and A. taylori were"/>
   <result pre="of enzootic circulation through lower primates have been found in" exact="Panama" post="[43]. However, seroconversions among indigenous Ayoreo Indians living in"/>
   <result pre="Medical Research and Faculty of Veterinary Medicine, Malaysia, and University" exact="Malaysia" post="Kelantan. Author Contributions All authors contributed equally to the"/>
   <result pre="Funding This work was supported by the Ministry of Education" exact="Malaysia" post="(MOE) through FRGS/1/2016/STG04/UIAM/02/1. Conflicts of Interest The authors declare"/>
   <result pre="Argent. Pediatr.201110923223621660390 31.Rigau-PérezJ.G.VorndamA.V.ClarkG.G.The Dengue and Dengue Hemorrhagic Fever Epidemic in" exact="Puerto Rico," post="1994–1995Am. J. Trop. Med. Hyg.200164677410.4269/ajtmh.2001.64.6711425166 32.ChenL.H.WilsonM.E.Transmission of Dengue Virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6789623/results/search/country/results.xml">
   <result pre="has a propensity for interspecies transmission. It was identified in" exact="Hong Kong" post="in 2012. Given that neither specific antiviral drugs nor"/>
   <result pre="chloride diammonium glycyrrhizinate apoptosis 1. Introduction PDCoV, first discovered in" exact="Hong Kong" post="in 2012, broke out in the United States in"/>
   <result pre="first discovered in Hong Kong in 2012, broke out in" exact="the United States" post="in early 2014 and then spread to China, Thailand,"/>
   <result pre="discovered in Hong Kong in 2012, broke out in the" exact="United States" post="in early 2014 and then spread to China, Thailand,"/>
   <result pre="supported by the National Key Research and Development Program of" exact="China" post="(2017YFD0500101), the National Natural Science Foundation of China (31922081),"/>
   <result pre="Program of China (2017YFD0500101), the National Natural Science Foundation of" exact="China" post="(31922081), the Natural Science Foundation of Jiangsu Province (BK20170721),"/>
   <result pre="(31922081), the Natural Science Foundation of Jiangsu Province (BK20170721), the" exact="China" post="Association for Science and Technology Youth Talent Lift Project"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6792045/results/search/country/results.xml">
   <result pre="Shandong First Medical University &amp;amp; Shandong Academy of Medical SciencesPeople’s" exact="Republic of" post="China[b], School of Public Health, Shandong First Medical University"/>
   <result pre="Shandong First Medical University &amp;amp; Shandong Academy of Medical SciencesPeople’s" exact="Republic of" post="China[c], National Virus Reference Laboratory, School of Medicine, University"/>
   <result pre="UniversityJapan[e], Department of Obstetrics and Gynecology, Central Hospital of TaianPeople’s" exact="Republic of" post="China CONTACT Weijia Xing xingweijia@hotmail.com Weifeng Shi shiwf@ioz.ac.cn *Co-first"/>
   <result pre="of Obstetrics and Gynecology, Central Hospital of TaianPeople’s Republic of" exact="China" post="CONTACT Weijia Xing xingweijia@hotmail.com Weifeng Shi shiwf@ioz.ac.cn *Co-first authors."/>
   <result pre="work was supported by the National Natural Science Foundation of" exact="China" post="[grant numbers 81802009, 81601773], the Natural Science Foundation of"/>
   <result pre="numbers 81802009, 81601773], the Natural Science Foundation of Shandong Province," exact="China" post="[grant numbers ZR2018PC012, ZR2015CL033], Projects of medical and health"/>
   <result pre="of medical and health technology development program in Shandong province," exact="China" post="[grant number 2015WS0123] and W.S. was supported by the"/>
   <result pre="was supported by the Taishan Scholars program of Shandong Province," exact="China" post="[grant number ts201511056]. fig-count: table-count: equation-count: ref-count: page-count: Introduction"/>
   <result pre="[7], Yunnan [8], and Jiangsu [9]. Other countries, such as" exact="Thailand" post="[2, 10], Australia [11] and Italy [12] have also"/>
   <result pre="and Jiangsu [9]. Other countries, such as Thailand [2, 10]," exact="Australia" post="[11] and Italy [12] have also reported CVA4 infections."/>
   <result pre="Other countries, such as Thailand [2, 10], Australia [11] and" exact="Italy" post="[12] have also reported CVA4 infections. Genetic recombination between"/>
   <result pre="of the inactivated EVA71 vaccine among children under five in" exact="China" post="[27, 28], it is conceivable that the EV-associated HFMD"/>
   <result pre="≤1.1%, the number of annual cases exceeds one million in" exact="China" post="[52]. Therefore, patients with HFMD should be treated with"/>
   <result pre="clinical features of hand, foot and mouth disease in northern" exact="Thailand" post="in 2016: a prospective cohort study. BMC Infect Dis."/>
   <result pre="ZhaoPSH, SridharS, et al.Molecular epidemiology of coxsackievirus A6 circulating in" exact="Hong Kong" post="reveals common neurological manifestations and emergence of novel recombinant"/>
   <result pre="al.The largest outbreak of hand; foot and mouth disease in" exact="Singapore" post="in 2008: the role of enterovirus 71 and coxsackievirus"/>
   <result pre="TaoZ, et al.Multiple transmission chains of coxsackievirus A4 co-circulating in" exact="China" post="and neighboring countries in recent years: phylogenetic and spatiotemporal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6819294/results/search/country/results.xml">
   <result pre="2019 Specialty type: Medicine, research and experimental Country of origin:" exact="China" post="Peer-review report classification Grade A (Excellent): 0 Grade B"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6821460/results/search/country/results.xml">
   <result pre="Schmidt-ChanasitJ., ImpoumaB., DialloA. K., FormentyP., Van HerpM., GüntherS., Emergence of" exact="Zaire" post="Ebola virus disease in Guinea. N. Engl. J. Med.371,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6831721/results/search/country/results.xml">
   <result pre="Diego, CAUnited States Edited by: Mariangela Bonizzoni, University of Pavia," exact="Italy" post="Reviewed by: Louis Lambrechts, Institut Pasteur, France; Michelle Marie"/>
   <result pre="Institut Pasteur, France; Michelle Marie Riehle, Medical College of Wisconsin," exact="United States" post="*Correspondence: John M. Marshall, john.marshall@berkeley.edu; Omar S. Akbari, oakbari@ucsd.edu"/>
   <result pre="world (Stanaway et al., 2016), Zika recently sweeping through Latin" exact="America" post="and the Caribbean (O’Reilly et al., 2018), and the"/>
   <result pre="affordability. Piperaquine was developed in the 1960s and used in" exact="China" post="and India for several years as a replacement for"/>
   <result pre="was developed in the 1960s and used in China and" exact="India" post="for several years as a replacement for chloroquine, which"/>
   <result pre="al., 2019), as seen in the 2005-2006 CHIKV outbreak in" exact="La Réunion" post="(Tsetsarkin et al., 2007). As the virus disseminates in"/>
   <result pre="2019), as seen in the 2005-2006 CHIKV outbreak in La" exact="Réunion" post="(Tsetsarkin et al., 2007). As the virus disseminates in"/>
   <result pre="acid substitution in the envelope glycoprotein. Proc. Natl. Acad. Sci." exact="U. S." post="A.101, 11344–11349. 10.1073/pnas.040290510115277679 BuchmanA.GamezS.LiM.AntoshechkinI.LeeS.-H.WangS.-W.et al. (2019a). Broad Dengue Neutralization"/>
   <result pre="(2015). Suppression of a Field Population of Aedes aegypti in" exact="Brazil" post="by Sustained Release of Transgenic Male Mosquitoes. PloS Negl."/>
   <result pre="vivo is constrained by host alternation. Proc. Natl. Acad. Sci." exact="U. S." post="A.105, 6970–6975. 10.1073/pnas.071213010518458341 CostaG. L.AmaralL. C.FontesC. J. F.CarvalhoL. H.de"/>
   <result pre="direct molecular test by using ribavirin. Proc. Natl. Acad. Sci." exact="U. S." post="A.98, 6895–6900. 10.1073/pnas.11108559811371613 DasA. T.BrummelkampT. R.WesterhoutE. M.VinkM.MadiredjoM.BernardsR.et al. (2004)."/>
   <result pre="2 in genetically modified Aedes aegypti. Proc. Natl. Acad. Sci." exact="U. S." post="A.103, 4198–4203. 10.1073/pnas.060047910316537508 FranzA. W. E.Sanchez-VargasI.RabanR. R.BlackW. C.JamesA. A.OlsonK."/>
   <result pre="the malaria vector mosquito Anopheles stephensi. Proc. Natl. Acad. Sci." exact="U. S." post="A.112, E6736–E6743. 10.1073/pnas.152107711226598698 GesaseS.GoslingR. D.HashimR.OrdR.NaidooI.MadebeR.et al. (2009). High resistance"/>
   <result pre="(2009). High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern" exact="Tanzania" post="and the emergence of dhps resistance mutation at Codon"/>
   <result pre="drug resistance by intensifying within-host competition. Proc. Natl. Acad. Sci." exact="U. S." post="A.114, 13774–13779. 10.1073/pnas.171587411529233945 WalkerP. G. T.GriffinJ. T.FergusonN. M.GhaniA. C."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6835697/results/search/country/results.xml">
   <result pre="algae Griffithsia sp. collected from waters off the shores of" exact="New Zealand." post="Researchers at the U.S. National Cancer Institute first reported"/>
   <result pre="measurable effect on cell viability and T-cell activation markers. [43]" exact="Guinea" post="pigBALB/c mice Single 50 mg/kg and 10 daily subcutaneous"/>
   <result pre="animal models. Models Used Dose Tested Effects of GRFT Ref." exact="Guinea" post="pigBALB/c mice Single 50 mg/kg and 10 daily subcutaneous"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6843332/results/search/country/results.xml">
   <result pre="the more common of the two viruses affecting 48% of" exact="the United States" post="population [87]. HHV-1 and HHV-2, however, are closely related,"/>
   <result pre="more common of the two viruses affecting 48% of the" exact="United States" post="population [87]. HHV-1 and HHV-2, however, are closely related,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6856223/results/search/country/results.xml">
   <result pre="de Santiago de ChileSantiagoChile Edited by: Banasri Hazra, Jadavpur University," exact="India" post="Reviewed by: Santhi Gorantla, University of Nebraska Medical Center,"/>
   <result pre="India Reviewed by: Santhi Gorantla, University of Nebraska Medical Center," exact="United States;" post="Mingze Qin, Shenyang Pharmaceutical University, China *Correspondence: Mohammad Hosein"/>
   <result pre="Nebraska Medical Center, United States; Mingze Qin, Shenyang Pharmaceutical University," exact="China" post="*Correspondence: Mohammad Hosein Farzaei, mh.farzaei@gmail.com; Javier Echeverria, javier.echeverriam@usach.cl This"/>
   <result pre="Anthocyanins: How to Overcome? The daily use of anthocyanins in" exact="the USA" post="is estimated about 200 mg/day (Wang and Stoner, 2008)."/>
   <result pre="of two extracts of the blackcurrant (Ribes nigrum L.) from" exact="New Zealand" post="and Poland. Fukushima J. Med. Sci.59 (1), 35–38. 10.5387/fms.59.3523842512"/>
   <result pre="antiviral and anti-leukemia terpene hydroquinones and methods of use. US5204367A," exact="United States," post="Google Patents. WuH.-Y.YangK.-M.ChiangP.-Y. (2018). Roselle anthocyanins: antioxidant properties and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6868923/results/search/country/results.xml">
   <result pre="Abstract Marcetia taxifolia is a neotropical plant present in South" exact="America" post="and it has been evaluated in several biological models"/>
   <result pre="et al., 2013[32]). Marcetia is a Neotropical genus distributed from" exact="Venezuela" post="to Uruguay (Berry and Luckana, 2001[4]). Baptista et al."/>
   <result pre="2013[32]). Marcetia is a Neotropical genus distributed from Venezuela to" exact="Uruguay" post="(Berry and Luckana, 2001[4]). Baptista et al. (2016[3]) described"/>
   <result pre="Virología Molecular, Caracas, Venezuela, and UNU Biotechnology Program for Latin" exact="America" post="and the Caribbean UNU-BIOLAC to OJT, FP and RC."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6882434/results/search/country/results.xml">
   <result pre="Mi-Sun Kim shfwk31@ewha.ac.krDepartment of Pharmacy, Ewha W. University, Seoul 03760," exact="Republic of" post="Korea Dong Hae Shin dhshin55@ewha.ac.krDepartment of Pharmacy, Ewha W."/>
   <result pre="Hae Shin dhshin55@ewha.ac.krDepartment of Pharmacy, Ewha W. University, Seoul 03760," exact="Republic of" post="Korea collection: 2020epub: 2019-11-11351145151received: 2019-8-26rev-recd: 2019-10-27accepted: 2019-10-29(C) The Author(s),"/>
   <result pre="grant granted by the Ministry of Education, Science and Technology," exact="Republic of" post="Korea (MEST). S. Jo was supported by Brain Korea"/>
   <result pre="spread of causal agent of severe acute respiratory syndrome in" exact="Hong Kong." post="Lancet2003;361:1761–6.12781533 6LiW, ShiZ, YuM, et al.Bats are natural reservoirs"/>
   <result pre="SARS-like coronaviruses. Science2005;310:676–9.16195424 7LauJT, YangX, PangE, et al.SARS-related perceptions in" exact="Hong Kong." post="Emerg Infect Dis2005;11:417–24.15757557 8RenZ, YanL, ZhangN, et al.The newly"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6886132/results/search/country/results.xml">
   <result pre="10.4103/ijmr.IJMR_2034_18 : Perspective Influenza pandemic preparedness: A special challenge for" exact="India" post="FedsonDavid S.[], davidsfedson@gmail.comppub: 2019-91503217220received: 2018-11-05(C) , 2019This is an"/>
   <result pre="to have killed 50-100 million people worldwide1. Its impact in" exact="India" post="was especially severe; 10-20 million people may have died23."/>
   <result pre="and angiotensin receptor blockers (ARBs). During the Ebola outbreak in" exact="Sierra Leone" post="in 2014, combination treatment with these two drugs apparently"/>
   <result pre="induced by avian influenza A H5N1 virus infection in mouseSci" exact="China" post="Life Sci2015582081125655897 24HungIFNToKKWChanJFWChengVCCLiuKSHTamAet al.Efficacy of clarithromycin-naproxen-oseltamivir combination in the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6889349/results/search/country/results.xml">
   <result pre="strains of extremophilic actinomycetes isolated from the unique ecosystems of" exact="Kazakhstan" post="were extracted and tested for antiviral activity against influenza"/>
   <result pre="extracts from strains that were isolated from extreme environments in" exact="Kazakhstan" post="against the influenza viruses (strains H7N1, H5N3, H1N1, H3N2)"/>
   <result pre="strains of extremophilic actinomycetes isolated from the unique ecosystems of" exact="Kazakhstan" post="were selected: these are strains K-192, K-340, K-362, K-522,"/>
   <result pre="deserts, solonchaks, and forests in Almaty and Kostanay regions of" exact="Kazakhstan" post="(Table 1). Table 1 Characteristics of collection site of"/>
   <result pre="study reported active antiviral activity of 27 plant extracts from" exact="Nigeria" post="against 3 serotypes of echoviruses which suggested the significance"/>
   <result pre="Bevins SN. A review of virulent Newcastle disease viruses in" exact="the United States" post="and the role of wild birds in viral persistence"/>
   <result pre="SN. A review of virulent Newcastle disease viruses in the" exact="United States" post="and the role of wild birds in viral persistence"/>
   <result pre="vitro antiviral activity of twenty-seven medicinal plant extracts from Southwest" exact="Nigeria" post="against three serotypes of echoviruses. Virol J. 2018; 10.1186/s12985-018-1022-7."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6898960/results/search/country/results.xml">
   <result pre="Anti-HSV drugs Mitoxantrone dihydrochloride Funding http://dx.doi.org/10.13039/501100001809National Natural Science Foundation of" exact="China" post="81701213YangPeng Background Herpes simplex virus-1 (henceforth HSV-1) is a"/>
   <result pre="We would like to express our gratitude to the professor" exact="Sudan" post="He for experimental design and data analysis. The abstract"/>
   <result pre="work was supported by the National Natural Science Foundation of" exact="China" post="[81701213]. None of the funding bodies was involved in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6901432/results/search/country/results.xml">
   <result pre="am MainGermany Edited by: Michael Nevels, University of St Andrews," exact="United Kingdom" post="Reviewed by: Junji Xing, Houston Methodist Research Institute, United"/>
   <result pre="United Kingdom Reviewed by: Junji Xing, Houston Methodist Research Institute," exact="United States;" post="Oliver H. Krämer, Johannes Gutenberg University Mainz, Germany *Correspondence:"/>
   <result pre="Institute, United States; Oliver H. Krämer, Johannes Gutenberg University Mainz," exact="Germany" post="*Correspondence: Jindrich Cinatl Jr., Cinatl@em.uni-frankfurt.de This article was submitted"/>
   <result pre="Vignuzzi, 2014; Koh and Liang, 2014; Galli et al., 2018;" exact="Jordan" post="et al., 2018; Keppeke et al., 2019). Our findings"/>
   <result pre="Germany), omeprazole from AstraZeneca (Wedel, Germany), ribavirin from Valeant Pharmaceuticals" exact="Germany" post="GmbH (Eschborn, Germany), and pantoprazole, rabeprazole, lansoprazole, and dexlansoprazole"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6907871/results/search/country/results.xml">
   <result pre="Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas," exact="United States" post="of America[2], Departments of Diagnostic Sciences, School of Dentistry,"/>
   <result pre="Dentistry, Louisiana State University Health Sciences Center, New Orleans, Louisiana," exact="United States" post="of America[3], State Key Laboratory of Virology, Wuhan Institute"/>
   <result pre="Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas," exact="United States" post="of America[5], Guangdong Key Laboratory of Virology, Institute of"/>
   <result pre="protein function. Proceedings of the National Academy of Sciences of" exact="the United States" post="of America113: 3609–3614. 10.1073/pnas.152368611326976570 37ThieulentCJ, HueES, FortierCI, DallemagneP, ZientaraS,"/>
   <result pre="function. Proceedings of the National Academy of Sciences of the" exact="United States" post="of America113: 3609–3614. 10.1073/pnas.152368611326976570 37ThieulentCJ, HueES, FortierCI, DallemagneP, ZientaraS,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6961902/results/search/country/results.xml">
   <result pre="work was funded by the National Natural Science Foundation of" exact="China" post="(Research on modernization of traditional Chinese Medicine: Major Research"/>
   <result pre="mo 12 mo 0 ①② Bhimma et al[18] 2002 Durban," exact="South Africa" post="CCT 8.9 M:34 F:5 IFN-α2b (10 million units/m2 3"/>
   <result pre="16 weeks 40 weeks 5 ①②③ Tang et al[19] 2005" exact="Hong Kong," post="China CCT 45.5±19.0 M:14 F:8 LAM 100mg/d+ACEI or ARB"/>
   <result pre="40 weeks 5 ①②③ Tang et al[19] 2005 Hong Kong," exact="China" post="CCT 45.5±19.0 M:14 F:8 LAM 100mg/d+ACEI or ARB (n"/>
   <result pre="12) NA 49.2±16.5 mo 0 ①③ Panomsak et al[20] 2006" exact="Thailand" post="CCT 40.9 M:10 F:7 1 month of prednisone, then"/>
   <result pre="mean 87 mo (8–187) 1 ① Lai et al[22] 1991" exact="Hong Kong," post="China CCT 30 M:14 F:2 IFN-α2b (3 million units,"/>
   <result pre="mo (8–187) 1 ① Lai et al[22] 1991 Hong Kong," exact="China" post="CCT 30 M:14 F:2 IFN-α2b (3 million units, 3"/>
   <result pre="weeks 55.1 mo 0 ①②③ Lin et al[23] 1995 Taiwan," exact="China" post="RCT 6.5±3.3 M:29 F:11 IFN-α2b (5μ if body weight&amp;lt;20"/>
   <result pre="pathological data of renal biopsy at one single center in" exact="China" post="from 1987 to 2012. Chin Med J (Engl.). 2014;127(9):1715–1720.24791880"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6963304/results/search/country/results.xml">
   <result pre="subfamily [5,6]. PR has been eradicated in several countries including" exact="the USA," post="New Zealand, and many European countries. However, PRV is"/>
   <result pre="PR has been eradicated in several countries including the USA," exact="New Zealand," post="and many European countries. However, PRV is still in"/>
   <result pre="Highly pathogenic PRV variants emerged in several pig farms in" exact="China" post="in late 2011 [7,8]. In previous reports, we analyzed"/>
   <result pre="We previously reported that variant PRV forms and recombination in" exact="China" post="could be the source of continued epidemics [9,10]. So"/>
   <result pre="decade, a number of novel viruses emerged in pigs in" exact="China" post="and caused huge economic losses [28,29]. As one of"/>
   <result pre="A case of suspected PRV infection in humans occurred in" exact="China" post="in 2017. The patient presented with fever, headaches, and"/>
   <result pre="supported by the National Key Research and Development Program of" exact="China" post="(2016YFD0500402) and the Fundamental Research Funds for the Central"/>
   <result pre="al.Genome Characteristics and Evolution of Pseudorabies Virus Strains in Eastern" exact="China" post="from 2017 to 2019Virol. Sin.201910.1007/s12250-019-00140-1 10.HeW.AuclertL.Z.ZhaiX.WongG.ZhangC.ZhuH.XingG.WangS.HeW.LiK.et al.Interspecies Transmission, Genetic"/>
   <result pre="of germacrone on feline calicivirusArch. Virol.20161611559156710.1007/s00705-016-2825-826997613 23.WangX.WuC.X.SongX.R.ChenH.C.LiuZ.F.Comparison of pseudorabies virus" exact="China" post="reference strain with emerging variants reveals independent virus evolution"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6963560/results/search/country/results.xml">
   <result pre="of Liver Diseases (AASLD) and the Infectious Diseases Society of" exact="America" post="(IDSA) have issued clinical guidelines in order to recommend"/>
   <result pre="Study of Liver Diseases (AASLD) and Infectious Disease Society of" exact="America" post="(IDSA)HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6968485/results/search/country/results.xml">
   <result pre="Medical UniversityPR China[b], The Second Hospital of Hebei Medical UniversityPR" exact="China" post="Supplemental data for this article can be accessed here."/>
   <result pre="Zhang 777yyy@sina.cnThe Second Hospital of Hebei Medical University, Shijiazhuang, 050000," exact="PR China" post="collection: 2020epub: 2020-1-1271137150received: 2019-10-28rev-recd: 2019-12-18accepted: 2019-12-24(C) The Author(s), 2020This"/>
   <result pre="777yyy@sina.cnThe Second Hospital of Hebei Medical University, Shijiazhuang, 050000, PR" exact="China" post="collection: 2020epub: 2020-1-1271137150received: 2019-10-28rev-recd: 2019-12-18accepted: 2019-12-24(C) The Author(s), 2020This"/>
   <result pre="was financially supported by the National Natural Science Foundation of" exact="China" post="[No. 81473180]. fig-count: table-count: page-count: word-count: 1. Introduction Ginkgo"/>
   <result pre="forced Ginkgo biloba L. (Ginkgoaceae) into two refuge areas in" exact="China" post="with limited subsequent postglacial expansion. Mol Phylogenet Evol48:1094–105.18554931 GuoX,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6968529/results/search/country/results.xml">
   <result pre="University of Traditional Chinese Medicine, 528 Zhangheng Road, Shanghai 201203," exact="China" post="collection: 2020epub: 2019-12-1258117received: 2018-9-17rev-recd: 2019-5-22accepted: 2019-10-26(C) The Author(s), 2019This"/>
   <result pre="Technology Major Project (2018ZX09737-010), the National Natural Science Foundation of" exact="China" post="(81730109), Programme for Outstanding Medical Academic Leader of Shanghai"/>
   <result pre="Huayu recipe (FZHY) is an anti-fibrotic agent approved by the" exact="China" post="Food and Drug Administration (CFDA), and has been used"/>
   <result pre="Huayu capsule for treating hepatic fibrosis in chronic hepatitis B." exact="China" post="Pharm. 8:77. WangL, SweetDH2013Competitive inhibition of human organic anion"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6970260/results/search/country/results.xml">
   <result pre="Drug Handbook by Ashley and Dunleavy.7 Only drugs registered in" exact="Poland" post="were assessed. The list of drugs and recommendations for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6977371/results/search/country/results.xml">
   <result pre="Peter Doherty Institute for Infection &amp;amp; Immunity, Melbourne VIC 3000," exact="Australia" post="For correspondence: Dr Shailesh D. Pawar, ICMR-National Institute of"/>
   <result pre="Institute Compound, Acharya Donde Marg, Parel, Mumbai 400 012, Maharashtra," exact="India" post="e-mail: shaileshpawarniv@gmail.com ppub: 2019-111505486491received: 2018-5-03(C) , 2019This is an"/>
   <result pre="HPAI H5N1 viruses. Methods: Two HPAI H5N1 viruses isolated from" exact="India" post="were used in the study. Fluorescence-based NAI assay was"/>
   <result pre="has caused &amp;gt;159 outbreaks in poultry in different parts of" exact="India" post="since 2006, with the most recent outbreaks in Odisha"/>
   <result pre="and prophylaxis of influenza4; peramivir is licensed for use in" exact="the United States" post="of America5. Recently resistance to the NAIs oseltamivir and"/>
   <result pre="prophylaxis of influenza4; peramivir is licensed for use in the" exact="United States" post="of America5. Recently resistance to the NAIs oseltamivir and"/>
   <result pre="were isolated from outbreaks of HPAI H5N1 in poultry from" exact="the States" post="of Maharashtra and Tripura, India, respectively. The following amino"/>
   <result pre="Influenza and High Containment Laboratory, ICMR-National Institute of Virology, Pune," exact="India" post="from December 2015 to October 2016. Fluorescence-based neuraminidase inhibitor"/>
   <result pre="pathogenic influenza A (H5N1) viruses isolated from avian species in" exact="India" post="(2006-2015)Antiviral Res2018158143630125616 7OhDYHurtACA review of the antiviral susceptibility of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6982783/results/search/country/results.xml">
   <result pre="indigotica Fort is a very famous antiviral traditional medicine in" exact="China" post="and is called Radix Isatidis (Banlangen in Chinese); during"/>
   <result pre="used to treat the patients with chronic hepatitis B in" exact="China" post="[80]. Rubrifloralignan A was isolated from another species of"/>
   <result pre="Province (Grant No. 2017CXGC1309); (3) Shandong Provincial Natural Science Foundation," exact="China" post="(Grant No. ZR2019MH078). Conflicts of Interest The authors declare"/>
   <result pre="Podophyllum peltatum (Berberidaceae) Roots and stems Papilloma virus Launched in" exact="China" post="waiting for the deeper research [3,11,56,57,58] Substituted tetrahydrofurans lariciresinol-4-O-β-"/>
   <result pre="Analogue of schizandrin C from Fructus Schiznadrae HBV Launched in" exact="China" post="inhibit virus replication in patients infected with HBV [76,77,78,79,80]"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6987146/results/search/country/results.xml">
   <result pre="München - Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH, Neuherber," exact="Germany" post="Funding Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit"/>
   <result pre="München - Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH, Neuherberg," exact="Germany" post="Introduction With over 37 million individuals globally living with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6996547/results/search/country/results.xml">
   <result pre="Animal Epidemiology of Ministry of Agriculture, College of Veterinary Medicine," exact="China" post="Agricultural UniversityBeijing100193People’s Republic of China[2], Key Laboratory of Veterinary"/>
   <result pre="Ministry of Agriculture, College of Veterinary Medicine, China Agricultural UniversityBeijing100193People’s" exact="Republic of" post="China[2], Key Laboratory of Veterinary Bioproduction and Chemical Medicine"/>
   <result pre="Chemical Medicine of the Ministry of Agriculture, Zhongmu Institutes of" exact="China" post="Animal Husbandry Industry Co., LtdBeijingPeople’s Republic of China[3], National"/>
   <result pre="Agriculture, Zhongmu Institutes of China Animal Husbandry Industry Co., LtdBeijingPeople’s" exact="Republic of" post="China[3], National Institute for Viral Disease Control and Prevention,"/>
   <result pre="Laboratory for Medical Virology, National Health and Family Planning CommissionBeijingPeople’s" exact="Republic of" post="China[4], Laboratory of Veterinary Pathology and Public Health, College"/>
   <result pre="of Veterinary Pathology and Public Health, College of Veterinary Medicine," exact="China" post="Agricultural UniversityBeijing100193People’s Republic of China Correspondence: Yanxin Hu Email"/>
   <result pre="and Public Health, College of Veterinary Medicine, China Agricultural UniversityBeijing100193People’s" exact="Republic of" post="China Correspondence: Yanxin Hu Email 07033@cau.edu.cn Tianlong Liu Email"/>
   <result pre="Health, College of Veterinary Medicine, China Agricultural UniversityBeijing100193People’s Republic of" exact="China" post="Correspondence: Yanxin Hu Email 07033@cau.edu.cn Tianlong Liu Email liutianlong@cau.edu.cn"/>
   <result pre="Animal experiments were approved by the Animal Ethics Committee of" exact="China" post="Agricultural University (approval number 201206078) in accordance with the"/>
   <result pre="epidemic of highly pathogenic avian influenza virus H5N1 occurred in" exact="Hong Kong." post="Since then, it has become well known for its"/>
   <result pre="acknowledge financial supports from the National Natural Science Foundation of" exact="China" post="(Grant no. 31772702), the Chinese Universities Scientific Fund (Grant"/>
   <result pre="no. 2018TC044) and the National Twelve-five Technological Supported Plan of" exact="China" post="(Grant no: 2015BAD12B01). The English in this document has"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC6998849/results/search/country/results.xml">
   <result pre="Animal Disease, Ministry of Science and Technology of the People’s" exact="Republic of" post="China, epub: 2020-2-2pmc-release: 2020-2-2collection: 20201718received: 2019-10-16accepted: 2020-1-20(C) , Open"/>
   <result pre="ganglioneuritis in pigs [15]. The Bartha-k61 vaccine was brought to" exact="China" post="from Hungary in the 1970s to prevent PRV infection,"/>
   <result pre="pigs [15]. The Bartha-k61 vaccine was brought to China from" exact="Hungary" post="in the 1970s to prevent PRV infection, which has"/>
   <result pre="Bartha-K61-vaccinated pigs have resulted in resurgence of PRV prevalence in" exact="China" post="since late 2011 [17]. In China, with the infection"/>
   <result pre="This study was founded by the National Transgenic Project of" exact="China" post="(Grant No. 2016ZX08006003–004), National Key R &amp;amp; D Program"/>
   <result pre="(Grant No. 2016ZX08006003–004), National Key R &amp;amp; D Program of" exact="China" post="(Grant No. 2017YFD0500201), and Hubei Province Natural Science Foundation"/>
   <result pre="a hunting dog infected by biting a wild boar in" exact="Japan" post="and its pathogenicity in a mouse modelVirus Genes20195532233110.1007/s11262-019-01659-x30919175 39.YangXZhouTYuLTanWZhouRHuYA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7000641/results/search/country/results.xml">
   <result pre="the hepatitis A virus and hepatitis B virus compared with" exact="the United States" post="and Western Europe. Thus, members of IBD research group"/>
   <result pre="hepatitis A virus and hepatitis B virus compared with the" exact="United States" post="and Western Europe. Thus, members of IBD research group"/>
   <result pre="for the HAV, while HBV shows moderate prevalence compared with" exact="United States" post="and Western Europe. Thus, members of the IBD research"/>
   <result pre="immunization of children. In areas of low endemicity (such as" exact="the United States" post="and Western Europe), infection is less frequent, but the"/>
   <result pre="of children. In areas of low endemicity (such as the" exact="United States" post="and Western Europe), infection is less frequent, but the"/>
   <result pre="and Prevention and the Advisory Committee on Immunization Practices of" exact="the United States" post="Centers for Disease Control and Prevention, recommend protection (ideally"/>
   <result pre="Prevention and the Advisory Committee on Immunization Practices of the" exact="United States" post="Centers for Disease Control and Prevention, recommend protection (ideally"/>
   <result pre="Western Europe, etc.), 2%–7% in those with moderate prevalence (e.g.," exact="South Korea," post="Mediterranean countries, Japan, Central Asia, Middle East, and parts"/>
   <result pre="South America), and more than 8% in West Africa and" exact="South Sudan," post="which have the highest prevalence rates [37,38]. In Korea,"/>
   <result pre="is not high [53,57], according to a study conducted in" exact="Spain" post="involving more than 2,000 patients with IBD, only 12%"/>
   <result pre="Infect Dis2007741041917521594 55MereckieneJCotterSLopalcoPet al.Hepatitis B immunisation programmes in European Union," exact="Norway" post="and Iceland: where we were in 2009?Vaccine2010284470447720451643 56collab: WHO"/>
   <result pre="traditional and biologic disease- modifying antirheumatic drugs: part II safety" exact="Canada" post="The Journal of Rheumatology 2012 39/1583-1602 van Assen et"/>
   <result pre="Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases" exact="Swiss" post="Swiss Medical Weekly 2015 145/W14159 Cordeiro et al. [16]"/>
   <result pre="recommendations for adult patients with autoimmune inflammatory rheumatic diseases Swiss" exact="Swiss" post="Medical Weekly 2015 145/W14159 Cordeiro et al. [16] Recommendations"/>
   <result pre="systemic inflammatory rheumatic diseases from the Portuguese Society of Rheumatology" exact="Portugal" post="Acta Reumatológica Portuguesa 2016 41/112-130 ACG, American College of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7002824/results/search/country/results.xml">
   <result pre="Tonka beans in 1820 independently by A. Vogel of Munich," exact="Germany" post="and by Nicholas Guibourt of France [21]. William Henry"/>
   <result pre="A. Vogel of Munich, Germany and by Nicholas Guibourt of" exact="France" post="[21]. William Henry Perkin, an English chemist first synthesized"/>
   <result pre="effects, and complicationsGut5520061350135916905701 31LyT.PermanenteK.CaliforniaN.DermatolA.A.TineaM.S.GesD.D.ManagementG.R.CosmetC.DermatolI.ScH.TineaB.J.JsM.InfectE.LmD.BgR.KhR.ControlI.EpidemiolH.PcS.RcS.JournalB.Cutaneous side-effects of antihepatitis C treatment;: the" exact="U. K." post="experienceBr. J. Dermatol.201420142015 32HenryB.Drug pricing &amp;amp; challenges to hepatitis"/>
   <result pre="Avian Influenza A (H5N1) Reported to WHO, 2003-20192019World Health OrganizationGeneva," exact="Switzerland" post="82World Health OrganizationUp to 650 000 people die of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7004585/results/search/country/results.xml">
   <result pre="Medicine, Chengdu University of Traditional Chinese Medicine, 610075, Sichuan Province," exact="China" post="(e-mail: zhangqi@cdutcm.edu.cn). collection: 2020-1epub: 2020-1-1995e18898received: 2019-12-20accepted: 2019-12-24(C) , 2020This"/>
   <result pre="EMBASE, Web of Science, The Cochrane Library, Chinese Biomedical Database," exact="China" post="National Knowledge Infrastructure, Chongqing VIP, Wangfang Data. Literature screening"/>
   <result pre="EMBASE, Web of Science, The Cochrane Library, Chinese Biomedical Database," exact="China" post="National Knowledge Infrastructure, Chongqing VIP, Wangfang Data. Medical subject"/>
   <result pre="work is supported by the National Natural Science Foundation of" exact="China" post="(No. 81873222). The authors have no conflicts of interest"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7010657/results/search/country/results.xml">
   <result pre="authors are thankful to DBT (Department of Biotechnology)-eLibrary Consortium (DeLCON)," exact="India" post="for providing access to e-resources. The authors are also"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7013637/results/search/country/results.xml">
   <result pre="of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in" exact="Germany" post="RungeMelanie1KrenselMagdalene2https://orcid.org/0000-0003-3442-8382WestermannClaudia1*BindlDominik3NagelsKlaus3https://orcid.org/0000-0002-4026-8728AugustinMatthias2NienhausAlbert14[1], melanierunge1994@gmail.comalbert.nienhaus@bgw-online.de[2], m.krensel@uke.dem.augustin@uke.de[3], dominik.bindl@uni-bayreuth.deklaus.nagels@uni-bayreuth.de[4], *Correspondence: c.westermann@uke.de epub: 2020-1-1ppub: 2020-1172440received:"/>
   <result pre="HP for whom an occupational CHC infection was recognised in" exact="Germany" post="between 2000 and 2017. The data records contain sociodemographic"/>
   <result pre="cost effectiveness of DAAs in an international comparison, however for" exact="Germany" post="there are as yet only a small number. In"/>
   <result pre="were measured using the SVR12 rate in a CEA from" exact="Germany" post="[43]; Giesel et al. calculated an ICER of €1560.13"/>
   <result pre="comprising both treatment-naive patients and patients with treatment experience from" exact="the USA." post="SOF-based therapies exhibited cost effectiveness with an ICER of"/>
   <result pre="occupational disease reports for HP from non-governmental health institutions in" exact="Germany" post="are taken into account. Health care systems, supply structures,"/>
   <result pre="cirrhosis. A study of 200 patientsJ. Hepatol.20044082383010.1016/j.jhep.2004.01.00515094231 38.ThuluvathP.J.GuidingerM.K.FungJ.J.JohnsonL.B.RayhillS.C.PelletierS.J.Liver transplantation in" exact="the United States," post="1999–2008Am. J. Transpl.2010101003101910.1111/j.1600-6143.2010.03037.x20420649 39.DavisG.L.AlterM.J.El-SeragH.PoynardT.JenningsL.W.Aging of hepatitis C virus (HCV)-infected"/>
   <result pre="A study of 200 patientsJ. Hepatol.20044082383010.1016/j.jhep.2004.01.00515094231 38.ThuluvathP.J.GuidingerM.K.FungJ.J.JohnsonL.B.RayhillS.C.PelletierS.J.Liver transplantation in the" exact="United States," post="1999–2008Am. J. Transpl.2010101003101910.1111/j.1600-6143.2010.03037.x20420649 39.DavisG.L.AlterM.J.El-SeragH.PoynardT.JenningsL.W.Aging of hepatitis C virus (HCV)-infected"/>
   <result pre="analysis modelLiver Transpl.20101674875910.1002/lt.2207220517909 42.WolfeR.A.RoysE.C.MerionR.M.Trends in organ donation and transplantation in" exact="the United States," post="1999–2008Am. J. Transpl.20101096197210.1111/j.1600-6143.2010.03021.x 43.GisselC.GötzG.MahlichJ.ReppH.Cost-effectiveness of Interferon-free therapy for Hepatitis"/>
   <result pre="modelLiver Transpl.20101674875910.1002/lt.2207220517909 42.WolfeR.A.RoysE.C.MerionR.M.Trends in organ donation and transplantation in the" exact="United States," post="1999–2008Am. J. Transpl.20101096197210.1111/j.1600-6143.2010.03021.x 43.GisselC.GötzG.MahlichJ.ReppH.Cost-effectiveness of Interferon-free therapy for Hepatitis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7016805/results/search/country/results.xml">
   <result pre="supplemented with 5% CO2 [29]. Viral stocks of DENV-2 (New" exact="Guinea" post="C; M29095) were propagated in C6/36 cells [30], and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7019229/results/search/country/results.xml">
   <result pre="60,000 neonates born every year with congenital HCMV infection in" exact="the United States" post="and the European Union combined [30,31,32,33]. Since congenital HCMV"/>
   <result pre="neonates born every year with congenital HCMV infection in the" exact="United States" post="and the European Union combined [30,31,32,33]. Since congenital HCMV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7019738/results/search/country/results.xml">
   <result pre="is a novel antiviral drug which has been approved by" exact="the USA" post="Food and Drug Administration (FDA) through a fast track"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7019903/results/search/country/results.xml">
   <result pre="vitro and in vivo activity on hantavirus replication [8,9]. In" exact="China" post="[10] and Russia [11], clinical trials have been conducted"/>
   <result pre="vivo activity on hantavirus replication [8,9]. In China [10] and" exact="Russia" post="[11], clinical trials have been conducted for the treatment"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7022795/results/search/country/results.xml">
   <result pre="transplant recipients, but although the recruitment of 20 patients in" exact="Israel" post="has been completed, no results are available yet (Table"/>
   <result pre="AS was given in association with IFN [57]. Interestingly, in" exact="the USA," post="an open-label study is currently investigating a novel nonsurgical"/>
   <result pre="combination, Coartem®, was used in a prospective observational study in" exact="Mali" post="in children (6 months–10 years) coinfected with HCMV and"/>
   <result pre="for the treatment of CHIKV infection in 2006 in French" exact="Reunion" post="Island (Indian Ocean). No significant difference was observed between"/>
   <result pre="the treatment of CHIKV infection in 2006 in French Reunion" exact="Island" post="(Indian Ocean). No significant difference was observed between the"/>
   <result pre="MRC-5 cells. In contrast, the administration of CQ to 12" exact="Guinea" post="pigs did not protect the infected animals against the"/>
   <result pre="CQ prophylaxis compared to no prophylaxis in HIV-positive patients in" exact="Malawi" post="(Table 1) [44,45]. Chloroquine and Hydroxychloroquine and Other RNA"/>
   <result pre="compared to that of placebo on IAV was started in" exact="Singapore" post="in 2005, and 1516 patients were recruited. However, CQ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7025587/results/search/country/results.xml">
   <result pre="Sapienza University of RomeRomeItaly Edited by: Yong Teng, Augusta University," exact="United States" post="Reviewed by: Binod Kumar, Loyola University Chicago, United States;"/>
   <result pre="University, United States Reviewed by: Binod Kumar, Loyola University Chicago," exact="United States;" post="Mariane De Montalembert, Necker-Enfants Malades Hospital, France *Correspondence: Roberta"/>
   <result pre="University Chicago, United States; Mariane De Montalembert, Necker-Enfants Malades Hospital," exact="France" post="*Correspondence: Roberta Risoluti roberta.risoluti@uniroma1.it This article was submitted to"/>
   <result pre="several studies from different population of thalassemic patients (United States," exact="Italy" post="and Greece) the prevalence of cirrhosis ranged from 10"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7026011/results/search/country/results.xml">
   <result pre="de ConcepciónConcepciónChile Edited by: Michael Nevels, University of St Andrews," exact="United Kingdom" post="Reviewed by: David Leib, Dartmouth College, United States; Guangdi"/>
   <result pre="St Andrews, United Kingdom Reviewed by: David Leib, Dartmouth College," exact="United States;" post="Guangdi Li, Central South University, China *Correspondence: Pablo A."/>
   <result pre="Leib, Dartmouth College, United States; Guangdi Li, Central South University," exact="China" post="*Correspondence: Pablo A. González, pagonzalez@bio.puc.cl This article was submitted"/>
   <result pre="Treister and Woo, 2010 Benzalkonium chloride Virucidal Alkylamine Stand-by in" exact="the United States" post="Taylor-Robinson and Ballard, 2001 Idoxuridine Inhibitor of viral DNA"/>
   <result pre="and Woo, 2010 Benzalkonium chloride Virucidal Alkylamine Stand-by in the" exact="United States" post="Taylor-Robinson and Ballard, 2001 Idoxuridine Inhibitor of viral DNA"/>
   <result pre="common used topical antiviral for this type of affection in" exact="the United States" post="(Chou and Hong, 2014), with considerable effectivity reported (Wilhelmus,"/>
   <result pre="used topical antiviral for this type of affection in the" exact="United States" post="(Chou and Hong, 2014), with considerable effectivity reported (Wilhelmus,"/>
   <result pre="al., 2012; Hassan et al., 2015). A study performed in" exact="Brazil" post="analyzed more than 36 species of algae from its"/>
   <result pre="the brown alga Sargassum henslowianum, a species found in southeastern" exact="China" post="and Asia (Sun et al., 2019). In this work,"/>
   <result pre="2015). Aqueous and hydroalcoholic extracts derived from native plants of" exact="Chile" post="have also been investigated for their antiviral activity against"/>
   <result pre="favor their progress into the clinic in countries such as" exact="the United States," post="as botanical drugs that are marketed in this country"/>
   <result pre="their progress into the clinic in countries such as the" exact="United States," post="as botanical drugs that are marketed in this country"/>
   <result pre="DinhT. H.DunneE. F.MarkowitzL. E.WeinstockH.BermanS. (2008). Assessing neonatal herpes reporting in" exact="the United States," post="2000-2005.Sex Transm. Dis.3519–21. 10.1097/olq.0b013e318162c4c618157062 DoiY.NinomiyaT.HataJ.YonemotoK.TanizakiY.ArimaH.et al. (2009). Seroprevalence of"/>
   <result pre="H.DunneE. F.MarkowitzL. E.WeinstockH.BermanS. (2008). Assessing neonatal herpes reporting in the" exact="United States," post="2000-2005.Sex Transm. Dis.3519–21. 10.1097/olq.0b013e318162c4c618157062 DoiY.NinomiyaT.HataJ.YonemotoK.TanizakiY.ArimaH.et al. (2009). Seroprevalence of"/>
   <result pre="O.LeeF. K.et al. (1997). Herpes simplex virus type 2 in" exact="the United States," post="1976 to 1994.N. Engl. J. Med.3371105–1111. 9329932 GanjhuR. K.MudgalP."/>
   <result pre="K.et al. (1997). Herpes simplex virus type 2 in the" exact="United States," post="1976 to 1994.N. Engl. J. Med.3371105–1111. 9329932 GanjhuR. K.MudgalP."/>
   <result pre="seroprevalence and trends in herpes simplex virus type 1 in" exact="the United States," post="1976-1994.Sex Transm. Dis.31753–760. 10.1097/01.olq.0000145852.43262.c315608591 SchnitzlerP.SchönK.ReichlingJ. (2001). Antiviral activity of"/>
   <result pre="and trends in herpes simplex virus type 1 in the" exact="United States," post="1976-1994.Sex Transm. Dis.31753–760. 10.1097/01.olq.0000145852.43262.c315608591 SchnitzlerP.SchönK.ReichlingJ. (2001). Antiviral activity of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7026129/results/search/country/results.xml">
   <result pre="Edited by: Lijun Rong, The University of Illinois at Chicago," exact="United States" post="Reviewed by: Takashi Irie, Hiroshima University, Japan; Alexander Freiberg,"/>
   <result pre="Alexander Freiberg, The University of Texas Medical Branch at Galveston," exact="United States" post="*Correspondence: Masayuki Saijo msaijo@nih.go.jp This article was submitted to"/>
   <result pre="trials evaluating the efficacy of favipiravir in SFTS patients in" exact="Japan" post="are underway, this has yet to be confirmed. Other"/>
   <result pre="antiviral ribavirin favipiravir Funding Ministry of Health, Labour and Welfare10.13039/501100003478H25-Shinko-Shitei-009" exact="Japan" post="Agency for Medical Research and Development10.13039/10000961916fk0108002j17fk0108202j18fk0108002j19fk0108072j19fk0108081j fig-count: table-count: equation-count:"/>
   <result pre="and multiorgan dysfunction in Hubei and Henan provinces in Central" exact="China" post="(Yu et al., 2011). Subsequently, the virus was isolated"/>
   <result pre="2011). Subsequently, the virus was isolated from sick patients in" exact="Japan" post="and South Korea, indicating that SFTSV was endemic not"/>
   <result pre="the virus was isolated from sick patients in Japan and" exact="South Korea," post="indicating that SFTSV was endemic not only to China,"/>
   <result pre="SFTSV was endemic not only to China, but also to" exact="South Korea" post="and Japan (Kim et al., 2013; Takahashi et al.,"/>
   <result pre="not only to China, but also to South Korea and" exact="Japan" post="(Kim et al., 2013; Takahashi et al., 2014). In"/>
   <result pre="In addition, recent studies have reported SFTS as endemic to" exact="Vietnam" post="(Tran et al., 2019) and Xinjiang, China (Zhu et"/>
   <result pre="as endemic to Vietnam (Tran et al., 2019) and Xinjiang," exact="China" post="(Zhu et al., 2019), indicating that the distribution of"/>
   <result pre="SFTS is found to vary between 6 and 30% in" exact="Japan" post="and South Korea, with a fatality rate of approximately"/>
   <result pre="found to vary between 6 and 30% in Japan and" exact="South Korea," post="with a fatality rate of approximately 30% (Choi et"/>
   <result pre="on the results of in vitro studies (Ministry of Health" exact="People's Republic of China," post="2011). However, a clinical study in China showed that"/>
   <result pre="the results of in vitro studies (Ministry of Health People's" exact="Republic of" post="China, 2011). However, a clinical study in China showed"/>
   <result pre="People's Republic of China, 2011). However, a clinical study in" exact="China" post="showed that the case fatality rate was similar between"/>
   <result pre="ribavirin treatment. Furthermore, according to a large-scale epidemiological study in" exact="China" post="including 2096 patients with laboratory-confirmed SFTS between 2011 and"/>
   <result pre="to treat a considerable number of patients (Ministry of Health" exact="People's Republic of China," post="2011). The in vitro and in vivo studies on"/>
   <result pre="treat a considerable number of patients (Ministry of Health People's" exact="Republic of" post="China, 2011). The in vitro and in vivo studies"/>
   <result pre="the efficacy of favipiravir for treating patients with SFTS in" exact="Japan" post="(Cyranoski, 2018; Spengler et al., 2018). Besides, it would"/>
   <result pre="the Ministry of Health, Labour, and Welfare (grant number H25-Shinko-Shitei-009)," exact="Japan" post="Agency for Medical Research and Development (AMED, 16fk0108002j, 17fk0108202j,"/>
   <result pre="Y.KimH. A.et al.. (2016). Severe fever with thrombocytopenia syndrome in" exact="South Korea," post="2013-2015. PLoS Negl. Trop. Dis.10:e0005264. 10.1371/journal.pntd.000526428033338 CliffordM. N. (1999)."/>
   <result pre="J.JunK. I.KimN. H.et al.. (2013). Severe fever with thrombocytopenia syndrome," exact="South Korea," post="2012. Emerg. Infect. Dis.19, 1892–189410.3201/eid1911.13079224206586 KimbroughR. D. (1973). Review"/>
   <result pre="infection. Immunotherapy. 9, 435–450. 10.2217/imt-2017-001028357917 collab: Ministry of Health and" exact="People's Republic of China" post="(2011). Guideline for prevention and treatment of severe fever"/>
   <result pre="Immunotherapy. 9, 435–450. 10.2217/imt-2017-001028357917 collab: Ministry of Health and People's" exact="Republic of" post="China (2011). Guideline for prevention and treatment of severe"/>
   <result pre="435–450. 10.2217/imt-2017-001028357917 collab: Ministry of Health and People's Republic of" exact="China" post="(2011). Guideline for prevention and treatment of severe fever"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7033156/results/search/country/results.xml">
   <result pre="66% over a 7-year period6. In this line, data from" exact="Spain" post="have shown the beneficial impact of an electronic alert"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7033915/results/search/country/results.xml">
   <result pre="Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover," exact="Germany" post="(maasoumy.benjamin@mh-hannover.de). collection: 2020-2epub: 2020-2-2pmc-release: 2020-2-272ofaa040received: 2019-11-28editorial-decision: 2020-1-27accepted: 2020-1-31corrected-typeset: 2020-2-21(C)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7036343/results/search/country/results.xml">
   <result pre="Internal Medicine, Incheon Medical Center, 217 Bangchuk-ro, Dong-gu, Incheon 22532," exact="Republic of" post="Korea. kjykey@gmail.com epub: 2020-2-2collection: 2020-2-2357e88received: 2020-2-15accepted: 2020-2-17(C) The Korean"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7036541/results/search/country/results.xml">
   <result pre="10, P.O. Box · Postfach · Case postale, CH–4009, Basel," exact="Switzerland" post="· Schweiz · Suisse, Phone: +41 61 306 11"/>
   <result pre="Box · Postfach · Case postale, CH–4009, Basel, Switzerland ·" exact="Schweiz" post="· Suisse, Phone: +41 61 306 11 11, Fax:"/>
   <result pre="She has HCV genotype 1b, which is more common in" exact="Japan" post="and Southeast Asia, and causes more severe hepatitis and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7038234/results/search/country/results.xml">
   <result pre="Wuhan, China[b], University of the Chinese Academy of Sciences, Beijing," exact="China" post="Address correspondence to Gengfu Xiao, xiaogf@wh.iov.cn, or Wei Wang,"/>
   <result pre="digoxin Na+/K+-ATPase Funding National Key Research and Development Program of" exact="China" post="2018YFA0507204WangWei National Natural Science Foundation of China (NSF)https://doi.org/10.13039/501100001809 31670165WangWei"/>
   <result pre="Development Program of China 2018YFA0507204WangWei National Natural Science Foundation of" exact="China" post="(NSF)https://doi.org/10.13039/501100001809 31670165WangWei fig-count: table-count: equation-count: ref-count: page-count: word-count: INTRODUCTION"/>
   <result pre="supported by the National Key Research and Development Program of" exact="China" post="(2018YFA0507204) and the National Natural Sciences Foundation of China"/>
   <result pre="of China (2018YFA0507204) and the National Natural Sciences Foundation of" exact="China" post="(31670165). References REFERENCES 1.YunSI, LeeYM2014Japanese encephalitis: the virus and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7040080/results/search/country/results.xml">
   <result pre="Microbiology, Jinan UniversityGuangzhouChina Edited by: Enzo Tramontano, University of Cagliari," exact="Italy" post="Reviewed by: Darren Hart, UMR 5075 Institut de Biologie"/>
   <result pre="Biologie Structurale (IBS), France; Aartjan Te Velthuis, University of Cambridge," exact="United Kingdom" post="*Correspondence: Xulin Chen, chenxl@wh.iov.cn This article was submitted to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7045215/results/search/country/results.xml">
   <result pre="herpes simplex virus type 1 and type 2 seroprevalence in" exact="the United States." post="JAMA2006;296:964–73. 10.1001/jama.296.8.96416926356 18LetenneurL, PérèsK, FleuryH, et al.Seropositivity to herpes"/>
   <result pre="simplex virus type 1 and type 2 seroprevalence in the" exact="United States." post="JAMA2006;296:964–73. 10.1001/jama.296.8.96416926356 18LetenneurL, PérèsK, FleuryH, et al.Seropositivity to herpes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7049240/results/search/country/results.xml">
   <result pre="to treat active PWID [9], while in many parts of" exact="the United States" post="of America active substance use remains an important barrier"/>
   <result pre="treat active PWID [9], while in many parts of the" exact="United States of America" post="active substance use remains an important barrier to treatment"/>
   <result pre="[9], while in many parts of the United States of" exact="America" post="active substance use remains an important barrier to treatment"/>
   <result pre="add crucial information to improve HCV service delivery and treatment." exact="Greece" post="has expressed its willingness to contribute to the WHO"/>
   <result pre="vulnerable population of PWID. The prevalence of HCV infection in" exact="Greece" post="is estimated to be between 0.83% and 1.79% [22],"/>
   <result pre="National and Kapodistrian University of Athens, Laiko General Hospital, Athens," exact="Greece" post="References 1NelsonPKMathersBMCowieBet al.Global epidemiology of hepatitis B and hepatitis"/>
   <result pre="the treatment cascade of chronic hepatitis B and C in" exact="Greece" post="using a telephone surveyJ Viral Hepat20152240941525209157 23GiannousisIPPapatheodoridisGVDeutschMJet al.The burden"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7049568/results/search/country/results.xml">
   <result pre="959,000 hospitalizations, and 79,400 deaths during the 2017–2018 season in" exact="the US" post="alone.1 Although vaccination is the most cost-effective preventive strategy"/>
   <result pre="annually, resulting in between 291,000 and 646,000 influenza-associated deaths.35 In" exact="the United States" post="alone, influenza viruses are estimated to infect more than"/>
   <result pre="resulting in between 291,000 and 646,000 influenza-associated deaths.35 In the" exact="United States" post="alone, influenza viruses are estimated to infect more than"/>
   <result pre="8Okomo-AdhiamboM.FryA.M.SuS.NguyenH.T.ElalA.A.NegronE.HandJ.GartenR.J.BarnesJ.XiyanX.collab: 2013–14 US Influenza Antiviral Working GroupOseltamivir-resistant influenza A(H1N1)pdm09 viruses," exact="United States," post="2013-14Emerg. Infect. Dis.21201513614125532050 9OmotoS.SperanziniV.HashimotoT.NoshiT.YamaguchiH.KawaiM.KawaguchiK.UeharaT.ShishidoT.NaitoA.CusackS.Characterization of influenza virus variants induced"/>
   <result pre="Rep.82018963329941893 10TandelK.SharmaS.DashP.K.ParidaM.Oseltamivir-resistant influenza A(H1N1)pdm09 virus associated with high case fatality," exact="India" post="2015J. Med. Virol.90201883684329288584 11GubarevaL.V.FryA.M.Baloxavir and Treatment-Emergent Resistance: Public Health"/>
   <result pre="12GubarevaL.V.MishinV.P.PatelM.C.ChesnokovA.NguyenH.T.De La CruzJ.SpencerS.CampbellA.P.SinnerM.ReidH.Assessing baloxavir susceptibility of influenza viruses circulating in" exact="the United States" post="during the 2016/17 and 2017/18 seasonsEuro Surveill.2420191800666 13TakashitaE.KawakamiC.OgawaR.MoritaH.FujisakiS.ShirakuraM.MiuraH.NakamuraK.KishidaN.KuwaharaT.Influenza A(H3N2)"/>
   <result pre="La CruzJ.SpencerS.CampbellA.P.SinnerM.ReidH.Assessing baloxavir susceptibility of influenza viruses circulating in the" exact="United States" post="during the 2016/17 and 2017/18 seasonsEuro Surveill.2420191800666 13TakashitaE.KawakamiC.OgawaR.MoritaH.FujisakiS.ShirakuraM.MiuraH.NakamuraK.KishidaN.KuwaharaT.Influenza A(H3N2)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7049676/results/search/country/results.xml">
   <result pre="continues to contribute to the burden of liver disease in" exact="the United States," post="causing chronic hepatitis, cirrhosis and decompensated disease, liver cancer,"/>
   <result pre="to contribute to the burden of liver disease in the" exact="United States," post="causing chronic hepatitis, cirrhosis and decompensated disease, liver cancer,"/>
   <result pre="remains one of the most prevalent chronic liver diseases in" exact="the United States" post="and beyond, but the infected population is shifting toward"/>
   <result pre="one of the most prevalent chronic liver diseases in the" exact="United States" post="and beyond, but the infected population is shifting toward"/>
   <result pre="from 1.3% in the Americas to 2.9% in Africa.4 In" exact="the United States," post="an epidemiological study of the National Health and Nutrition"/>
   <result pre="1.3% in the Americas to 2.9% in Africa.4 In the" exact="United States," post="an epidemiological study of the National Health and Nutrition"/>
   <result pre="million people with chronic HCV in the United States.6 In" exact="the United States," post="although the disease burden from HCV is decreasing, the"/>
   <result pre="people with chronic HCV in the United States.6 In the" exact="United States," post="although the disease burden from HCV is decreasing, the"/>
   <result pre="identification, yet effective screening has persistently been a challenge in" exact="the United States." post="A recent study of screening strategies identified that reflex"/>
   <result pre="yet effective screening has persistently been a challenge in the" exact="United States." post="A recent study of screening strategies identified that reflex"/>
   <result pre="the exception of pregnant women AASLD, Infectious Disease Society of" exact="America" post="(IDSA)13 2019 Risk behavior, risk exposure, or other conditions*"/>
   <result pre="between 0.20% in the Americas to 22.38% in Africa. In" exact="the United States," post="HBsAg seroprevalence was 0.27%, corresponding to 843,724 individuals with"/>
   <result pre="0.20% in the Americas to 22.38% in Africa. In the" exact="United States," post="HBsAg seroprevalence was 0.27%, corresponding to 843,724 individuals with"/>
   <result pre="nucleotide reverse‐transcriptase inhibitor and prodrug of tenofovir, was approved in" exact="the United States" post="in 2016 and has emerged as one effective first‐line"/>
   <result pre="reverse‐transcriptase inhibitor and prodrug of tenofovir, was approved in the" exact="United States" post="in 2016 and has emerged as one effective first‐line"/>
   <result pre="et al. Estimating prevalence of hepatitis C virus infection in" exact="the United States," post="2013‐2016. Hepatology2019;69:1020‐1031.30398671 6collab: Centers for Disease Control and Prevention"/>
   <result pre="al. Estimating prevalence of hepatitis C virus infection in the" exact="United States," post="2013‐2016. Hepatology2019;69:1020‐1031.30398671 6collab: Centers for Disease Control and Prevention"/>
   <result pre="MishraA, RafiqN, et al. Epidemiology of chronic liver diseases in" exact="the USA" post="in the past three decades. Gut2019 Jul 31. 10.1136/gutjnl-2019-318813."/>
   <result pre="KabiriM, ChungRT, HurC, et al. Hepatitis C disease burden in" exact="the United States" post="in the era of oral direct‐acting antivirals. Hepatology2016;64:1442‐1450.27015107 12ChapkoMK,"/>
   <result pre="ChungRT, HurC, et al. Hepatitis C disease burden in the" exact="United States" post="in the era of oral direct‐acting antivirals. Hepatology2016;64:1442‐1450.27015107 12ChapkoMK,"/>
   <result pre="targets. J Hepatol2019;70:e748. 28HolmbergSD, SpradlingPR, MoormanAC, DennistonMM. Hepatitis C in" exact="the United States." post="N Engl J Med2013;368:1859‐1861.23675657 29LinasBP, BarterDM, LeffJA, AssoumouSA, SalomonJA,"/>
   <result pre="J Hepatol2019;70:e748. 28HolmbergSD, SpradlingPR, MoormanAC, DennistonMM. Hepatitis C in the" exact="United States." post="N Engl J Med2013;368:1859‐1861.23675657 29LinasBP, BarterDM, LeffJA, AssoumouSA, SalomonJA,"/>
   <result pre="of the Hepatitis C Care Cascade: A Real‐World Analysis from" exact="the United States." post="Vienna, Austria: European Association for the Study of the"/>
   <result pre="the Hepatitis C Care Cascade: A Real‐World Analysis from the" exact="United States." post="Vienna, Austria: European Association for the Study of the"/>
   <result pre="etiology of liver disease among adults awaiting liver transplantation in" exact="the United States." post="Gastroenterology2015;148:547‐555.25461851 40YounossiZ, AnsteeQM, MariettiM, HardyT, HenryL, EslamM, et al."/>
   <result pre="of liver disease among adults awaiting liver transplantation in the" exact="United States." post="Gastroenterology2015;148:547‐555.25461851 40YounossiZ, AnsteeQM, MariettiM, HardyT, HenryL, EslamM, et al."/>
   <result pre="of the most common causes of chronic liver diseases in" exact="the United States" post="from 1988 to 2008. Clin Gastroenterol Hepatol2011;9:524‐530.e521.21440669 42SugimotoR, IwasaM,"/>
   <result pre="the most common causes of chronic liver diseases in the" exact="United States" post="from 1988 to 2008. Clin Gastroenterol Hepatol2011;9:524‐530.e521.21440669 42SugimotoR, IwasaM,"/>
   <result pre="Prevalence of hepatitis B and hepatitis D virus infections in" exact="the United States," post="2011‐2016. Clin Infect Dis2019;69:709‐712.30605508 69LemppFA, NiY, UrbanS. Hepatitis delta"/>
   <result pre="of hepatitis B and hepatitis D virus infections in the" exact="United States," post="2011‐2016. Clin Infect Dis2019;69:709‐712.30605508 69LemppFA, NiY, UrbanS. Hepatitis delta"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7050564/results/search/country/results.xml">
   <result pre="(Amsterdam University Medical Centers) is funded by the Aidsfonds, The" exact="Netherlands" post="(grant P-22605) and by the National Institute of Allergy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7054296/results/search/country/results.xml">
   <result pre="other RNA viruses NguyenTuan M.1ZhangYang1PandolfiPier Paolopierpaolo.pandolfiderinaldis@unito.it12[1], 000000041936754Xgrid.38142.3cCancer Research Institute, Beth" exact="Israel" post="Deaconess Medical Center, Harvard Medical School, [2], 0000 0001"/>
   <result pre="(SARS-CoV-2) RNA genome from 19 patients in China, USA and" exact="Australia" post="reveals that these viruses have differences in sequence (Fig."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7054408/results/search/country/results.xml">
   <result pre="Cell biology Molecular biology Funding https://doi.org/10.13039/501100001809National Natural Science Foundation of" exact="China" post="(National Science Foundation of China) 31621061HuZhihong Funding the National"/>
   <result pre="including 81 deaths. Additionally, 19 confirmed cases were identified in" exact="Hong Kong," post="Macao and Taiwan, and 39 imported cases were identified"/>
   <result pre="deaths. Additionally, 19 confirmed cases were identified in Hong Kong," exact="Macao" post="and Taiwan, and 39 imported cases were identified in"/>
   <result pre="Taiwan, and 39 imported cases were identified in Thailand, Japan," exact="South Korea," post="United States, Vietnam, Singapore, Nepal, France, Australia and Canada."/>
   <result pre="39 imported cases were identified in Thailand, Japan, South Korea," exact="United States," post="Vietnam, Singapore, Nepal, France, Australia and Canada. The pathogen"/>
   <result pre="Thailand, Japan, South Korea, United States, Vietnam, Singapore, Nepal, France," exact="Australia" post="and Canada. The pathogen was soon identified as a"/>
   <result pre="Prof. Song Li) (2018ZX09711003), the National Natural Science Foundation of" exact="China" post="(31621061), and the Emergency Scientific Research Project for 2019-nCoV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7054940/results/search/country/results.xml">
   <result pre="(WHO). As on February 4, 2020, 425 deaths reported in" exact="China" post="only and one death outside China (Philippines). In a"/>
   <result pre="425 deaths reported in China only and one death outside" exact="China" post="(Philippines). In a short span of time, the virus"/>
   <result pre="were identified in the horseshoe bats (non-caged) in 2005 from" exact="Hong Kong" post="(Lau et al. 2005). Since then, bats are considered"/>
   <result pre="on February 4, 2020, 425 deaths have been reported in" exact="China" post="only (World Health Organization 2020b). Further, the spread of"/>
   <result pre="emerged and was named 2019-nCoV. As on February 4th 2020," exact="China" post="has confirmed 20471 cases with 425 deaths and 2788"/>
   <result pre="As of now, around 15 complete 2019-nCoV genome sequences (10" exact="China" post="and 5 USA) have been reported. To note, a"/>
   <result pre="In the whole genome phylogenetic analysis, the 2019-nCoV strains from" exact="China" post="and the USA clustered in a monophyletic clade (Figure"/>
   <result pre="whole genome phylogenetic analysis, the 2019-nCoV strains from China and" exact="the USA" post="clustered in a monophyletic clade (Figure 3). The nearest"/>
   <result pre="(Figure 3). The nearest neighbors of the 2019-nCoV isolates from" exact="China" post="and USA were two Bat_SARS-like coronaviruses (Bat-SL-CoVZC45, Accession no."/>
   <result pre="the complete genome sequences between current outbreaks 2019-nCoV isolates from" exact="China" post="and the USA ranges 99.8 to 100% on the"/>
   <result pre="genome sequences between current outbreaks 2019-nCoV isolates from China and" exact="the USA" post="ranges 99.8 to 100% on the nucleotide level indicating"/>
   <result pre="animal origin. The solid-black circles are for nCoV isolates from" exact="China" post="and solid-black squares are for the isolates from the"/>
   <result pre="from China and solid-black squares are for the isolates from" exact="the USA." post="4.2. Analysis targeting the spike (S)-gene of CoVs We"/>
   <result pre="coronavirus, bat_coronaviruses. The solid-black circles are for nCoV isolates from" exact="China" post="and the USA. Additionally, for S-gene, per cent similarity"/>
   <result pre="The solid-black circles are for nCoV isolates from China and" exact="the USA." post="Additionally, for S-gene, per cent similarity range pattern was"/>
   <result pre="evaluated in amino acid based index where 2019-nCoV isolates from" exact="China" post="and USA were 100% identical. The range varied between"/>
   <result pre="(World Health Organization 2020a). The live-animal markets such as in" exact="China" post="could provide chances to animal CoVs to get transmitted"/>
   <result pre="of time. Since its origin from Wuhan, Hubei province of" exact="China" post="in the first week of December 2019, it has"/>
   <result pre="week of December 2019, it has claimed 425 lives in" exact="China" post="and infected 20630 in 24 countries including China. Additionally,"/>
   <result pre="are emerging in different countries and three confirmed cases from" exact="India" post="also emerged till compilation of this paper, February 4th,"/>
   <result pre="4th, 2020. As of now deaths were reported only from" exact="China" post="but now causality in Philippines reported for the first"/>
   <result pre="deaths were reported only from China but now causality in" exact="Philippines" post="reported for the first time outside China. The nCoV"/>
   <result pre="developing better diagnostics and effective vaccines. A report emerged from" exact="China" post="where the scientists claimed successful isolation of the 2019-nCoV"/>
   <result pre="al.2014Middle East respiratory syndrome coronavirus infection in dromedary camels in" exact="Saudi Arabia." post="MBio. 5(2):e00884–00814. doi:10.1128/mBio.00884-1424570370 ChengVC, WongS-C, ToKK, HoP, YuenK-Y2020Preparedness and"/>
   <result pre="relative of human Middle East respiratory syndrome coronavirus in bat," exact="South Africa." post="Emerg Infect Dis. 19(10):1697–1699. doi:10.3201/eid1910.13094624050621 JiangS, HeY, LiuS2005SARS vaccine"/>
   <result pre="of a novel coronavirus from a man with pneumonia in" exact="Saudi Arabia." post="N Engl J Med. 367(19):1814–1820.23075143 ZhouP, YangX-L, WangX-G, HuB,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7057540/results/search/country/results.xml">
   <result pre="at nine academic and nine community oncology institutions affiliated with" exact="the US" post="Southwest Oncology Group Cancer Research network reported on the"/>
   <result pre="diagnosed with cancer.10 As noted in this report, currently, in" exact="the US" post="universal hepatitis viral screening is not routine in oncology"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7064180/results/search/country/results.xml">
   <result pre="substitution in people who inject drugs—First real world data from" exact="Austria" post="Glecaprevir/pibrentasvir to cure hepatitis C in people who inject"/>
   <result pre="hepatitis C in people who inject drugs—Real world data from" exact="Austria" post="http://orcid.org/0000-0001-7762-7483SchmidbauerCarolineData curationFormal analysisInvestigationVisualizationWriting – original draftWriting – review &amp;amp;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7067438/results/search/country/results.xml">
   <result pre="Department of Emergency Medicine, Sutter Medical Center Sacramento, Sacramento, California," exact="United States" post="of America[2], Department of Pathology, Microbiology, and Immunology, School"/>
   <result pre="School of Veterinary Medicine, University of California Davis, Davis, California," exact="United States" post="of America[3], Division of Biostatistics, Department of Public Health"/>
   <result pre="of Public Health Sciences, University of California Davis, Davis, California," exact="United States" post="of AmericaCormierStephania AEditor[], Louisiana State University System, UNITED STATES"/>
   <result pre="by PCR again making antivirals of limited practical clinical use.[17]" exact="Jordan" post="et al found decreased clinical scores with FPI monotherapy"/>
   <result pre="seen as an official policy or interpretation of the USDA," exact="the US" post="government, or any other entity. References References 1PelletierAJ, MansbachJM,"/>
   <result pre="1PelletierAJ, MansbachJM, CamargoCAJr. Direct medical costs of bronchiolitis hospitalizations in" exact="the United States." post="Pediatrics. 2006;118(6):2418–23. Epub 2006/12/05. 10.1542/peds.2006-1193 .17142527 2MansbachJM, PelletierAJ, CamargoCAJr."/>
   <result pre="MansbachJM, CamargoCAJr. Direct medical costs of bronchiolitis hospitalizations in the" exact="United States." post="Pediatrics. 2006;118(6):2418–23. Epub 2006/12/05. 10.1542/peds.2006-1193 .17142527 2MansbachJM, PelletierAJ, CamargoCAJr."/>
   <result pre="severity among children hospitalized with bronchiolitis: multicenter cohort studies in" exact="the United States" post="and Finland. J Infect Dis. 2015;211(10):1550–9. Epub 2014/11/25. 10.1093/infdis/jiu65825425699"/>
   <result pre="among children hospitalized with bronchiolitis: multicenter cohort studies in the" exact="United States" post="and Finland. J Infect Dis. 2015;211(10):1550–9. Epub 2014/11/25. 10.1093/infdis/jiu65825425699"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7070519/results/search/country/results.xml">
   <result pre="by Influenza A subtype H2N2 occurred in 1957 and the" exact="Hong Kong" post="Influenza caused by Influenza A subtype H3N2 took place"/>
   <result pre="a few limited geographical areas such as northern Europe (Finland," exact="Sweden" post="and Russia), South Africa, Australia and China [100]. 1,3,4-Thiadiazole"/>
   <result pre="geographical areas such as northern Europe (Finland, Sweden and Russia)," exact="South Africa," post="Australia and China [100]. 1,3,4-Thiadiazole derivatives 50–55 were tested"/>
   <result pre="such as northern Europe (Finland, Sweden and Russia), South Africa," exact="Australia" post="and China [100]. 1,3,4-Thiadiazole derivatives 50–55 were tested for"/>
   <result pre="northern Europe (Finland, Sweden and Russia), South Africa, Australia and" exact="China" post="[100]. 1,3,4-Thiadiazole derivatives 50–55 were tested for antiviral activity"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7070539/results/search/country/results.xml">
   <result pre="by the Ministry of Science and Higher Education of the" exact="Russian Federation" post="(Agreement No. 075-15-2019-1660). Conflicts of Interest The authors declare"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7073089/results/search/country/results.xml">
   <result pre="with CMV infections. 3.1. Letermovir Letermovir has been approved by" exact="the USA" post="Food and Drug Administration (FDA) and the European Medicines"/>
   <result pre="maternal populationAm. J. Obstet. Gynecol.2010202297.e1297.e810.1016/j.ajog.2009.11.01820060091 30.StarasS.A.DollardS.C.RadfordK.W.FlandersW.D.PassR.F.CannonM.J.Seroprevalence of cytomegalovirus infection in" exact="the United States," post="1988–1994Clin. Infect. Dis.2006431143115110.1086/50817317029132 31.HargettD.ShenkT.E.Experimental human cytomegalovirus latency in CD14+"/>
   <result pre="populationAm. J. Obstet. Gynecol.2010202297.e1297.e810.1016/j.ajog.2009.11.01820060091 30.StarasS.A.DollardS.C.RadfordK.W.FlandersW.D.PassR.F.CannonM.J.Seroprevalence of cytomegalovirus infection in the" exact="United States," post="1988–1994Clin. Infect. Dis.2006431143115110.1086/50817317029132 31.HargettD.ShenkT.E.Experimental human cytomegalovirus latency in CD14+"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7073332/results/search/country/results.xml">
   <result pre="C virus, HDV hepatitis delta virus, EBOV Ebola viruses, ZEBOV-GP" exact="Zaire" post="Ebola virus glycoprotein, HIV human immunodeficiency virus, EBV Epstein-Barr"/>
   <result pre="proven to have moderate activity in inhibiting the entry of" exact="Zaire" post="Ebola virus glycoprotein and human immunodeficiency virus (ZEBOV-GP/HIV)18. Altogether,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7076512/results/search/country/results.xml">
   <result pre="the oral bioavailability of the drug studied in vivo in" exact="New Zealand" post="rabbits, a reduced frequency of dosing being needed in"/>
   <result pre="November 2019) 7.SzucsT.D.BergerK.FismanD.N.HarbarthS.The estimated economic burden of genital herpes in" exact="the United States." post="An analysis using two costing approachesBMC Infect. Dis.20011510.1186/1471-2334-1-511472635 8.GonzaloT.García"/>
   <result pre="2019) 7.SzucsT.D.BergerK.FismanD.N.HarbarthS.The estimated economic burden of genital herpes in the" exact="United States." post="An analysis using two costing approachesBMC Infect. Dis.20011510.1186/1471-2334-1-511472635 8.GonzaloT.García"/>
   <result pre="Route of Administration REF Epaxal® Crucell (former Berna Biotech Ltd.);1994" exact="Switzerland" post="Virosomes (around 150 nm spherical liposomal vesicles)—intrinsic adjuvant properties;"/>
   <result pre="Intramuscular vaccine [186,187] Inflexal® V Crucell (former Berna Biotech Ltd.);1997" exact="Switzerland" post="Virosomes (around 150 nm spherical liposomal vesicles)—biodegradable and biocompatible"/>
   <result pre="stability; HBV, HCV Subcutaneous [190,191] Influvac® Plus BGP Pharma ULC,2005," exact="Canada" post="Virosome vaccine Influenza Intramuscularvaccine [192] VivaGel® BV Starpharma, Australia;Mundipharma,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7076579/results/search/country/results.xml">
   <result pre="African (6.1%) areas, but less common in Europe (1.6%) and" exact="America" post="(0.7%).2 However, the streams of immigration and influx of"/>
   <result pre="immigration and influx of refugees to Western Europe and North" exact="America" post="is likely to be changing the prevalence and endemicity"/>
   <result pre="in geographical areas with lower prevalence, such as Europe and" exact="the United States." post="Taken together, these data would suggest that, in ABA-treated"/>
   <result pre="geographical areas with lower prevalence, such as Europe and the" exact="United States." post="Taken together, these data would suggest that, in ABA-treated"/>
   <result pre="intervals.114 A new two-dose HBV vaccine was recently approved by" exact="the United States" post="Food and Drug Administration (FDA) and is already recommended"/>
   <result pre="A new two-dose HBV vaccine was recently approved by the" exact="United States" post="Food and Drug Administration (FDA) and is already recommended"/>
   <result pre="Clin Rheumatol2016; 30: 946–963.27964798 114KimDKHunterPWoodsLD, et al.Recommended adult immunization schedule," exact="United States," post="2019. Ann Intern Med2019; 170: 182–192.30716757 115SchillieSHarrisALink-GellesR, et al.Recommendations"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7076747/results/search/country/results.xml">
   <result pre="Medical CenterThe Netherlands[2], Department of Hematology, Leiden University Medical CenterThe" exact="Netherlands" post="Correspondence: S. M. Arend, Department of Infectious Diseases, C5-P-40,"/>
   <result pre="University Medical Center, PO Box 9600, 2300 RC Leiden, The" exact="Netherlands" post="(s.m.arend@lumc.nl). ppub: 2020-4-4epub: 2019-5-5pmc-release: 2019-5-570714381441received: 2019-4-25accepted: 2019-5-07corrected-typeset: 2019-7-19(C) ,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7076820/results/search/country/results.xml">
   <result pre="otherwise stated. Abstract Background Radix isatidis has been used in" exact="China" post="and other Asian countries for its antiviral and anti-inflammatory"/>
   <result pre="are urgently needed. Herbal medicine has been widely used in" exact="China" post="for thousands of years [11, 12] and numerous studies"/>
   <result pre="used for the prevention and cure of viral diseases in" exact="China" post="and other Asian countries for thousands of years. The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7077210/results/search/country/results.xml">
   <result pre="of rabies from dog bites around the world [2]. In" exact="the United States," post="an average of two people die annually of rabies,"/>
   <result pre="rabies from dog bites around the world [2]. In the" exact="United States," post="an average of two people die annually of rabies,"/>
   <result pre="in Rabies Postexposure ProphylaxisJ. Infect. Dis.20162131253126110.1093/infdis/jiv58626655300 36.Bat Rabies Outbreak in" exact="Peru" post="Claims One, but Others Survive: Mass Vaccination Campaign UnderwayAvailable"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7077228/results/search/country/results.xml">
   <result pre="for treating chronic hepatic diseases for over 40 years in" exact="China" post="and Japan clinically. Oleanane acid (OA) triterpene is probably"/>
   <result pre="chronic hepatic diseases for over 40 years in China and" exact="Japan" post="clinically. Oleanane acid (OA) triterpene is probably the most"/>
   <result pre="were kindly provided by the Veterinary Technology Center of South" exact="China" post="Agricultural University (Guangzhou, China). The H1N1 IAV strain A/Puerto"/>
   <result pre="antiserum were provided by the Veterinary Technology Center of South" exact="China" post="Agricultural University, Guangzhou, China) or OA-10 at indicated concentrations"/>
   <result pre="release. Arbidol, a licensed antiviral agent against IAV infection in" exact="Russia" post="and China, was demonstrated to inhibit IAV replication by"/>
   <result pre="funded by the National Key Research and Development Program of" exact="China" post="(grant number 2017YFD0501404) and the National Natural Science Foundation"/>
   <result pre="(grant number 2017YFD0501404) and the National Natural Science Foundation of" exact="China" post="(grant numbers 31572565 and 31872521) to Jianxin Chen. Conflicts"/>
   <result pre="of pathogenicity potentialAvian Dis.19964042543710.2307/15922418790895 36.YeM.collab: College of Veterinary Medicine, South" exact="China" post="Agricultural University, Guangzhou, ChinaPersonal Communication2019 37.KadamR.U.WilsonI.A.Structural basis of influenza"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7077276/results/search/country/results.xml">
   <result pre="(PK15) (BH0370, ATCC, Manassas, VA, USA) cells were supplied by" exact="China" post="Institute of Veterinary Drugs Control and cultured in Opti-MEM"/>
   <result pre="funded by the National Key Research &amp;amp; Development Program of" exact="China" post="(Grant No. 2017YFD0500101 &amp;amp; 2015BAD12B01) and the National Natural"/>
   <result pre="2017YFD0500101 &amp;amp; 2015BAD12B01) and the National Natural Science Foundation of" exact="China" post="(Grant No. 31402198). Conflicts of Interest The authors declare"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7077318/results/search/country/results.xml">
   <result pre="in Asia, and these outbreaks have been particularly severe in" exact="China" post="[4,5,6]. The vaccines based on classic strains failed to"/>
   <result pre="control infection [2]. Furthermore, a vaccine-resistant PEDV strain emerged in" exact="the United States" post="for the first time and spread rapidly throughout the"/>
   <result pre="infection [2]. Furthermore, a vaccine-resistant PEDV strain emerged in the" exact="United States" post="for the first time and spread rapidly throughout the"/>
   <result pre="This work was supported by National Key R&amp;amp;D Plan of" exact="China" post="Grant 2018YFD0500100, National Natural Science Foundation of China Grants"/>
   <result pre="Plan of China Grant 2018YFD0500100, National Natural Science Foundation of" exact="China" post="Grants 31873020 and the Natural Science Foundation of Hubei"/>
   <result pre="31873020 and the Natural Science Foundation of Hubei Province of" exact="China" post="(Grant No. 2016CFA069). Conflicts of Interest The authors declare"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7078228/results/search/country/results.xml">
   <result pre="terms Autophagy Transcription Funding the National Natural Science Foundation of" exact="China" post="(grant no. 31621061 to Z.H.), and the Hubei Science"/>
   <result pre="(sixth edition) published by National Health Commission of the People’s" exact="Republic of" post="China. CQ (N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine) has long been used to treat"/>
   <result pre="Development&quot; (2018ZX09711003 to W.Z.), the National Natural Science Foundation of" exact="China" post="(31621061 to Z.H.), and the Hubei Science and Technology"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7087576/results/search/country/results.xml">
   <result pre="in GhanaBr. J. Ophthalmol.19705462863010.1136/bjo.54.9.6285458256 69.LimK. H.Yin-MurphyM.An epidemic of conjunctivitis in" exact="Singapore" post="in 1970Singapore Med. J.1971122472495134044 70.WrightP. W.StraussG. H.LangfordM. P.Acute hemorrhagic"/>
   <result pre="aseptic meningitis caused by coxsackievirus A9 in Gansu, the People’s" exact="Republic of" post="ChinaVirol. J.201077210.1186/1743-422X-7-7220367886 78.IraniD. N.Aseptic meningitis and viral myelitisNeurol. Clin.20082663510.1016/j.ncl.2008.03.00318657719"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7089181/results/search/country/results.xml">
   <result pre="in 2013–2014, followed by a more recent one in the" exact="Republic of" post="Congo with 1891 fatalities [37], has attracted extensive media"/>
   <result pre="followed by a more recent one in the Republic of" exact="Congo" post="with 1891 fatalities [37], has attracted extensive media attention."/>
   <result pre="countries were revaccinated in the early 2000s for fear that" exact="Iraq" post="might have weaponized smallpox virus (which it had not,"/>
   <result pre="drug effective against orthopoxviruses, tecovirimat, has recently been approved by" exact="the United States" post="Federal Drug Administration [55]. Smallpox as an exclusively human"/>
   <result pre="effective against orthopoxviruses, tecovirimat, has recently been approved by the" exact="United States" post="Federal Drug Administration [55]. Smallpox as an exclusively human"/>
   <result pre="biological warfare agent by British and American forces in North" exact="America" post="[36], and remains on the top of the list"/>
   <result pre="stocks are officially kept in only two designated laboratories in" exact="Russia" post="and the US. Monkeypox virus (BSL-3), a zoonotic agent"/>
   <result pre="officially kept in only two designated laboratories in Russia and" exact="the US." post="Monkeypox virus (BSL-3), a zoonotic agent causing sequelae similar"/>
   <result pre="smallpox but less fatal, is endemic in central Africa (Democratic" exact="Republic of" post="Congo; DRC); recent introductions to the UK were travel-related."/>
   <result pre="OPV infections was cidofovir, a bisphosphonate developed at REGA, in" exact="Belgium" post="[31, 35]) and FDA approved against human cytomegalovirus (HCMV)."/>
   <result pre="[55, 104, 118, 146]. Tecovirimat (TPOXX®) is currently stockpiled in" exact="the US" post="and production for similar stockpiles in Europe is planned."/>
   <result pre="decade mainly in South-East Asia and in South America, Central" exact="America" post="and the Caribbean, globally amounting to millions of cases."/>
   <result pre="cases. Autochthonous cases of Chikungunya fever have been reported in" exact="Italy" post="[93]. Viremia with rashes and fever usually lead to"/>
   <result pre="rates over 30%. Recently a person-to-person transmission of Lassavirus in" exact="Germany" post="[148] and an outbreak in Nigeria raised public health"/>
   <result pre="transmission of Lassavirus in Germany [148] and an outbreak in" exact="Nigeria" post="raised public health concerns. Arenaviruses are enveloped viruses incorporating"/>
   <result pre="years or older [80, 110]. Favipiravir developed and approved in" exact="Japan" post="specifically for treatment of influenza virus infections, and its"/>
   <result pre="viruses, in the genus Henipavirus, are considered zoonotic agents in" exact="Australia" post="(horses) and South-East Asia (pigs), respectively. Both viruses may"/>
   <result pre="17.BugertJJWelzelTMZeierMDaraiGHantavirus infection-haemorrhagic fever in the Balkans—potential nephrological hazards in the" exact="Kosovo" post="warNephrol Dial Transpl1999141843184410.1093/ndt/14.8.1843 18.Bullard-FeibelmanKMGoveroJZhuZSalazarVVeselinovicMDiamondMSGeissBJThe FDA-approved drug sofosbuvir inhibits Zika"/>
   <result pre="the British Empire in North America2005NormanUniversity of Oklahoma Press 37.DyerOEscalating" exact="Congo" post="Ebola epidemic passes 2000 cases amid violence and suspicionBMJ2019365l406210.1136/bmj.l406231167752"/>
   <result pre="delayed brincidofovir treatment against a lethal rabbitpox virus challenge in" exact="New Zealand" post="White rabbitsAntivir Res201714327828610.1016/j.antiviral.2017.04.00228392420 57.GubarevaLVBesselaarTGDanielsRSFryAGregoryVHuangWHurtACJorqueraPALackenbyALeangS-KLoJPereyaslovDRebelo-de-AndradeHSiqueiraMMTakashitaEOdagiriTWangDZhangWMeijerAGlobal update on the susceptibility of"/>
   <result pre="in a measles encephalitis modelAntivir Res20098126126610.1016/j.antiviral.2008.12.00619133295 70.JohnsonSHenschkeNMaayanNMillsIBuckleyBSKakourouAMarshallRRibavirin for treating Crimean" exact="Congo" post="haemorrhagic feverCochrane Database Syst Rev201810.1002/14651858.CD012713.pub230362116 71.JonssonCBHooperJMertzGTreatment of hantavirus pulmonary"/>
   <result pre="of renal and pulmonary syndrome in a region of northeast" exact="Germany" post="where Tula hantavirus circulatesJ Clin Microbiol200341104894489710.1128/jcm.41.10.4894-4897.200314532254 77.KobanRNeumannMDaugsABlochONitscheALanghammerSEllerbrokHA novel three-dimensional"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7089605/results/search/country/results.xml">
   <result pre="Human Coronavirus (HCoV) is reported two months ago in Wuhan," exact="China" post="(COVID-19). Until today &amp;gt;2700 deaths from the 80,000 confirmed"/>
   <result pre="&amp;gt;2700 deaths from the 80,000 confirmed cases reported mainly in" exact="China" post="and 40 other countries. Human to human transmission is"/>
   <result pre="countries. Human to human transmission is confirmed for COVID-19 by" exact="China" post="a month ago. Based on the World Health Organization"/>
   <result pre="human coronavirus (COVID-19) is reported in December 2019 in Wuhan," exact="China" post="[1,2]. According to the World Health Organization (WHO) surveillance"/>
   <result pre="[9][63]]. On 20 January 2020, the National Health Commission of" exact="China" post="confirmed the human-to-human transmission of the Wuhan outbreak (COVID-19)"/>
   <result pre="through) [25,26]. Several in vitro and clinical trials started in" exact="China" post="during the last month with the first approved drug,"/>
   <result pre="approved drug, Favilavir, by the National Medical Products Administration of" exact="China" post="is announced yesterday (18 February 2020) in Zhejiang province."/>
   <result pre="the National Center for Biotechnology Information (NCBI) nucleotide database [33]." exact="Swiss" post="Model web server is used to build a model"/>
   <result pre="3. (B) The newly emerged COVID-19 RdRp model built by" exact="Swiss" post="Model in the green cartoon (right) and surface (left)"/>
   <result pre="is built by the aid of the automated homology modeling," exact="Swiss" post="Model, web server using SARS HCoV RdRp (PDB ID:"/>
   <result pre="4 Conclusion The newly emerged coronavirus in Wuhan city in" exact="China" post="has a health concern since the last outbreak of"/>
   <result pre="Organization 6ParrJ.Pneumonia in China: Lack of Information Raises Concerns Among" exact="Hong Kong" post="Health Workers2020British Medical Journal Publishing Group 7ElfikyA.A.I.N. SAnti-SARS and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7090474/results/search/country/results.xml">
   <result pre="University), Department of Laboratory Medicine, the First Affiliated Hospital of" exact="China" post="Medical University, [2], grid.412636.4National Clinical Research Center for Laboratory"/>
   <result pre="Research Center for Laboratory Medicine, The First Affiliated Hospital of" exact="China" post="Medical University, [3], grid.413107.0Department of Respiratory and Critical Care"/>
   <result pre="wish to thank Feng Li for helpful discussions and Jennifer" exact="Guernsey" post="for editorial assistance. Compliance with Ethical Standards Conflict of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7090514/results/search/country/results.xml">
   <result pre="of 50 mg/kg Arbidol ≥ 2 years for influenza in" exact="Russia" post="No recommendation Using with caution in patients with liver"/>
   <result pre="and neonates within 14 days based on drug instructions in" exact="the USA" post="[15]. In China, LPVr oral solution is suitable for"/>
   <result pre="forms and age restrictions of ribavirin can be seen in" exact="China" post="and other countries. In China, ribavirin is available in"/>
   <result pre="Arbidol Arbidol (umifenovir) is a broad-spectrum antiviral compound approved in" exact="Russia" post="and China for prophylaxis and treatment of influenza. This"/>
   <result pre="(umifenovir) is a broad-spectrum antiviral compound approved in Russia and" exact="China" post="for prophylaxis and treatment of influenza. This compound shows"/>
   <result pre="vitro [28]. Arbidol is available in oral dosage forms in" exact="China" post="and Russia [29]. The dosage regimen of arbidol (0.2"/>
   <result pre="Arbidol is available in oral dosage forms in China and" exact="Russia" post="[29]. The dosage regimen of arbidol (0.2 g every"/>
   <result pre="past 36 months. References References 1.National Health Commission of the" exact="People's Republic of China." post="Notice on printing and distributing the diagnosis and treatment"/>
   <result pre="36 months. References References 1.National Health Commission of the People's" exact="Republic of" post="China. Notice on printing and distributing the diagnosis and"/>
   <result pre="pneumonia in clinical studiesBiosci Trends202010.5582/bst.2020.0104732074550 24.National Health Commission of the" exact="People's Republic of China." post="Notice on printing and distributing the adjustment of dosage"/>
   <result pre="in clinical studiesBiosci Trends202010.5582/bst.2020.0104732074550 24.National Health Commission of the People's" exact="Republic of" post="China. Notice on printing and distributing the adjustment of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7090748/results/search/country/results.xml">
   <result pre="Ebola in western Africa, Zika in South America, H7N9 in" exact="China" post="and many Asian countries, and H1N1 influenza worldwide. In"/>
   <result pre="syndrome (SARS) coronavirus (SARS-CoV) emerged in November 2002 in Guangdong," exact="China" post="and caused globally 8098 human infections with 774 deaths"/>
   <result pre="East respiratory syndrome (MERS) coronavirus (MERS-CoV) emerged in 2012 in" exact="Saudi Arabia" post="and caused 2494 infections with 858 associated deaths (34.4%)"/>
   <result pre="in other 16 countries (National Health Commission of the People’s" exact="Republic of" post="China 2020; WHO 2020c). Since the emerging viruses are"/>
   <result pre="16 countries (National Health Commission of the People’s Republic of" exact="China" post="2020; WHO 2020c). Since the emerging viruses are previously"/>
   <result pre="virus, human immunodeficiency virus, dengue virus, West Nile virus, Crimean" exact="Congo" post="hemorrhagic fever virus, and hepatitis A virus (García-Serradilla et"/>
   <result pre="and timely as the 2019-nCoV is currently spreading rapidly in" exact="China" post="and causing severe respiratory diseases and deaths of many"/>
   <result pre="The author was supported by the Natural Science Foundation of" exact="China" post="(Grant #81620108020), Shenzhen Science and Technology Program (Grant No."/>
   <result pre="Pneumo-, and ParamyxovirusesSci Rep201774339510.1038/srep4339528262699 National Health Commission of the People’s" exact="Republic of" post="China (2020) http://www.nhc.gov.cn/xcs/yqfkdt/202001/e71bd2e7a0824ca69f87bbf1bef2a3c9.shtml RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of hydroxychloroquine"/>
   <result pre="ParamyxovirusesSci Rep201774339510.1038/srep4339528262699 National Health Commission of the People’s Republic of" exact="China" post="(2020) http://www.nhc.gov.cn/xcs/yqfkdt/202001/e71bd2e7a0824ca69f87bbf1bef2a3c9.shtml RainsfordKDParkeALClifford-RashotteMKeanWFTherapy and pharmacological properties of hydroxychloroquine and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7091034/results/search/country/results.xml">
   <result pre="50 million people – the Spanish influenza pandemic of 1918." exact="India" post="was the focal point of this pandemic in terms"/>
   <result pre="8% of the population at that time). The epidemic in" exact="India" post="originated in Bombay in September 1918 where the troops"/>
   <result pre="peak season had just begun [5]. Influenza surveillance studies from" exact="India" post="have identified three major patterns of influenza circulation: Srinagar"/>
   <result pre="and Vellore situated in the South west. Whereas rest of" exact="India" post="has peak activity coinciding with the rains (June–October) with"/>
   <result pre="2019. 6.ChadhaMSPotdarVASahaSet al.Dynamics of influenza seasonality at sub-regional levels in" exact="India" post="and implications for vaccination timingPLoS One201510e012412210.1371/journal.pone.012412225938466 7.BridgesCBKuehnertMJHallCBTransmission of influenza:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7091548/results/search/country/results.xml">
   <result pre="47ClaraW.ArmeroJ.RodriguezD.et al.Estimated incidence of influenza-virus-associated severe pneumonia in children in" exact="El Salvador," post="2008–2010Bulletin of the World Health Organization20129075676310.2471/BLT.11.09820223109743 48MeterskyM. L.MastertonR. G.LodeH.FileT."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7091927/results/search/country/results.xml">
   <result pre="mortality. Zidovudine (azidothymidine) was first approved for HIV treatment by" exact="the US" post="Food and Drug Administration in 1987. This drug had"/>
   <result pre="liver cirrhosis and hepatocellular carcinoma.60 Current antiviral drugs approved by" exact="the US" post="Food and Drug Administration include immunomodulators (interferon-α and pegylated"/>
   <result pre="Nipah virus in Malaysia, Hendra virus in Australia, Hantavirus in" exact="the United States," post="Ebola virus in Africa, severe acute respiratory syndrome and"/>
   <result pre="virus in Malaysia, Hendra virus in Australia, Hantavirus in the" exact="United States," post="Ebola virus in Africa, severe acute respiratory syndrome and"/>
   <result pre="acute respiratory syndrome and Middle East respiratory syndrome coronaviruses in" exact="China" post="and Mideast, Zika virus in Oceania and Americas, and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7092597/results/search/country/results.xml">
   <result pre="health concern with 200,000 hospitalizations and 36,000 deaths annually in" exact="the United States" post="alone [2]. To date, conventional commercialized antiviral agents for"/>
   <result pre="concern with 200,000 hospitalizations and 36,000 deaths annually in the" exact="United States" post="alone [2]. To date, conventional commercialized antiviral agents for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7092853/results/search/country/results.xml">
   <result pre="first isolated from rhesus monkeys near the Zika Forest in" exact="Uganda" post="in 1947 [1,2]. The viral genome of ZIKV encodes"/>
   <result pre="microcephaly in infants [8,9]. Prior to the outbreak which affected" exact="Brazil" post="and other Central and South American countries, ZIKV infection"/>
   <result pre="p &amp;lt; 0.001. 4 Discussion The outbreak of ZIKV in" exact="Brazil" post="in 2015 was one of most uncontrollable epidemics that"/>
   <result pre="findings, and public health implicationsJ. Clin. Virol.632015323525600600 12VenturaC.V.MaiaM.Bravo-FilhoV.GoisA.L.BelfortR.Jr.Zika virus in" exact="Brazil" post="and macular atrophy in a child with microcephalyLancet3872016228 13Zika"/>
   <result pre="systems by harringtonineEur. J. Biochem.721977323330319998 28JiaK.YuanY.LiuW.LiuL.QinQ.YiM.Identification of inhibitory compounds against" exact="Singapore" post="grouper iridovirus infection by cell viability-based screening assay and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7093024/results/search/country/results.xml">
   <result pre="ChicagoChicago, ILUnited States Edited by: Chunfu Zheng, Fujian Medical University," exact="China" post="Reviewed by: Qi Wang, Harbin Veterinary Research Institute (CAAS),"/>
   <result pre="Research Institute (CAAS), China; Jun Wang, The University of Arizona," exact="United States" post="*Correspondence: Lijun Rong, Lijun@uic.edu Qinghua Cui, cuiqinghua1122@163.com †These authors"/>
   <result pre="Province (Grant No. 2017CXGC1309); (3) Shandong Provincial Natural Science Foundation," exact="China" post="(Grant No. ZR2019MH078); (4) Project for function implementation of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7093072/results/search/country/results.xml">
   <result pre="COVID-19 patients person-1ZhuShudong1*person-2GuoXialing1person-3GearyKyla2person-4ZhangDianzheng2[], [], Shudong Zhu, PhD, Argus Pharmaceuticals, Changsha," exact="China" post="Address: 8 LuJing Ave., Changsha, China; Email: 1125537080@qq.com :"/>
   <result pre="Since the beginning of December 2019, numerous hospitals in Wuhan," exact="China" post="have reported an increasing number of patients with pneumonia"/>
   <result pre="infection. 2. Nucleotide analogs The first case of COVID-19 in" exact="the United States" post="was confirmed on January 20, 2020, by qPCR assay"/>
   <result pre="2. Nucleotide analogs The first case of COVID-19 in the" exact="United States" post="was confirmed on January 20, 2020, by qPCR assay"/>
   <result pre="and/or II clinical trials3,4. Therefore, Gilead has been working with" exact="China" post="since February 2020 to conduct a phase 3 randomized,"/>
   <result pre="are undergoing clinical trials. Fapivir is a drug approved in" exact="Japan" post="for flu treatment. Figure 1 The structure of remdesivir,"/>
   <result pre="in Xiangya Hospital in China, which has been registered in" exact="the US" post="clinical trial database10. 5. Lopinavir/ritonavir Lopinavir/ritonavir is a combination"/>
   <result pre="treatment of COVID-19, especially since darunavir has been approved in" exact="China" post="since 2018 for HIV treatment. 6. Plasma The company"/>
   <result pre="function. Clinical trials on this antibody are now underway in" exact="China" post="to potentially reduce both lung damage and death caused"/>
   <result pre="the agenda. A search with the word &quot;COVID-19&quot; in the" exact="China" post="Clinical Trials Registry (http://www.chictr.org.cn) revealed that 218 clinical trials"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7093363/results/search/country/results.xml">
   <result pre="of an outbreak of viral pneumonia first detected in Wuhan," exact="China" post="and it continues to spread. We summarized the characteristics"/>
   <result pre="outbreak of viral pneumonia first detected in Wuhan city of" exact="China" post="and it continues to spread throughout the world (Perlman,"/>
   <result pre="of the severe acute respiratory syndrome coronavirus (SARS-CoV) outbreak in" exact="China" post="in 2003, and the Middle East Respiratory Syndrome coronavirus"/>
   <result pre="2003, and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) in" exact="Saudi Arabia" post="in 2012 (Hilgenfeld and Peiris, 2013; Paules et al.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7094090/results/search/country/results.xml">
   <result pre="features of patients infected with 2019 novel coronavirus in Wuhan," exact="China" post="January 24, 2020 Department of Pulmonary and Critical Care"/>
   <result pre="and Prevention, Beijing, China; School of Public Health, University of" exact="Hong Kong," post="Hong Kong; Hubei Center for Disease Control and Prevention,"/>
   <result pre="Beijing, China; School of Public Health, University of Hong Kong," exact="Hong Kong;" post="Hubei Center for Disease Control and Prevention, Wuhan, Hubei,"/>
   <result pre="30, 2020 Tuberculosis and Respiratory Department, Wuhan Jinyintan Hospital, Wuhan," exact="China" post="7 The New England Journal of Medicine First case"/>
   <result pre="Journal of Medicine First case of 2019 novel coronavirus in" exact="the United States" post="January 31, 2020 The Washington State Department of Health"/>
   <result pre="of Medicine First case of 2019 novel coronavirus in the" exact="United States" post="January 31, 2020 The Washington State Department of Health"/>
   <result pre="Public Health, Li Ka Shing Faculty of Medicine, University of" exact="Hong Kong," post="Hong Kong, Chinab 10 Nature A new coronavirus associated"/>
   <result pre="Li Ka Shing Faculty of Medicine, University of Hong Kong," exact="Hong Kong," post="Chinab 10 Nature A new coronavirus associated with human"/>
   <result pre="Nature A new coronavirus associated with human respiratory disease in" exact="China" post="February 3, 2020 Shanghai Public Health Clinical Center &amp;amp;"/>
   <result pre="138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan," exact="China" post="February 7, 2020 Department of Critical Care Medicine, Zhongnan"/>
   <result pre="Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei," exact="China" post="16 Cell Host &amp;amp; Microbe Genome composition and divergence"/>
   <result pre="composition and divergence of the novel coronavirus (2019-nCoV) originating in" exact="China" post="February 7, 2020 National Institute for Viral Disease Control"/>
   <result pre="7, 2020 National Institute for Viral Disease Control and Prevention," exact="China" post="CDC, Beijing, China; Department of Microbiology, Immunology and Molecular"/>
   <result pre="Basic Medical Sciences, Fudan-Jinbo Joint Research Center, Fudan University, Shanghai," exact="China" post="aNote: The publication date is the date for electronic"/>
   <result pre="currently being studied in phase III clinical trials in both" exact="China" post="and the USA. Favipiravir, a purine nucleoside leading to"/>
   <result pre="studied in phase III clinical trials in both China and" exact="the USA." post="Favipiravir, a purine nucleoside leading to inaccurate viral RNA"/>
   <result pre="endonuclease (CEN) inhibitors and prodrugs thereof Shionogi and Co., Ltd.," exact="Japan" post="US20160122374 20141029 Preparation of nucleosides and methods for treating"/>
   <result pre="USA WO2007075145 20070704 Preparation of benzopyranone derivatives as anti-coronaviral agents" exact="Singapore" post="Polytechnic, Singapore; Shanghai Institute of Materia Medica Chinese Academy"/>
   <result pre="Singapore; Shanghai Institute of Materia Medica Chinese Academy of Sciences," exact="China" post="WO2005021518 20050310 Preparation of 3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid derivatives as cysLT2"/>
   <result pre="antagonists for treatment of respiratory diseases Ono Pharmaceutical Co., Ltd.," exact="Japan" post="WO2007120160 20071025 Preparation of N-heterocyclic acetamides useful for viral"/>
   <result pre="WO2009119167 20091001 Aniline derivative having anti-RNA viral activity KinoPharma, Inc.," exact="Japan" post="WO2013049382 20130404 Broad-spectrum antivirals against 3c or 3c-like proteases"/>
   <result pre="inhibitors: new structures for antivirals and osteoarthritis therapeutics Academia Sinica," exact="Taiwan" post="Patent application WO2013049382 discloses both structures and syntheses of"/>
   <result pre="WO2006051091 spike protein Compositions against SARS-coronavirus and uses thereof Crucell" exact="Holland" post="BV 20041111 WO2006051091 spike protein Compositions against SARS-coronavirus comprising"/>
   <result pre="with non-competing epitopes, and therapeutic and diagnostic uses thereof Crucell" exact="Holland" post="BV 20041111 CN1673231 spike protein Monoclonal antibody of SARS"/>
   <result pre="monoclonal antibodies, and diagnostic, therapeutic and vaccine preparation uses Health" exact="Canada" post="20031205 WO2005060520 spike protein Antibodies specific to SARS-CoV spike"/>
   <result pre="N proteins Antibody binding molecules specific for SARS coronavirus Crucell" exact="Holland" post="BV 20030722 CN1566155 S, N, and M proteins Antibody"/>
   <result pre="vaccine called INO-4800 to be planned for human trials in" exact="the United States" post="in April.57 Protein-Based Vaccines Patent application WO2010063685 by GlaxoSmithKline"/>
   <result pre="called INO-4800 to be planned for human trials in the" exact="United States" post="in April.57 Protein-Based Vaccines Patent application WO2010063685 by GlaxoSmithKline"/>
   <result pre="following a contractual agreement with a Chinese consortium comprised of" exact="China" post="Technology Exchange, Beijing Zhonghua Investment Fund Management, Biology Institute"/>
   <result pre="titers compared to mRNA encoding the S protein S2 subunit." exact="New Zealand" post="white rabbits immunized with MERS-CoV mRNA vaccine encoding the"/>
   <result pre="to be used in the planned Phase 1 study in" exact="the United States." post="Moderna reports that mRNA-1273 is an mRNA vaccine targeting"/>
   <result pre="be used in the planned Phase 1 study in the" exact="United States." post="Moderna reports that mRNA-1273 is an mRNA vaccine targeting"/>
   <result pre="inhibition by the antiviral drug Arbidol. Proc. Natl. Acad. Sci." exact="U. S." post="A.2017, 114 (2), 206–214. 10.1073/pnas.1617020114.28003465 Therapeutic options for the"/>
   <result pre="respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci." exact="U. S." post="A.2004, 101 (26), 9804–9809. 10.1073/pnas.0403492101.15210961 GlaxoSmithKline press release on"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7094151/results/search/country/results.xml">
   <result pre="against adenovirus type 5 infection in vitro and in a" exact="New Zealand" post="rabbit ocular model. Antiviral Res. 1996;31(3):165–172. doi:10.1016/0166-3542(95)00962-08811201 49.RomanowskiEG, YatesKA,"/>
   <result pre="RomanowskiEG, Araullo-CruzT. Topical HPMPC inhibits adenovirus type 5 in the" exact="New Zealand" post="rabbit ocular replication model. Invest Ophthalmol Vis Sci. 1994;35(12):4135–4143.7960596"/>
   <result pre="antiviral resistance and replication of cidofovir-resistant adenovirus variants in the" exact="New Zealand" post="White rabbit ocular model. Invest Ophthalmol Vis Sci. 2001;42(8):1812–1815.11431446"/>
   <result pre="to steroid drops for control of post cataract surgery inflammation." exact="Oman" post="J Ophthalmol. 2016;9(3):150–156. doi:10.4103/0974-620X.19226827843229 76.DunnJP. Uveitis. Prim Care. 2015;42(3):305–323."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7095077/results/search/country/results.xml">
   <result pre="of unknown cause, which raised intense attention not only within" exact="China" post="but also internationally. By the 7th of January 2020,"/>
   <result pre="health measures to reduce further spread of the virus within" exact="China" post="and elsewhere [3, 4]. Spread of COVID-19 According to"/>
   <result pre="1368 deaths. 4127 patients fully recovered. 447 confirmed cases outside" exact="China" post="with one death. By the middle of February 2020,"/>
   <result pre="had been reported in the Western Pacific region (Singapore, Japan," exact="Republic of" post="Korea, Malaysia, Viet Nam, Australia, Philippines, Cambodia), South-East Asia"/>
   <result pre="the Western Pacific region (Singapore, Japan, Republic of Korea, Malaysia," exact="Viet Nam," post="Australia, Philippines, Cambodia), South-East Asia (Thailand, India, Nepal, Sri"/>
   <result pre="Philippines, Cambodia), South-East Asia (Thailand, India, Nepal, Sri Lanka), North" exact="America" post="(the USA and Canada), Europe (Russian Federation, Spain, Belgium,"/>
   <result pre="the WHO has conducted risk assessments, which have concluded that" exact="China" post="is at &quot;very high&quot; risk, while the threat of"/>
   <result pre="in some cases, death [8]. Management of COVID-19 According to" exact="the US" post="Centers for Disease Control and Prevention (CDC), there is"/>
   <result pre="and interim clinical guidance for the 2019 novel coronavirus outbreak:" exact="United States." post="Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6905e1.htm. Accessed 14 Feb 2020. 13.Centers for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7095524/results/search/country/results.xml">
   <result pre="of SARS-CoV-2 infection reported by the National Health Commission of" exact="China" post="(NHC), some of the patients first went to see"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7096384/results/search/country/results.xml">
   <result pre="Edited by: Jayachandran N. Kizhakkedathu, The University of British Columbia," exact="Canada" post="Reviewed by: Peter G. Barlow, Edinburgh Napier University, United"/>
   <result pre="Columbia, Canada Reviewed by: Peter G. Barlow, Edinburgh Napier University," exact="United Kingdom;" post="Yipeng Wang, Soochow University, China *Correspondence: Edwin J. A."/>
   <result pre="Barlow, Edinburgh Napier University, United Kingdom; Yipeng Wang, Soochow University," exact="China" post="*Correspondence: Edwin J. A. Veldhuizen, e.j.a.veldhuizen@uu.nl This article was"/>
   <result pre="Materials and Methods Peptides All the peptides were synthesized by" exact="China" post="Peptides (Shanghai, China) using Fmoc-chemistry. All peptides were purified"/>
   <result pre="This work was supported by a personal fellowship from the" exact="China" post="Scholarship Council (CSC) to LP. Supplementary Material The Supplementary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7097340/results/search/country/results.xml">
   <result pre="6.GoncalvesJLLopesRCOliveiraDBCostaSSMirandaMMRomanosMTSantosNSWiggMDIn vitro anti-rotavirus activity of some medicinal plants used in" exact="Brazil" post="against diarrheaJ Ethnopharmacol200599340340710.1016/j.jep.2005.01.03215876501 7.MaregesiSMPietersLNgassapaODApersSVingerhoetsRCosPBergheDAVlietinckAJScreening of some Tanzanian medicinal plants"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7097450/results/search/country/results.xml">
   <result pre="information LINK Supplementary information S1 (figure) Antiviral drugs approved by" exact="the US" post="FDA. (PDF 109 kb)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7097833/results/search/country/results.xml">
   <result pre="font-style : italic;} Infect Dis RepIDRInfectious Disease Reports2036-74302036-7449PAGEPress Publications, Pavia," exact="Italy" post="pmcid: 7097833 pmid: 32218915 doi: 10.4081/idr.2020.8543 : Expert Opinion"/>
   <result pre="Group (ICOTREG)*[], National Institute for Infectious Diseases &quot;L. Spallanzani&quot;IRCCS, Rome," exact="Italy" post="National Institute for Infectious Diseases &quot;L. Spallanzani&quot;, IRCCS, Via"/>
   <result pre="On March 9 2020, WHO declared COVID-19 a global pandemic." exact="Italy" post="is the second most affected country by COVID-19 infection"/>
   <result pre="spreading outbreak of human respiratory disease (COVID-2019), both within People’s" exact="Republic of" post="China and in several other countries worldwide. On March"/>
   <result pre="of human respiratory disease (COVID-2019), both within People’s Republic of" exact="China" post="and in several other countries worldwide. On March 9"/>
   <result pre="March 9 2020, WHO declared COVID-19 a global pandemic. Currently," exact="Italy" post="is the second most affected country by COVID-19 infection"/>
   <result pre="after China. The first autochthonous infection case was confirmed in" exact="Italy" post="on February 21 2020 and up to now (March"/>
   <result pre="remdesivir in inhibiting replication of SARS-COV2. Moreover, emerging reports from" exact="China" post="suggests that chloroquine has shown a superiority in reducing"/>
   <result pre="In light of this results, an expert consensus group in" exact="China" post="has recommended chloroquine for COVID-19 treatment. Dosage The recommended"/>
   <result pre="for compassionate use, in the first patients with COVID-19 in" exact="the United States." post="Two ongoing clinical randomized clinical trials in China are"/>
   <result pre="compassionate use, in the first patients with COVID-19 in the" exact="United States." post="Two ongoing clinical randomized clinical trials in China are"/>
   <result pre="the United States. Two ongoing clinical randomized clinical trials in" exact="China" post="are evaluating remdesivir for moderate and sever COVID-19 infections."/>
   <result pre="the lack of data on SARSCoV- 2 pathogenesis, studies in" exact="China" post="showed a possible correlation of massive inflammation and severe"/>
   <result pre="trials on TCZ efficacy and safety for COVID-19 treatment, in" exact="China" post="TCZ was recently approved for patients affected by severe"/>
   <result pre="pulmonary complications by the National Health Commission of the People’s" exact="Republic of" post="China. Preliminary data from an observational study conducted in"/>
   <result pre="of China. Preliminary data from an observational study conducted in" exact="China" post="on 21 severe cases receiving TCZ, showed an improvement"/>
   <result pre="doi: 10.1038/s41422-020-0282-0. HolshueMLDeBoltCLindquistSet al.First Case of 2019 Novel Coronavirus in" exact="the United States." post="N Engl J Med2020 Jan 31. doi: 10.1056/NEJMoa2001191. SheahanTPSimsACLeistSRet"/>
   <result pre="10.1038/s41422-020-0282-0. HolshueMLDeBoltCLindquistSet al.First Case of 2019 Novel Coronavirus in the" exact="United States." post="N Engl J Med2020 Jan 31. doi: 10.1056/NEJMoa2001191. SheahanTPSimsACLeistSRet"/>
   <result pre="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study." exact="Hong Kong" post="Med J2003;9:399-406.14660806 ChanJFYaoYYeungMLet al.Treatment With Lopinavir/Ritonavir or Interferon- β1b"/>
   <result pre="exoribonuclease. mBio2018;9:e00221-18.29511076 HolshueMLDeBoltCLindquistSet al.First Case of 2019 Novel Coronavirus in" exact="the United States." post="N Engl J Med2020;382:929-36.32004427 collab: European Medicine Agency. Available"/>
   <result pre="mBio2018;9:e00221-18.29511076 HolshueMLDeBoltCLindquistSet al.First Case of 2019 Novel Coronavirus in the" exact="United States." post="N Engl J Med2020;382:929-36.32004427 collab: European Medicine Agency. Available"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7098069/results/search/country/results.xml">
   <result pre="advanced into human clinical trials to treat COVID-19 in both" exact="China" post="and the U.S., was reported to improve patient outcomes"/>
   <result pre="high morbidity and mortality. The outbreak of SARS in southern" exact="China" post="between November 2002 and July 2003 eventually resulted in"/>
   <result pre="a mortality rate of 9%, while MERS, first identified in" exact="Saudi Arabia" post="in 2012, has caused a total of 2519 laboratory-confirmed"/>
   <result pre="PillaiS. K. (2020) First case of 2019 novel coronavirus in" exact="the United States." post="N. Engl. J. Med.10.1056/NEJMoa2001191. AshburnT. T.; ThorK. B. (2004)"/>
   <result pre="K. (2020) First case of 2019 novel coronavirus in the" exact="United States." post="N. Engl. J. Med.10.1056/NEJMoa2001191. AshburnT. T.; ThorK. B. (2004)"/>
   <result pre="and its complex with an inhibitor. Proc. Natl. Acad. Sci." exact="U. S." post="A.100, 13190–13195. 10.1073/pnas.1835675100.14585926 ChouK.-C.; WeiD.-Q.; ZhongW.-Z. (2003) Binding mechanism"/>
   <result pre="for public health preparedness for mass gatherings at the 2016" exact="Brazil" post="Olympic Games. Int. J. Infect. Dis.44, 11–5. 10.1016/j.ijid.2016.02.001.26854199 Cao-LormeauV.-M.;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7100427/results/search/country/results.xml">
   <result pre="epidemic of coronavirus disease 2019 (COVID-19) has spread rapidly throughout" exact="China" post="and the world since 2019.As of March 3rd 2020,"/>
   <result pre="China and the world since 2019.As of March 3rd 2020," exact="China" post="had reported a total of 80,304 cases of COVID-19,"/>
   <result pre="(the Sixth version) issued by the National Health Commission of" exact="China" post="is only available for adults in the field of"/>
   <result pre="prevention of COVID-19 infection in children was found in the" exact="China" post="Clinical Trial Registry Center; another clinical trial of darunavir"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7100484/results/search/country/results.xml">
   <result pre="doi: 10.1007/s11095-020-02799-8 : Perspective Tilorone: a Broad-Spectrum Antiviral Invented in" exact="the USA" post="and Commercialized in Russia and beyond EkinsSeansean@collaborationspharma.com1LaneThomas R.1MadridPeter B.2[1],"/>
   <result pre="a Broad-Spectrum Antiviral Invented in the USA and Commercialized in" exact="Russia" post="and beyond EkinsSeansean@collaborationspharma.com1LaneThomas R.1MadridPeter B.2[1], grid.492575.8Collaborations Pharmaceuticals, Inc., [2],"/>
   <result pre="a small-molecule orally bioavailable drug that was originally discovered in" exact="the USA" post="and is currently used clinically as an antiviral in"/>
   <result pre="USA and is currently used clinically as an antiviral in" exact="Russia" post="and the Ukraine. Over the years there have been"/>
   <result pre="Ebola virus outbreaks in Africa (1), the Zika virus in" exact="Brazil" post="(2) and currently we are in the midst of"/>
   <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2) (3,4) currently spreading globally from" exact="China" post="at the time of writing. Some of these viruses"/>
   <result pre="currently used clinically as an antiviral in several countries outside" exact="the USA" post="and is sold under the trade names Amixin® or"/>
   <result pre="names Amixin® or Lavomax®. It is approved for use in" exact="Russia" post="for several viral disease indications (influenza, acute respiratory viral"/>
   <result pre="in the list of vital and essential medicines of the" exact="Russian Federation" post="(10). Tilorone is also registered for human use in"/>
   <result pre="in Ukraine, Kazakhstan, Belarus, Armenia, Georgia, Kyrgyzstan, Moldova, Turkmenistan, and" exact="Uzbekistan" post="as an antiviral and immunomodulating medication. In Russia, tilorone"/>
   <result pre="coronaviruses including MERS-CoV (18) (Table I). Human clinical studies outside" exact="the US" post="evaluated tilorone as a treatment for Acute Respiratory Viral"/>
   <result pre="Russian journals (23,25,27,28). Besides this track record of use in" exact="Russia" post="and neighboring countries, tilorone has never been evaluated and"/>
   <result pre="Virus Strain Genus Type Cell line EC50(μM) CC50(μM) Reference EBOV" exact="Zaire" post="Filovirus -ssRNA HeLa 0.23 6.2 (31) EBOV Zaire Filovirus"/>
   <result pre="Reference EBOV Zaire Filovirus -ssRNA HeLa 0.23 6.2 (31) EBOV" exact="Zaire" post="Filovirus - ssRNA Vero 76 &amp;gt;11* 11 (32) MARV"/>
   <result pre="influenza etc., there are currently no broad-spectrum antivirals approved in" exact="the USA." post="In contrast, tilorone has been widely used outside the"/>
   <result pre="the USA. In contrast, tilorone has been widely used outside" exact="the USA" post="for several decades and recent data suggests efficacy in"/>
   <result pre="addition, there are other broad spectrum antiviral drugs approved in" exact="Russia" post="or elsewhere which may also be worthy of further"/>
   <result pre="controls Secondary Efficacy Endpoints Target: Broad species coverage (Zaire and" exact="Sudan" post="EBOV and Marburg virus; Bundibugyo EBOV) Minimal: Zaire and"/>
   <result pre="(Zaire and Sudan EBOV and Marburg virus; Bundibugyo EBOV) Minimal:" exact="Zaire" post="and Sudan EBOV Expected Safety Outcomes Target: No serious"/>
   <result pre="Sudan EBOV and Marburg virus; Bundibugyo EBOV) Minimal: Zaire and" exact="Sudan" post="EBOV Expected Safety Outcomes Target: No serious adverse effects"/>
   <result pre="State -nCo VCIT. First Case of 2019 Novel Coronavirus in" exact="the United States" post="N Engl J Med 2020. 5.CDC. Influenza (flu). Available"/>
   <result pre="-nCo VCIT. First Case of 2019 Novel Coronavirus in the" exact="United States" post="N Engl J Med 2020. 5.CDC. Influenza (flu). Available"/>
   <result pre="Oral Pyronaridine Tetraphosphate and Favipiravir Against Ebola Virus Infection in" exact="Guinea" post="Pig Submitted. 2020. 34.Ekins S, Madrid PB. Tilorone: A"/>
   <result pre="change of mitochondrial potential of rat hepatocytes. Fiziolohichnyi zhurnal (Kiev," exact="Ukraine" post=": 1994). 2012;58(2):39–43. 44.DuttaMRobertsonSJOkumuraAScottDPChangJWeissJMSturdevantGLFeldmannFHaddockEChiramelAIPoniaSSDoughertyJDKatzeMGRasmussenALBestSMA systems approach reveals MAVS signaling"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7101875/results/search/country/results.xml">
   <result pre="Abstract The coronavirus disease 19 (COVID-19) is quickly spreading across" exact="China" post="and globally. Pharmacy services are an important pillar in"/>
   <result pre="international pharmacy community in the response to these needs. Keywords" exact="China" post="Coronavirus COVID-19 Pharmaceutical care Pharmacists Pharmacy service Public health"/>
   <result pre="acute respiratory syndrome coronavirus (SARS-CoV-2) began in Wuhan, Hubei Province," exact="China" post="in December 2019 [1]. The genetic characteristics of SARS-CoV-2"/>
   <result pre="of March 12, 2020, there were 80,981 confirmed cases in" exact="China" post="(3173 deaths) and 44,067 cases in 117 countries/territories/areas outside"/>
   <result pre="China (3173 deaths) and 44,067 cases in 117 countries/territories/areas outside" exact="China" post="(1440 deaths) [3]. Currently there are no approved antiviral"/>
   <result pre="hospitals, the &quot;Square Cabin Hospitals&quot; have been built in Wuhan," exact="China" post="(the epidemic epicenter in China) to treat patients with"/>
   <result pre="Pharmacists are actively engaging in the public health operation in" exact="China" post="since the outbreak, either at their home hospitals and"/>
   <result pre="share our experiences of providing pharmacy services combating coronavirus in" exact="China" post="to disseminate what we have learned to the international"/>
   <result pre="pharmacy’s responses in meeting the needs of pharmacy services in" exact="China" post="during the epidemic. Pharmacy responses to combat the coronavirus"/>
   <result pre="the epidemic. Pharmacy responses to combat the coronavirus epidemic in" exact="China" post="Response 1: Draft professional service guidance to pharmacists and"/>
   <result pre="specific vaccine and no effective antiviral therapy against SARS-CoV-2. The" exact="China" post="National Health Commission (CNHC) has released the &quot;Diagnosis and"/>
   <result pre="are based on past experiences during the SARS outbreak in" exact="China" post="in 2003 with the consideration of lack of drug"/>
   <result pre="activities Event-driven pharmaceutical care is provided to COVID-19 patients in" exact="China" post="during the epidemic. The event-driven pharmaceutical care goes beyond"/>
   <result pre="China) groups are established by pharmacy experts and pharmacists in" exact="China" post="to provide clinical support for front-line pharmacists in Hubei,"/>
   <result pre="through person-to-person transmission during the coronavirus epidemic, medical institutions across" exact="China" post="have launched remote pharmacy services such as online drug"/>
   <result pre="regarding the epidemic [13]. For example, after the media in" exact="China" post="reported that Shuanghuanglian, a TCM that contains extracts from"/>
   <result pre="for a coronavirus treatment. During the first week of February," exact="China" post="launched two placebo-controlled trials of remdesivir, slated to include"/>
   <result pre="high-quality evidence of treatment efficacy and safety. In response, the" exact="China" post="State Council issued the &quot;Notice on Standardizing Medical Institutions"/>
   <result pre="to the COVID-19 epidemic. The experiences and lessons learned in" exact="China" post="not only allow the Chinese pharmacy profession to improve"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102518/results/search/country/results.xml">
   <result pre="K.rplemper@gsu.edu⁎[], ⁎Reprint requests: Richard K. Plemper, Institute for Biomedical Sciences," exact="Georgia" post="State University, Atlanta, GA 30303. rplemper@gsu.edu pmc-release: 2020-2-2ppub: 2020-6epub:"/>
   <result pre="other influenza drug classes in circulating viruses, many countries including" exact="the United States" post="and China have banned their use in agriculture. In"/>
   <result pre="influenza drug classes in circulating viruses, many countries including the" exact="United States" post="and China have banned their use in agriculture. In"/>
   <result pre="in circulating viruses, many countries including the United States and" exact="China" post="have banned their use in agriculture. In the past"/>
   <result pre="due to high level of preexisting resistance †conditionally approved in" exact="Japan" post="against emerging influenza viruses resistant to other antivirals Neuraminidase"/>
   <result pre="founding member of the PA endonuclease inhibitor class Licensed in" exact="Japan" post="and the United States since 2018, baloxavir marboxil (Fig"/>
   <result pre="of the PA endonuclease inhibitor class Licensed in Japan and" exact="the United States" post="since 2018, baloxavir marboxil (Fig 1) is the first"/>
   <result pre="the PA endonuclease inhibitor class Licensed in Japan and the" exact="United States" post="since 2018, baloxavir marboxil (Fig 1) is the first"/>
   <result pre="through mice.85,86 A small percentage of influenza viruses circulating in" exact="the United States" post="in the 2016/2017 and 2017/2018 seasons, and thus prior"/>
   <result pre="mice.85,86 A small percentage of influenza viruses circulating in the" exact="United States" post="in the 2016/2017 and 2017/2018 seasons, and thus prior"/>
   <result pre="close to the approved human dose.99,102 Although conditionally licensed in" exact="Japan" post="for the treatment of pathogenic influenza viruses resistant to"/>
   <result pre="with proteolytic cleavageJ Gen Virol71Pt 51990118911971693166 3GartenR.BlantonL.ElalA.I.A.AlabiN.BarnesJ.BiggerstaffM.Update: influenza activity in" exact="the United States" post="during the 2017-18 season and composition of the 2018-19"/>
   <result pre="proteolytic cleavageJ Gen Virol71Pt 51990118911971693166 3GartenR.BlantonL.ElalA.I.A.AlabiN.BarnesJ.BiggerstaffM.Update: influenza activity in the" exact="United States" post="during the 2017-18 season and composition of the 2018-19"/>
   <result pre="Infect Dis2212020637031419295 87GubarevaL.V.MishinV.P.PatelM.C.Assessing baloxavir susceptibility of influenza viruses circulating in" exact="the United States" post="during the 2016/17 and 2017/18 seasonsEuro Surveill2420191800666 88KoszalkaP.TilmanisD.RoeM.VijaykrishnaD.HurtA.C.Baloxavir marboxil"/>
   <result pre="Dis2212020637031419295 87GubarevaL.V.MishinV.P.PatelM.C.Assessing baloxavir susceptibility of influenza viruses circulating in the" exact="United States" post="during the 2016/17 and 2017/18 seasonsEuro Surveill2420191800666 88KoszalkaP.TilmanisD.RoeM.VijaykrishnaD.HurtA.C.Baloxavir marboxil"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102521/results/search/country/results.xml">
   <result pre="was identified [1]. This virus has affected many persons in" exact="China" post="and spread to other countries in a very short"/>
   <result pre="the International Health Regulations[2]. According to the Daily Report of" exact="China" post="National Health Commission, as of this writing on February"/>
   <result pre="of the pneumonia that it can cause. While mainly in" exact="China" post="at this point, viral spread is ongoing and has"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102522/results/search/country/results.xml">
   <result pre="discovery of another four new human coronaviruses, namely (iii) HCoV-" exact="Hong Kong" post="University 1 (HKU1) 7, 8 (iv) HCoV-NL63, (v) severe"/>
   <result pre="2013 [22]. However, the major outbreak was happened in the" exact="Republic of" post="Korea in 2015 [23]. The virus infection was majorly"/>
   <result pre="with the mortality of rate of ∼39% worldwide, while in" exact="Saudi Arabia" post="alone it was 37.5%[25].In the last two decades, there"/>
   <result pre="vitro, remdesivir showed potent antiviral activity against both Malaysian and" exact="Bangladesh" post="genotypes of Nipah virus and reduced replication of Nipah"/>
   <result pre="genotypes of Nipah virus and reduced replication of Nipah virus" exact="Malaysia" post="in primary human lung microvascular endothelial cells by more"/>
   <result pre="novel viruses from patients with respiratory diseaseProc. Natl. Acad. Sci." exact="U. S." post="A.5719679339405231356 7LauS.K.P.Coronavirus HKU1 and other coronavirus infections in Hong"/>
   <result pre="receptor-binding domain complexed with its human receptorProc. Natl. Acad. Sci." exact="U. S." post="A.1062009199701997419901337 38Van DoremalenN.Host species restriction of Middle East respiratory"/>
   <result pre="targeting severe acute respiratory syndrome human coronavirusProc. Natl. Acad. Sci." exact="U. S." post="A.1012004100121001715226499 76ShinJ.S.Saracatinib inhibits Middle East respiratory syndrome-coronavirus replication in"/>
   <result pre="papain-like protease/deubiquitinase inhibitors blocks SARS virus replicationProc. Natl. Acad. Sci." exact="U. S." post="A.1052008161191612418852458 103ParkJ.Y.Evaluation of polyphenols from Broussonetia papyrifera as coronavirus"/>
   <result pre="two-step, furin-mediated activation of the spike proteinProc. Natl. Acad. Sci." exact="U. S." post="A.1112014152141521925288733 156AdedejiA.O.Novel inhibitors of severe acute respiratory syndrome coronavirus"/>
   <result pre="supervision of Prof. Dr Sang-Hun Jung at Chungnam National University," exact="South Korea." post="In 2011, he won a ‘Japanese Society for the"/>
   <result pre="Chemicals and Pharmaceuticals. Then, he moved to Chungam National University," exact="South Korea," post="to continue his research as a Postdoctoral Researcher and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102548/results/search/country/results.xml">
   <result pre="humans, a novel coronavirus (SARS-CoV-2) was detected recently in Wuhan," exact="China" post="[3,4]. Like the other two highly pathogenic coronaviruses SARS-CoV"/>
   <result pre="Fourth/Fifth/Sixth/Seventh Edition) issued by National Health Commission of the People’s" exact="Republic of" post="China and also recommended by 20 provincial health commissions"/>
   <result pre="issued by National Health Commission of the People’s Republic of" exact="China" post="and also recommended by 20 provincial health commissions including"/>
   <result pre="(2019-nCoV) Pneumonia issued by National Health Commission of the People’s" exact="Republic of" post="China The purpose of this study was to demonstrate"/>
   <result pre="issued by National Health Commission of the People’s Republic of" exact="China" post="The purpose of this study was to demonstrate whether"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102570/results/search/country/results.xml">
   <result pre="trials of treatments for seasonal influenza have been performed in" exact="Japan" post="and US, and favipiravir was approved as a treatment"/>
   <result pre="as a treatment for novel or re-emerging influenza viruses in" exact="Japan" post="in 2014. Favipiravir is considered for administration to patients"/>
   <result pre="al., 2016). Since children died of avian influenza A(H5N1) in" exact="Hong Kong" post="in 1997 (Ku &amp;amp; Chan, 1999), concern regarding novel"/>
   <result pre="has been used to treat patients with severe influenza in" exact="China" post="(Cao, 2018; Wang et al., 2019). Although each novel"/>
   <result pre="trials of treatments for seasonal influenza have been performed in" exact="Japan" post="and the US, and favipiravir was approved as a"/>
   <result pre="treatments for seasonal influenza have been performed in Japan and" exact="the US," post="and favipiravir was approved as a treatment for novel"/>
   <result pre="as a treatment for novel or re-emerging influenza viruses in" exact="Japan" post="in 2014. However, favipiravir (Avigan®) is only considered for"/>
   <result pre="been performed to assess its efficacy in treating SFTS in" exact="Japan" post="(Yasukawa, 2016) and as a combination therapy with oseltamivir"/>
   <result pre="therapy with oseltamivir to treat patients with severe influenza in" exact="China" post="(Cao, 2018; Wang et al., 2019). In addition to"/>
   <result pre="possessing an NA H275Y substitution spread globally, 12.3% (142/1155) in" exact="the US" post="(Dharan et al., 2009), 64% in South Africa, Oceania"/>
   <result pre="(142/1155) in the US (Dharan et al., 2009), 64% in" exact="South Africa," post="Oceania and SE Asia (Hurt et al., 2009), and"/>
   <result pre="have elapsed since an avian influenza case was reported in" exact="Hong Kong" post="in 1997, and a decade has elapsed since the"/>
   <result pre="treating patients with severe influenza in combination with oseltamivir in" exact="China" post="(Cao, 2018; Wang et al., 2019). Favipiravir and oseltamivir"/>
   <result pre="day for 9 days, and the approved favipiravir dose in" exact="Japan" post="is 1600 mg twice a day on day 1"/>
   <result pre="model (Smither et al., 2014). An Ebola study conducted in" exact="Guinea" post="included 126 patients, and 111 were analyzed and compared"/>
   <result pre="significant (Sissoko et al., 2016). An Ebola study conducted in" exact="Sierra Leone" post="included 39 favipiravir-treated patients and 85 historical control patients."/>
   <result pre="clinical recovery compared to oseltamivir monotherapy in severe influenza in" exact="China" post="(Cao, 2018; Wang et al., 2019). 5.4 The dose"/>
   <result pre="mg package insert). The approved favipiravir dose for influenza in" exact="Japan" post="is 1600 mg twice a day on day 1"/>
   <result pre="al., 2013). Since children died of avian influenza A(H5N1) in" exact="Hong Kong" post="in 1997 (Ku &amp;amp; Chan, 1999), concern has been"/>
   <result pre="Novartis, and research funding from Maruho Co., Ltd., MSD, and" exact="Japan" post="Blood Products Organization; all payments were sent to the"/>
   <result pre="Favipiravir (T-705)-Sierra Leone, 2014Clinical Infectious Diseases6320161288129427553371 BakerL.Bat rabies outbreak in" exact="Peru" post="claims one, but others survive: Mass vaccination campaign underwayhttps://rabiesalliance.org/resource/bat-rabies-outbreak-peru-claims-one-others-survive-mass-vaccination-campaign-underway2017"/>
   <result pre="among RNA virusesProceedings of the National Academy of Sciences of" exact="the United States" post="of America901993417141758387212 ElionG.B.Mechanism of action and selectivity of acyclovirThe"/>
   <result pre="RNA virusesProceedings of the National Academy of Sciences of the" exact="United States" post="of America901993417141758387212 ElionG.B.Mechanism of action and selectivity of acyclovirThe"/>
   <result pre="a broad spectrum inhibitor of viral RNA polymeraseProceedings of the" exact="Japan" post="Academy. Series B, Physical and Biological Sciences932017449463 FurutaY.TakahashiK.FukudaY.KunoM.KamiyamaT.KozakiK. …ShirakiK.In"/>
   <result pre="favipiravir in influenzaProceedings of the National Academy of Sciences of" exact="the United States" post="of America1152018116131161830352857 GowenB.B.JuelichT.L.SefingE.J.BraselT.SmithJ.K.ZhangL. …FreibergA.N.Favipiravir (T-705) inhibits Junin virus infection"/>
   <result pre="in influenzaProceedings of the National Academy of Sciences of the" exact="United States" post="of America1152018116131161830352857 GowenB.B.JuelichT.L.SefingE.J.BraselT.SmithJ.K.ZhangL. …FreibergA.N.Favipiravir (T-705) inhibits Junin virus infection"/>
   <result pre="(T-705) inhibits Junin virus infection and reduces mortality in a" exact="Guinea" post="pig model of argentine hemorrhagic feverPLoS Neglected Tropical Diseases72013e2614"/>
   <result pre="influenza A virusesProceedings of the National Academy of Sciences of" exact="the United States" post="of America107201088288720080770 KuA.S.ChanL.T.The first case of H5N1 avian influenza"/>
   <result pre="A virusesProceedings of the National Academy of Sciences of the" exact="United States" post="of America107201088288720080770 KuA.S.ChanL.T.The first case of H5N1 avian influenza"/>
   <result pre="Lassa feverClinical Infectious Diseases65201785585929017278 RenaultP.JosseranL.PierreV.Chikungunya-related fatality rates, Mauritius, India, and" exact="Reunion" post="IslandEmerging Infectious Diseases1420081327 Rocha-PereiraJ.JochmansD.DallmeierK.LeyssenP.NascimentoM.S.NeytsJ.Favipiravir (T-705) inhibits in vitro norovirus"/>
   <result pre="syndromeAntimicrobial Agents and Chemotherapy5720134673468023856782 SafronetzD.RosenkeK.WestoverJ.B.MartellaroC.OkumuraA.FurutaY. …GowenB.B.The broad-spectrum antiviral favipiravir protects" exact="Guinea" post="pigs from lethal Lassa virus infection post-disease onsetScientific Reports520151477526456301"/>
   <result pre="the Ministry of Education, Culture, Sports, Science and Technology of" exact="Japan" post="and joint research project with Toyama Chemical Co., Ltd."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102586/results/search/country/results.xml">
   <result pre="study, the results are very encouraging. Further, a report from" exact="China" post="showed good efficacy of CQ in patients with COVID-19,"/>
   <result pre="4 Use of ibuprofen and other NSAIDs A doctor from" exact="France" post="cited four cases of young patients with COVID-19 and"/>
   <result pre="search and a narrative review with a special reference to" exact="India" post="and other developing countriesDiabetes Metab Syndr: Clin Res RevMarch"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102587/results/search/country/results.xml">
   <result pre="search and a narrative review with a special reference to" exact="India" post="and other developing countries SinghAwadhesh Kumardraksingh_2001@yahoo.coma∗SinghAkritibShaikhAltamashcSinghRituaMisraAnoopdef[a], [b], [c], [d],"/>
   <result pre="been approved in the treatment of type 2 diabetes in" exact="India" post="since 2014 as a third- or fourth-line drug, it"/>
   <result pre="disease (e.g. rheumatic diseases). Approved for treatment of T2DM in" exact="India" post="Remdesivir Adenosine nucleotide analogues Inhibits viral application Effective against"/>
   <result pre="available in a letter form, interestingly, this early result led" exact="China" post="to include chloroquine in the prevention and treatment of"/>
   <result pre="COVID-19 pneumonia. Moreover, The National Health Commission of the People’s" exact="Republic of" post="China recommended inclusion of chloroquine in the next version"/>
   <result pre="Moreover, The National Health Commission of the People’s Republic of" exact="China" post="recommended inclusion of chloroquine in the next version of"/>
   <result pre="preventing community transmission of COVID-19. Since the data from Wuhan," exact="China" post="showed that some patients were carrier as long as"/>
   <result pre="Control Trial (THDMS-COVID19) Treatment Antiviral drugs plus Chloroquine PBO 80" exact="Thailand" post="NCT04303299 Chloroquine Prevention of Coronavirus Disease (COVID-19) in the"/>
   <result pre="prophylaxis in two separate groups Darunavir/Cobicistat plus Chloroquine PBO 3040" exact="Germany" post="NCT04304053 The Clinical Study of Carrimycin on Treatment Patients"/>
   <result pre="Patients With COVID-19 Treatment Carrimycin Lopinavir/ritonavir Arbidol Chloroquine PBO 520" exact="China" post="NCT04286503 Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients with"/>
   <result pre="of Pneumonia Caused by 2019-nCoV (HC-nCoV) Treatment HCQ PBO 30" exact="China" post="NCT04261517 Post-exposure Prophylaxis for SARS-Coronavirus-2 Post exposure prophylaxis HCQ"/>
   <result pre="Post-exposure Prophylaxis for SARS-Coronavirus-2 Post exposure prophylaxis HCQ PBO 1500" exact="United States" post="NCT04308668 HCQ-hydroxychloroquine, PBO- placebo, N - number. Future directions:"/>
   <result pre="further studies. 4.Use of HCQ in patients with diabetes in" exact="India" post="where it is already approved for treatment: It would"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102605/results/search/country/results.xml">
   <result pre="work was supported by 10.13039/501100001809Chinese National Natural Science Foundation of" exact="China" post="(31400769, 31870903, 31870868, and 31670930), 10.13039/501100004608Jiangsu Province Natural Science"/>
   <result pre="for the effect of lithium on developmentProc. Natl. Acad. Sci." exact="U. S." post="A.931996845584598710892 19YanagitaT.MarutaT.UezonoY.SatohS.YoshikawaN.NemotoT.Lithium inhibits function of voltage-dependent sodium channels and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102632/results/search/country/results.xml">
   <result pre="originNature579202027027332015507 2.MenacheryV.D.SARS-like WIV1-CoV poised for human emergenceProc. Natl. Acad. Sci." exact="U. S." post="A.11320163048305326976607 3.ZhuN.A novel coronavirus from patients with pneumonia in"/>
   <result pre="sequential proteolytic cleavage at two distinct sitesProc. Natl. Acad. Sci." exact="U. S." post="A.10620095871587619321428 10.ZhouY.Protease inhibitors targeting coronavirus and filovirus entryAntivir. Res.1162015768425666761"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102646/results/search/country/results.xml">
   <result pre="designated SARS-CoV-2, began spreading in December 2019 in Wuhan City," exact="China" post="causing pneumonia called COVID-19. The spread of SARS-CoV-2 has"/>
   <result pre="novel coronavirus designated COVID-19, emerged in the city of Wuhan," exact="China" post="[[1], [2], [3]]. According to the World Health Organization"/>
   <result pre="with 11,268 confirmed deaths, mostly in China, Europe, and the" exact="Islamic Republic of Iran." post="On 20 January 2020, the National Health Commission of"/>
   <result pre="11,268 confirmed deaths, mostly in China, Europe, and the Islamic" exact="Republic of Iran." post="On 20 January 2020, the National Health Commission of"/>
   <result pre="Iran. On 20 January 2020, the National Health Commission of" exact="China" post="confirmed human-to-human transmission of the COVID-19 outbreak [8]. Ten"/>
   <result pre="homology model for the SARS-CoV-2 RdRp was built using the" exact="Swiss" post="Model web server [31]. We used the SARS HCoV"/>
   <result pre="the sequence identity between the SARS-CoV-2 and SARS RdRps, the" exact="Swiss" post="model constructed a valid, high-quality model. Fig. 1(A) shows"/>
   <result pre="model (801 residues) was generated by homology modeling using the" exact="Swiss" post="Model web server. The SARS HCoV RdRp (PDB ID:"/>
   <result pre="Organization 7ParrJ.Pneumonia in China: lack of information raises concerns among" exact="Hong Kong" post="health workersBMJ36856202010.1136/bmj.m56Published 2020 Jan 8 8YangL.China Confirms Human-to-Human Transmission"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102647/results/search/country/results.xml">
   <result pre="caused approximately 710,000 hospitalizations and up to 79,400 deaths in" exact="the United States" post="alone (CDC, 2018; Rolfes et al., 2019). Of particular"/>
   <result pre="approximately 710,000 hospitalizations and up to 79,400 deaths in the" exact="United States" post="alone (CDC, 2018; Rolfes et al., 2019). Of particular"/>
   <result pre="collab: CDCEstimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths in" exact="the United States" post="— 2017–2018 Influenza Season2018CDC[WWW Document]. Influ. URLhttps://www.cdc.gov/flu/about/burden/2017-2018.htmaccessed 7.20.19 ChenB.J.LeserG.P.JacksonD.LambR.A.The"/>
   <result pre="CDCEstimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths in the" exact="United States" post="— 2017–2018 Influenza Season2018CDC[WWW Document]. Influ. URLhttps://www.cdc.gov/flu/about/burden/2017-2018.htmaccessed 7.20.19 ChenB.J.LeserG.P.JacksonD.LambR.A.The"/>
   <result pre="the V27A mutantJ. Med. Chem.5620139265927410.1021/jm401340p24237039 RolfesM.A.FlanneryB.ChungJ.O'HalloranA.GargS.BelongiaE.A.GaglaniM.ZimmermanR.JacksonM.L.MontoA.S.AldenN.B.AndersonE.BennettN.M.BillingL.EckelS.KirleyP.D.LynfieldR.MonroeM.L.SpencerM.SpinaN.TalbotH.K.ThomasA.TorresS.Yousey-HindesK.SingletonJ.PatelM.ReedC.FryA.M.Effects of influenza vaccination in" exact="the United States" post="during the 2017–2018 influenza seasonClin. Infect. Dis.201910.1093/cid/ciz075 RosenbergM.R.CasarottoM.G.Coexistence of"/>
   <result pre="V27A mutantJ. Med. Chem.5620139265927410.1021/jm401340p24237039 RolfesM.A.FlanneryB.ChungJ.O'HalloranA.GargS.BelongiaE.A.GaglaniM.ZimmermanR.JacksonM.L.MontoA.S.AldenN.B.AndersonE.BennettN.M.BillingL.EckelS.KirleyP.D.LynfieldR.MonroeM.L.SpencerM.SpinaN.TalbotH.K.ThomasA.TorresS.Yousey-HindesK.SingletonJ.PatelM.ReedC.FryA.M.Effects of influenza vaccination in the" exact="United States" post="during the 2017–2018 influenza seasonClin. Infect. Dis.201910.1093/cid/ciz075 RosenbergM.R.CasarottoM.G.Coexistence of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7102657/results/search/country/results.xml">
   <result pre="Article Advance of promising targets and agents against COVID-19 in" exact="China" post="DuanYongtao[], ZhuHai-Liangzhuhl@nju.edu.cn⁎⁎[], ZhouChongchenzhouchongchen@163.com⁎[], ⁎⁎Corresponding author: zhuhl@nju.edu.cn ⁎Corresponding author: zhouchongchen@163.com"/>
   <result pre="and has affected &amp;gt;46 countries with 3664 cases confirmed outside" exact="China" post="and 57 related deaths recorded. Particularly, the abruptness and"/>
   <result pre="speed of the COVID-19 outbreak in Japan, Iran, Korea and" exact="Italy" post="in late February 2020, indicating that a global catastrophe"/>
   <result pre="Remdesivir cured the first case of SARS-CoV-2 infection confirmed in" exact="the USA," post="which prompted Gilead and the Chinese authorities to move"/>
   <result pre="ritonavir, targeting 3Clpro, were used to treat SARS patients from" exact="China" post="in 2003. Shortly after the emergence of MERS-CoV, researchers"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7103671/results/search/country/results.xml">
   <result pre="ICAR –Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh 243122," exact="India" post="collection: 2020epub: 2020-3-317received: 2020-2-08rev-recd: 2020-2-20accepted: 2020-2-22(C) Taylor &amp;amp; Francis,"/>
   <result pre="Coronavirus disease 2019) that emerged from Wuhan, Hubei province of" exact="China" post="has spread to many countries worldwide. Efforts have been"/>
   <result pre="syndrome coronavirus (SARS-CoV).1 The ongoing coronavirus threat that emerged in" exact="China" post="has rapidly spread to other countries and has been"/>
   <result pre="interferon-α 2b therapy has been registered for hospitalized patients in" exact="China" post="(ChiCTR2000029308).76 Oral administration of neuraminidase inhibitors such as oseltamivir"/>
   <result pre="used as an empirical drug for COVID-19 suspected cases in" exact="China" post="hospitals even though there is no evidence of its"/>
   <result pre="ShiZLCross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci" exact="China" post="Life Sci. 2017;60(12):1399–402. doi:10.1007/s11427-017-9189-3.29134417 40.CohenJNew coronavirus threat galvanizes scientists."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7103696/results/search/country/results.xml">
   <result pre="Hospital, Peking Union Medical College, Chinese Academy of Medical SciencesPeople’s" exact="Republic of" post="China[b], Shanghai Public Health Clinical CenterPeople’s Republic of China[c],"/>
   <result pre="Medical SciencesPeople’s Republic of China[b], Shanghai Public Health Clinical CenterPeople’s" exact="Republic of" post="China[c], Department of Infectious Diseases, Huashan Hospital, Shanghai Medical"/>
   <result pre="of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan UniversityPeople’s" exact="Republic of" post="China CONTACT Wenhong Zhang zhangwenhong@fudan.edu.cnDepartment of Infectious Diseases, Huashan"/>
   <result pre="Diseases, Huashan Hospital, Shanghai Medical College, Fudan UniversityPeople’s Republic of" exact="China" post="CONTACT Wenhong Zhang zhangwenhong@fudan.edu.cnDepartment of Infectious Diseases, Huashan Hospital,"/>
   <result pre="Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, People’s" exact="Republic of" post="China Taisheng Li litsh@263.netDepartment of Infectious Diseases, Peking Union"/>
   <result pre="Shanghai Medical College, Fudan University, Shanghai 200040, People’s Republic of" exact="China" post="Taisheng Li litsh@263.netDepartment of Infectious Diseases, Peking Union Medical"/>
   <result pre="Union Medical College, Chinese Academy of Medical Sciences, Beijing, People’s" exact="Republic of" post="China Hongzhou Lu luhongzhou@fudan.edu.cnShanghai Public Health Clinical Center, Shanghai"/>
   <result pre="College, Chinese Academy of Medical Sciences, Beijing, People’s Republic of" exact="China" post="Hongzhou Lu luhongzhou@fudan.edu.cnShanghai Public Health Clinical Center, Shanghai 201508,"/>
   <result pre="Hongzhou Lu luhongzhou@fudan.edu.cnShanghai Public Health Clinical Center, Shanghai 201508, People’s" exact="Republic of" post="China collection: 2020epub: 2020-3-391687690received: 2020-3-06accepted: 2020-3-08(C) The Author(s), 2020This"/>
   <result pre="luhongzhou@fudan.edu.cnShanghai Public Health Clinical Center, Shanghai 201508, People’s Republic of" exact="China" post="collection: 2020epub: 2020-3-391687690received: 2020-3-06accepted: 2020-3-08(C) The Author(s), 2020This is"/>
   <result pre="properly cited.TEMI_9_1741327.pdf Abstract ABSTRACT Three leading infectious disease experts in" exact="China" post="were invited to share their bedside observations in the"/>
   <result pre="therapy are very important. Professor Hongzhou Lu, a leader in" exact="China" post="to try various anti-viral drugs, expresses concern on the"/>
   <result pre="current commentary, EMI invited three leading infectious disease experts in" exact="China" post="who have personally participated in the clinical management of"/>
   <result pre="type of COVID-19 patients. Professor Hongzhou Lu (a leader in" exact="China" post="to try various anti-viral drugs to treat COVID-19 cases)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7103900/results/search/country/results.xml">
   <result pre="along with immune-modulating drugs is justifiable. A quick search through" exact="the US" post="National Library of Medicine Clinical Trials registry (https://clinicaltrials.gov/) and"/>
   <result pre="disease management. Preliminary evidence from a small uncontrolled trial in" exact="China" post="proves that tocilizumab in addition to routine therapy is"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7104000/results/search/country/results.xml">
   <result pre="trials of hydroxychloroquine treatment for COVID-19 pneumonia are underway in" exact="China" post="(NCT04261517 and NCT04307693). We are reviewing the results from"/>
   <result pre="China (NCT04261517 and NCT04307693). We are reviewing the results from" exact="China" post="as they emerge. The first study (NCT04261517) has showed"/>
   <result pre="vaccine in preventing Ebola virus disease: final results from the" exact="Guinea" post="ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Lancet389201750551828017403 We"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7104317/results/search/country/results.xml">
   <result pre="immunodeficiency syndrome (AIDS). Currently, the drug has been approved in" exact="Argentina" post="for the treatment of severe cases of myalgic encephalomyelitis/chronic"/>
   <result pre="and/or encapsulated into particles Research laboratories in Germany, China, Italy," exact="the Netherlands," post="Canada, Belgium, Australia, USA Laboratory studies Oncological diseases of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7105343/results/search/country/results.xml">
   <result pre="severe acute respiratory syndrome (SARS)-CoV-2 or COVID-19 coronavirus started in" exact="China" post="in December 2019, there is increasing evidence that those"/>
   <result pre="MIG were highly elevated in the acute phase sera of" exact="Taiwan" post="SARS patients, being IL-18, IP-10, MIG, and MCP-1 were"/>
   <result pre="levels of various inflammatory cytokines in 29, COVID-19 patients in" exact="China" post="and compared the levels between general, severe and critically"/>
   <result pre="Another study involving 20 consecutive SARS patients admitted to a" exact="Hong Kong" post="hospital identified significantly elevated levels of IL-1β within the"/>
   <result pre="outbreak of the 2019 novel coronavirus disease Zhu et al" exact="China" post="2020 COVID-19 complicates the clinical scenario of pulmonary infiltrates"/>
   <result pre="under the outbreak of novel coronavirus pneumonia Li et al" exact="China" post="2020 Recommendations based on stage of cancer: Recurrent metastatic"/>
   <result pre="with coronavirus OC43 in an immunocompromised child Nilsson et al" exact="Sweden" post="2020 A one-year-old child with pre-B acute lymphoblastic leukaemia"/>
   <result pre="Pediatric Patients With Cancer Undergoing Chemotherapy Aydin Köker et al" exact="Turkey" post="2019 Nasopharyngeal aspirates were analysed in patients younger than"/>
   <result pre="Febrile Neutropenia - A Prospective Follow-Up Study Söderman et al" exact="Sweden" post="2016 Nasopharyngeal aspirates were collected during 87 episodes of"/>
   <result pre="Cancer or Undergoing Hematopoietic Cell Transplant. [Review] Hijano et al" exact="Switzerland" post="2018 Clinical manifestations vary significantly depending on the type"/>
   <result pre="infections in paediatric cancer patients undergoing chemotherapy Benites et al" exact="Brazil" post="2014 Paediatric patients with cancer and acute respiratory infection"/>
   <result pre="papain-like protease, a deubiquitinating and deISGylating enzyme Chen et al" exact="Taiwan" post="2009 6-mercaptopurine (6MP) and 6-thioguanine (6TG) have been used"/>
   <result pre="future cornerstone for the chemotherapy of enveloped viruses? Balzarini, J." exact="Belgium" post="2007 Carbohydrate-binding agents (CBA) may be able to block"/>
   <result pre="of infectious complications in hemoblastosis and myelodepression Chebotkevich et al" exact="Russia" post="2006 Only abstract available, article in Russian and not"/>
   <result pre="chemotherapy of severe acute respiratory syndrome [18]. [Review] Kesel AJ" exact="United Arab Emirates" post="2005 25 test materials including interferon-inducer Bananin (BN) was"/>
   <result pre="severe acute respiratory syndrome [18]. [Review] Kesel AJ United Arab" exact="Emirates" post="2005 25 test materials including interferon-inducer Bananin (BN) was"/>
   <result pre="and E genes against SARS-CoV in mice Huali et al" exact="China" post="2005 The M and E are play a role"/>
   <result pre="anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol. Keseal AJ." exact="Germany" post="2003 Bananin acts as zinc (Zn2+) chelator Targets and"/>
   <result pre="From Mechanisms to Potential Therapeutic Tools Fu, Cheng and Wu" exact="China" post="2020 This review suggests that: SARS-CoV S protein can"/>
   <result pre="at increased risk for COVID-19 infection? Fang, Karakiulakis and Roth" exact="Greece" post="2020 The expression of ACE2 is substantially increased in"/>
   <result pre="Drug treatment options for the 2019-new coronavirus (2019- nCoV) Lu" exact="China" post="2020 No evidence given for or against using ibuprofen"/>
   <result pre="acute respiratory syndrome: clinical and laboratory manifestations. Lam, Chan, Wong" exact="China" post="2004 Corticosteroid treatment reduced interleukin 8 (IL-8), monocyte chemoattractant"/>
   <result pre="regulate all? Mahmud-Al-Rafat et al Bangladesh, Germany, Canada, UK and" exact="Australia" post="2019 This review article aimed to look at multiple"/>
   <result pre="illness compared to patients who received placebo).9.9% of patients in" exact="Hong Kong" post="cohort study also suffered opportunitistic infections such as aspergillosis"/>
   <result pre="Martella V, Decaro N, Buonavoglia C, Capobianchi MR, Santoro MG" exact="Italy" post="2006 Utilised observation that cyclopentenone cyclooxygenase (COX) metabolites are"/>
   <result pre="Qu JM, Pan J, Hu BJ, Zhang J, Li ZZ" exact="China" post="(full article only available in Chinese but informative abstract)"/>
   <result pre="treatment for severe acute respiratory syndrome. Chihrin S, Loutfy MR" exact="Canada" post="2014 Anti-inflammatory agents heavily utilised during SARS outbreak as"/>
   <result pre="cells. Cinatl J Jr, Michaelis M, Morgenstern B, Doerr HW" exact="Germany" post="(needs to be purchased) 2005 Investigated influence of SARS-CoV"/>
   <result pre="Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ" exact="Hong Kong" post="2004 Overproduction of TNF-alpha, IL-1, IL-6 and IL-10 hallmark"/>
   <result pre="viral infection.Investigated inflammatory profiles of patients infected with SARS in" exact="Hong Kong" post="hospital.Use of corticosteroids significantly reduced IL-8, MCP-1 and IP-10"/>
   <result pre="early outbreak of severe acute respiratory syndrome [18] in Guangzhou," exact="PR China." post="Zhao Z, Zhang F, Xu M, Huang K, Zhong"/>
   <result pre="Huang S, Deng Z, Wei M, Xiong J, Hawkey PM" exact="China" post="2003 Patients treated in different methods. 2 groups of"/>
   <result pre="in pigs. Atanasova K; Van Gucht S; Van Reeth K." exact="Netherlands" post="2010 22 piglets were assessed to to elucidate the"/>
   <result pre="Xu Y; Zhu Y; Liu Y; Wang X; Wang L." exact="China" post="2020 They investigated forty‐three adult patients with COVID‐19. The"/>
   <result pre="Caraffa, A; Gallenga, C; Ross, R; Frydas, I; Kritas, S." exact="Italy" post="2020 When COVID-19 infect the upper and lower respiratory"/>
   <result pre="Nomura K; Shimotai Y; Momma H; Ichinose M; Kawase T." exact="Netherlands" post="2020 Primary human nasal (HNE) and tracheal (HTE) epithelial"/>
   <result pre="Liu, J; Liu, K; Shang, J; Deng, Y; Wei, S." exact="China" post="2020 29 patients with 2019-ncov admitted to the isolation"/>
   <result pre="Christopher W K; Chan, Michael H M; Wong, Chun K." exact="Australia" post="2004 They have investigated daily changes in plasma inflammatory"/>
   <result pre="Chen M; Cao H; Zhu Y; Zheng J; Zhou H." exact="France" post="2013 They identified a set of SARS-CoV specific GU-rich"/>
   <result pre="Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y" exact="Australia" post="2009 The efficacy of three SARS vaccine candidates was"/>
   <result pre="Qu JM; Pan J; Hu BJ; Zhang J; Li ZZ." exact="China" post="2005 The pulmonary inflammatory reaction in rat models were"/>
   <result pre="Chen YC; Hsiao CH; Hseuh PR; Chie WC; Yang PC." exact="Singapore" post="2005 Fourteen hospitalised patients with a diagnosis of SARS-associated"/>
   <result pre="TNFRI, were highly elevated in the acute phase sera of" exact="Taiwan" post="SARS patients. IL-18, IP-10, MIG, and MCP-1 were significantly"/>
   <result pre="blood cytokines in severe acute respiratory syndrome Wang and Pang" exact="China" post="2003 (Abstract only) This study observed changed in various"/>
   <result pre="in Children With Severe Acute Respiratory Syndrome Ng et al" exact="Hong Kong" post="2004 The authors of this study set out to"/>
   <result pre="IRE1α-Mediated Manipulation of the MicroRNA miR-30a-5p/SOCS1/3 Axis Ma et al" exact="China" post="2018 JAK-signal transducer and activator of transcription (STAT), the"/>
   <result pre="Comprehensive and Ultimate Inhibition of Coronaviral Activity Yang et al" exact="Taiwan" post="2017 Tylophorine-based compounds exert broad spectral, potent inhibition of"/>
   <result pre="29 patients with 2019 novel coronavirus pneumonia. Chen et al" exact="China" post="2020 The levels of several inflammatory markers weremeasured in"/>
   <result pre="RespiratorySyndrome Coronavirus Viroporin 3a Activates the NLRP3Inflammasome. Chen et al" exact="Japan" post="and Taiwan 2019 The authors provide evidence that SARS-CoV"/>
   <result pre="Viroporin 3a Activates the NLRP3Inflammasome. Chen et al Japan and" exact="Taiwan" post="2019 The authors provide evidence that SARS-CoV 3a protein"/>
   <result pre="to coronavirus-induced inflammation: new anti-inflammatory strategy. Kritas et al Greece," exact="Italy" post="and USA 2020 (Abstract Only)Infection with coronavirus activates mast"/>
   <result pre="support this statement. [67] SARS Immunity and Vaccination. Zhu M" exact="China" post="2004 SARS-CoV binds to host cells via a specific"/>
   <result pre="Ye L, Xu S, Sun R, Wang Y, Lou J" exact="China" post="2004 Following the discovery of SARS-CoV, no specific or"/>
   <result pre="Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ" exact="Hong Kong" post="2004 Known that over-expression of IL-1beta hallmark of SARS"/>
   <result pre="and chemokines including IL-1beta in 20 consecutive patients admitted to" exact="Hong Kong" post="hospital.IL-1beta was significantly elevated above normal range within first"/>
   <result pre="SARS coronavirus papain-like proteases via different modes Lin et al" exact="Taiwan" post="2018 (In vitro)Note. (PLpros)= Papain-like proteases MERS-CoV and SARS-CoV"/>
   <result pre="protease of Middle East respiratory syndrome coronavirus Cheng et al" exact="Taiwan" post="2015 (In vitro)At the time of the study, there"/>
   <result pre="Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses. Shen et al" exact="China" post="2019 (In vitro)The authors sought to identify potent broad-spectrum"/>
   <result pre="liquorice roots, and replication of SARS-associated coronavirus Cinatl et al" exact="Germany" post="2003 (In vitro but using clinical samples - Abstract"/>
   <result pre="(MERS CoV) infection at a coronavirus referral center in the" exact="Kingdom of Saudi Arabia." post="Al Ghamdi et al Saudi Arabia 2016 (Clinical example)Eight"/>
   <result pre="infection at a coronavirus referral center in the Kingdom of" exact="Saudi Arabia." post="Al Ghamdi et al Saudi Arabia 2016 (Clinical example)Eight"/>
   <result pre="in the Kingdom of Saudi Arabia. Al Ghamdi et al" exact="Saudi Arabia" post="2016 (Clinical example)Eight patients (15.7%) received mycophenolate mofetil, seven"/>
   <result pre="treatment modalities for Middle East Respiratory Syndrome Mo and Fisher" exact="Singapore" post="2016 (Review)Mycophenolic acid also inhibits purine nucleotide synthesis in"/>
   <result pre="combination therapy was described in a retrospective observational study in" exact="Saudi Arabia" post="involving 51 patients; all of the 8 patients who"/>
   <result pre="for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Al-Tawfiq and Memish" exact="Saudi Arabia" post="2017 (Review)MPA mechanism of action - Direct and indirect"/>
   <result pre="East respiratory syndrome from a molecular perspective. Rabaan et al" exact="Saudi Arabia" post="2017 (Review)Reiteration of the promising results of MPA in"/>
   <result pre="two renal transplant recipients: Case report Al Ghamdi et al" exact="Saudi Arabia" post="2015 Pneumonia caused by MERS-CoV associated with severe morbidity"/>
   <result pre="cyclophilinA-dependent and inhibited by non-immunosuppressivecyclosporine A-derivativesincluding Alisporivir Carbajo-Lozoya et al" exact="Germany" post="2014 Previous study shown that FK506 inhibit coronavirus replication.This"/>
   <result pre="patients with severe acute respiratory syndromeJ Formosan Med Assoc =" exact="Taiwan" post="yi zhi20051041071572316385373 35.HuangK-JSuI-JTheronMet al.An interferon-gamma-related cytokine storm in SARS"/>
   <result pre="patients with severe acute respiratory syndromeJ Formosan Med Assoc =" exact="Taiwan" post="yi zhi20051041071572316385373 51.TsengC-TKPerroneLAZhuHet al.Severe acute respiratory syndrome and the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7106583/results/search/country/results.xml">
   <result pre="epidemic phase [6, 7]. Its incidence was first reported in" exact="Thailand" post="in 1989, and since then, several outbreaks have been"/>
   <result pre="Ph.D. scholarship of Research and Researcher for Industries Projects (RRi)," exact="Thailand" post="Science Research and Innovation, under contract no. PHD61I0042. The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7110985/results/search/country/results.xml">
   <result pre="work was supported by the National Natural Science Foundation of" exact="China" post="(Nos. 81822027 and 81630090), the National Key R&amp;amp;D Program"/>
   <result pre="(Nos. 81822027 and 81630090), the National Key R&amp;amp;D Program of" exact="China" post="(No. 2019YFA0904400), the National Science and Technology Major Projects"/>
   <result pre="al.Isolation of avian influenza A (H5N1) viruses from humans —" exact="Hong Kong," post="May–December 1997JAMA1998279426326410.1001/jama.279.4.2639450697 9.TangRBChenHLAn overview of the recent outbreaks of"/>
   <result pre="13.StegemanABoumaAElbersARde JongMCNodelijkGde KlerkFKochGvan BovenMAvian influenza A virus (H7N7) epidemic in" exact="the Netherlands" post="in 2003: course of the epidemic and effectiveness of"/>
   <result pre="JongMCNodelijkGde KlerkFKochGvan BovenMAvian influenza A virus (H7N7) epidemic in the" exact="Netherlands" post="in 2003: course of the epidemic and effectiveness of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7113931/results/search/country/results.xml">
   <result pre="infection—A brief review of literature BhatiaMohit1GuptaEkta2[1], Department of Microbiology, All" exact="India" post="Institute of Medical Sciences, Rishikesh, Uttarakhand, India[2], Department of"/>
   <result pre="of Virology, Institute of Liver and Biliary Sciences, New Delhi," exact="India" post="Address for correspondence: Dr. Ekta Gupta, Department of Virology,"/>
   <result pre="Africa and the Middle East. China, India, Egypt, Pakistan, and" exact="Indonesia" post="account for approximately half of the global HCV-infected subjects.[31323334]"/>
   <result pre="Japan. Genotype 1a is distributed widely in Northern Europe and" exact="United States." post="Genotype 1b is commonly found in Europe and Asia."/>
   <result pre="prevalent in industrialized countries, it is also found in South" exact="America" post="and Asia. Genotype 2a has commonly been isolated from"/>
   <result pre="America and Asia. Genotype 2a has commonly been isolated from" exact="Japan" post="and China. Genotype 2b is widespread in Northern Europe"/>
   <result pre="and China. Genotype 2b is widespread in Northern Europe and" exact="United States." post="Genotype 2c is the most common subtype found in"/>
   <result pre="Europe, Pakistan, and India. Genotype 3a is prevalent in Europe," exact="United States," post="Australia, and Southern Asia.[383940] Genotypes 4 and 5 are"/>
   <result pre="in Central Africa. Genotype 5 has mainly been reported from" exact="South Africa." post="Genotype 6 and its numerous subtypes are found mainly"/>
   <result pre="40SievertWAltraifIRazaviHAAbdoAAhmedEAAlomairAet al.Asystematic review of hepatitis C virus epidemiology in Asia," exact="Australia" post="and EgyptLiver Int201131Suppl 2618021651703 41ChaoDTAbeKNguyenMHSystematic review: Epidemiology of hepatitis"/>
   <result pre="46CornbergMRazaviHAAlbertiABernasconiEButiMCooperCet al.Asystematic review of hepatitis C virus epidemiology in Europe," exact="Canada" post="and IsraelLiver Int201131Suppl 2306021651702 47Porter L. Hepatitis C: The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7114107/results/search/country/results.xml">
   <result pre="I and type II interferon-induced antiviral factorsProc. Natl. Acad. Sci." exact="U. S." post="A.1091120124239424422371602 MorfinF.ThouvenotD.Herpes simplex virus resistance to antiviral drugsJ. Clin."/>
   <result pre="tuberculosis using a macrophage cell culture modelProc. Natl. Acad. Sci." exact="U. S." post="A.2016 SunX.VilarS.TatonettiN.P.High-throughput methods for combinatorial drug discoverySci. Transl. Med.52052013205rv1"/>
   <result pre="drugs guided by a stochastic search algorithmProc. Natl. Acad. Sci." exact="U. S." post="A.1051320085105511018356295 Appendix A Supplementary data The following are the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7114176/results/search/country/results.xml">
   <result pre="of Biosafety, National Institute for Viral Disease Control and Prevention," exact="China" post="CDC; Center for Biosafety Mega-Science, Chinese Academy of Sciences;"/>
   <result pre="syndrome (SARS), a lethal zoonotic CoV infection, was reported in" exact="China" post="and associated with SARS-CoV (Ksiazek et al., 2003). In"/>
   <result pre="luciferase reporter gene expression in living miceProc. Natl. Acad. Sci." exact="U. S." post="A.99200237738211752410 BurksJ.S.DeValdB.L.JankovskyL.D.GerdesJ.C.Two coronaviruses isolated from central nervous system tissue"/>
   <result pre="coronavirus associated with respiratory disease in humansProc. Natl. Acad. Sci." exact="U. S." post="A.10120046212621615073334 GralinskiL.E.BaricR.S.Molecular pathology of emerging coronavirus infectionsJ. Pathol.235201518519525270030 HungE.C.ChimS.S.ChanP.K.TongY.K.NgE.K.ChiuR.W.LeungC.B.SungJ.J.TamJ.S.LoY.M.Detection"/>
   <result pre="from patients with upper respiratory tract diseaseProc. Natl. Acad. Sci." exact="U. S." post="A.581967226822734298953 Milne-PriceS.MiazgowiczK.L.MunsterV.J.The emergence of the Middle East respiratory syndrome"/>
   <result pre="mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazineProc. Natl. Acad. Sci." exact="U. S." post="A.10120041702170714755051 RaabenM.PrinsH.J.MartensA.C.RottierP.J.De HaanC.A.Non-invasive imaging of mouse hepatitis coronavirus infection"/>
   <result pre="funded by the National Key Research and Development Program of" exact="China" post="(2016YFD0500301, 2016YFC1200901, and 2018YFC1200602) and the National Major Project"/>
   <result pre="Major Project for Control and Prevention of Infectious Disease in" exact="China" post="(2016ZX10004001-003) from the Ministry of Science and Technology of"/>
   <result pre="China (2016ZX10004001-003) from the Ministry of Science and Technology of" exact="China" post="and National Health Commissions of China. The funders had"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7114316/results/search/country/results.xml">
   <result pre="Multimedia component 4 Acknowledgements This work was supported by the" exact="Thailand" post="Research Fund (grant numbers MRG6080067); Thailand Science Research and"/>
   <result pre="was supported by the Thailand Research Fund (grant numbers MRG6080067);" exact="Thailand" post="Science Research and Innovation (grant number RTA6280011); Kasetsart Veterinary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7114806/results/search/country/results.xml">
   <result pre="the treatment of genotype 1 chronic hepatitis C infection in" exact="the United States" post="in 2014 and in Japan in 2015. Approval of"/>
   <result pre="treatment of genotype 1 chronic hepatitis C infection in the" exact="United States" post="in 2014 and in Japan in 2015. Approval of"/>
   <result pre="C infection in the United States in 2014 and in" exact="Japan" post="in 2015. Approval of LDV/SOF for additional indication for"/>
   <result pre="according to the results of a phase 3 trial in" exact="Japan" post="[1, 2], and the breakdown was headache (3.1%) as"/>
   <result pre="form of Ledipasvir Acetonate/Sofosbuvir. https://www.info.pmda.go.jp/go/interview/1/230867_6250107F1026_1_008_1F.pdf. Accessed 30 Jan 2020. 3.The" exact="Japan" post="Society of Hepatology. JSH guidelines for the management of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7115022/results/search/country/results.xml">
   <result pre="are believed to be the seventh cause of death in" exact="the USA" post="[26]. Influenza A and B infections start in childhood"/>
   <result pre="and BHealth Technol Assess2003735iiiiv14609480 26.DushoffJet al.Mortality due to influenza in" exact="the United States" post="– an annualized regression approach using multiple-cause mortality dataAm"/>
   <result pre="BHealth Technol Assess2003735iiiiv14609480 26.DushoffJet al.Mortality due to influenza in the" exact="United States" post="– an annualized regression approach using multiple-cause mortality dataAm"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7118351/results/search/country/results.xml">
   <result pre="five different species: Zaire, Sudan, Bundibugyo, Reston and TaiForest (1)." exact="Zaire" post="ebolavirus [ZEBOV or simply Ebola virus (EBOV)] is an"/>
   <result pre="and 11,316 deaths (available online at https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/cost-of-ebola.html). More recently, the" exact="Zaire" post="Ebola outbreak in the Democratic Republic of Congo caused"/>
   <result pre="at https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/cost-of-ebola.html). More recently, the Zaire Ebola outbreak in the" exact="Democratic Republic of Congo" post="caused at least 139 deaths as of August 2018"/>
   <result pre="https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/cost-of-ebola.html). More recently, the Zaire Ebola outbreak in the Democratic" exact="Republic of" post="Congo caused at least 139 deaths as of August"/>
   <result pre="recently, the Zaire Ebola outbreak in the Democratic Republic of" exact="Congo" post="caused at least 139 deaths as of August 2018"/>
   <result pre="increased cortisol levels, it has yet to be approved by" exact="the US" post="Food and Drug Administration (FDA) (28, 29). Nevertheless, the"/>
   <result pre="lipid bilayerJ Virol755205521410.1128/JVI.75.11.5205-5214.200111333902 11ArieS2018Ebola: WHO expresses &quot;very serious concern&quot; about" exact="Congo" post="outbreakBMJ363k443010.1136/bmj.k443030341056 12CohenNJBrownCMAlvarado-RamyFet al.2016Travel and border health measures to prevent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7118362/results/search/country/results.xml">
   <result pre="affected by a mysterious pneumonia has been documented in Wuhan," exact="China" post="(1). Around the end of last year, the causative"/>
   <result pre="the World Health Organization. The COVID-19 epidemic is spreading in" exact="China" post="and all over the world now as pandemic infection"/>
   <result pre="more attention and care (8,9). Recent evidences demonstrate that in" exact="Italy" post="there is the highest proportion of older patients with"/>
   <result pre="compared with other countries, might reflect the older population of" exact="Italy" post="and underline the need to adapt the mitigation plan"/>
   <result pre="in the treatment of a patient with COVID-19 disease in" exact="the United States" post="(22). However, the efficacy of all these antiviral drugs"/>
   <result pre="the treatment of a patient with COVID-19 disease in the" exact="United States" post="(22). However, the efficacy of all these antiviral drugs"/>
   <result pre="administered intravenous experimentally in the treatment of COVID-19 disease in" exact="China" post="and now in Italy with some encouraging results (25)."/>
   <result pre="the treatment of COVID-19 disease in China and now in" exact="Italy" post="with some encouraging results (25). However, the hypothesis that"/>
   <result pre="At present there is no scientific evidence even if in" exact="Italy" post="Sarilumab is used experimentally in some patients. Future clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7118423/results/search/country/results.xml">
   <result pre="a novel coronavirus (2019-nCoV; SARS-CoV-2) has affected many provinces in" exact="China" post="and multiple countries worldwide. The viral outbreak has aroused"/>
   <result pre="worldwide. There have been significant outbreaks in many regions of" exact="China" post="as well as global expansion including to Asia, Europe,"/>
   <result pre="of SARS-CoV [47]. The first case of SARS-CoV-2-infected pneumonia in" exact="the USA" post="experienced significant improvement in clinical symptoms after receiving an"/>
   <result pre="8.1 Antiviral therapy At present, different institutions and organisations in" exact="China" post="have issued several guidelines for the diagnosis and treatment"/>
   <result pre="previously, the first case of new coronavirus pneumonia treated in" exact="the USA" post="received only supportive treatment for nausea, vomiting and other"/>
   <result pre="prognosis than untreated animals [76]. A non-critical SARS-CoV-2-infected patient in" exact="South Korea" post="received lopinavir/ritonavir (Kaletra; AbbVie) on the eighth day of"/>
   <result pre="modeling of its spike protein for risk of human transmissionSci" exact="China" post="Life Sci63202045746010.1007/s11427-020-1637-532009228 13JiW.WangW.ZhaoX.ZaiJ.LiX.Cross-species transmission of the newly identified coronavirus"/>
   <result pre="2019-nCoV infected patients linked to viral loads and lung injurySci" exact="China" post="Life Sci63202036437410.1007/s11427-020-1643-832048163 21ZhangH.KangZ.GongH.XuD.WangJ.LiZ.The digestive system is a potential route"/>
   <result pre="work was supported by the National Natural Science Foundation of" exact="China" post="[contract nos. 31672290, 31100764 and 30901874], the Natural Science"/>
   <result pre="31100764 and 30901874], the Natural Science Foundation of Hunan Province," exact="China" post="[no. 2016JJ3180] and the Valuable Instrument and Equipment Fund"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7118541/results/search/country/results.xml">
   <result pre="The infection of a novel coronavirus found in Wuhan of" exact="China" post="(SARS-CoV-2) is rapidly spreading, and the incidence rate is"/>
   <result pre="coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) in Wuhan," exact="China" post="[5], [9]. SARS-CoV-2, which belongs to Betacoronavirus, contains a"/>
   <result pre="approximately $2 million worth of Kaletra doses were donated to" exact="China" post="[29], and a previous clinical study of SARS by"/>
   <result pre="consists of darunavir and cobicistat, was to be sent to" exact="China" post="[29], and darunavir is also predicted to have a"/>
   <result pre="hope our prediction results may support experimental therapeutic options for" exact="China" post="and other countries suffering from the SARS-CoV-2 pandemic and"/>
   <result pre="R&amp;amp;D Program for Cancer Control, Ministry of Health &amp;amp; Welfare," exact="Republic of" post="Korea (1720100). Appendix ASupplementary data to this article can"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7118644/results/search/country/results.xml">
   <result pre="were formally collected during a clinical trial conducted in the" exact="Democratic Republic of Congo" post="that randomized 175 patients to be treated with remdesivir"/>
   <result pre="formally collected during a clinical trial conducted in the Democratic" exact="Republic of" post="Congo that randomized 175 patients to be treated with"/>
   <result pre="during a clinical trial conducted in the Democratic Republic of" exact="Congo" post="that randomized 175 patients to be treated with remdesivir"/>
   <result pre="The NIH-sponsored clinical trial, ongoing in the U.S. and the" exact="Republic of" post="Korea, is a double-blinded, placebo-controlled trial in which patients"/>
   <result pre="Two double-blinded placebo-controlled trials are also recruiting in Hubei Province," exact="China" post="[44,45]. One targets hospitalized patients with mild-to-moderate COVID-19 [44],"/>
   <result pre="of the clinical trials currently underway in the U.S. and" exact="China" post="will provide crucial information about whether remdesivir represents a"/>
   <result pre="the rhesus macaque model of MERS-CoV infectionProc. Natl. Acad. Sci." exact="U. S." post="A.2020 19MartyA.M.JonesM.K.The novel coronavirus (SARS-CoV-2) is a one health"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7118659/results/search/country/results.xml">
   <result pre="trials of chloroquine repurposing in the treatment of COVID-19 in" exact="China" post="have been encouraging, leading to several new trials. Here"/>
   <result pre="an amine acidotropic form of quinine that was synthesised in" exact="Germany" post="by Bayer in 1934 and emerged approximately 70 years"/>
   <result pre="compound found in the bark of Cinchona trees native to" exact="Peru" post="and was the previous drug of choice against malaria"/>
   <result pre="assessed in human patients suffering from COVID-19 [49]. Recently, the" exact="China" post="National Center for Biotechnology Development indicated that chloroquine is"/>
   <result pre="chloroquine is probably the first molecule to be used in" exact="China" post="and abroad on the front line for the treatment"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7120034/results/search/country/results.xml">
   <result pre="[ID2], grid.10784.3a0000000419370482, School of Biomedical Sciences, The Chinese University of" exact="Hong Kong," post="BahClara Shui Fern1 Clara Bah completed her Bachelor’s Degree"/>
   <result pre="Bachelor’s Degree in Chemical-Bioprocess Engineering at the University of Technology," exact="Malaysia" post="(UTM). After working as a research and development engineer,"/>
   <result pre="Master’s of Science (Food Science) at the University of Otago," exact="New Zealand." post="Her research topic explored the availability of bioactive compounds"/>
   <result pre="the School of Biomedical Sciences in the Chinese University of" exact="Hong Kong." post="Currently Clara is working towards completing her PhD at"/>
   <result pre="Fang received his Ph.D. degree from The Chinese University of" exact="Hong Kong" post="and currently works with Prof. Vilhelm A. Bohr on"/>
   <result pre="finalist in the Young Investigator Award 2011 conducted by the" exact="Hong Kong" post="Institute of Science. NgTzi Bunb021770@mailserv.cuhk.edu.hk3 Tzi Bun Ng Tzi"/>
   <result pre="Biochemistry at the Faculty of Medicine, The Chinese University of" exact="Hong Kong," post="HKSAR. After completing his B.Sc. studies at The University"/>
   <result pre="HKSAR. After completing his B.Sc. studies at The University of" exact="Hong Kong," post="he obtained his Ph.D. degree from the Memorial University"/>
   <result pre="of Biomedical Sciences, Faculty of Medicine, The Chinese University of" exact="Hong Kong," post="epub: 2012-12-125574(C) , This article is made available via"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7120377/results/search/country/results.xml">
   <result pre="patientsExpert Rev Anti Infect Ther200754031310.1586/14787210.5.3.40317547505 50.StarasSADollardSCRadfordKWFlandersWDPassRFCannonMJSeroprevalence of cytomegalovirus infection in" exact="the United States," post="1988–1994Clin Infect Dis20064311435110.1086/50817317029132 51.KunnoAAbeMYamadaMMurakamiKClinical and histological features of cytomegalovirus"/>
   <result pre="Rev Anti Infect Ther200754031310.1586/14787210.5.3.40317547505 50.StarasSADollardSCRadfordKWFlandersWDPassRFCannonMJSeroprevalence of cytomegalovirus infection in the" exact="United States," post="1988–1994Clin Infect Dis20064311435110.1086/50817317029132 51.KunnoAAbeMYamadaMMurakamiKClinical and histological features of cytomegalovirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7120516/results/search/country/results.xml">
   <result pre="million people worldwide, and last but not least, at current," exact="India" post="has an HIV/AIDS population of approximately 2.4 million people"/>
   <result pre="developed countries and the most common chronic blood-borne infection in" exact="the USA." post="There is a wide range of prevalence estimates among"/>
   <result pre="developed world with relatively low rates of HCV seroprevalence include" exact="Germany" post="(0.6 %) (Palitzsch et al. 1999), Canada (0.8 %)"/>
   <result pre="HCV seroprevalence include Germany (0.6 %) (Palitzsch et al. 1999)," exact="Canada" post="(0.8 %) (Zou et al. 2000), France (1.1 %)"/>
   <result pre="et al. 1999), Canada (0.8 %) (Zou et al. 2000)," exact="France" post="(1.1 %) (Desenclos 2000), and Australia (1.1 %) (Law"/>
   <result pre="(Zou et al. 2000), France (1.1 %) (Desenclos 2000), and" exact="Australia" post="(1.1 %) (Law et al. 2003; Australian Census 2001)."/>
   <result pre="Low, but slightly higher, seroprevalence rates have been reported in" exact="the USA" post="(1.8 %) (Alter et al. 1999), Japan (1.5–2.3 %)"/>
   <result pre="reported in the USA (1.8 %) (Alter et al. 1999)," exact="Japan" post="(1.5–2.3 %) (Ohshima et al. 2000), and Italy (2.2"/>
   <result pre="al. 1999), Japan (1.5–2.3 %) (Ohshima et al. 2000), and" exact="Italy" post="(2.2 %). Human papillomavirus (HPV) causes cervical cancer, the"/>
   <result pre="Africa, Central and South America, and Asia. Epidemiological studies in" exact="the USA" post="have reported that 75 % of the 15–50-year-old population"/>
   <result pre="even so, there were 11,000 cases and 3,900 deaths in" exact="the USA" post="in 2008. Cervical cancer has substantial mortality in resource-poor"/>
   <result pre="syndrome, or AIDS. CDC estimates that about 56,000 people in" exact="the United States" post="contracted HIV in 2006. There are two types of"/>
   <result pre="or AIDS. CDC estimates that about 56,000 people in the" exact="United States" post="contracted HIV in 2006. There are two types of"/>
   <result pre="There are two types of HIV, HIV-1 and HIV-2. In" exact="the USA," post="unless otherwise noted, the term &quot;HIV&quot; primarily refers to"/>
   <result pre="14,110 deaths among people living with HIV were reported in" exact="the USA." post="The above-discussed diseases are continuously threatening the whole world"/>
   <result pre="found in studies in Singapore, Italy, Japan, Taiwan, Indonesia, and" exact="Brunei" post="(Hsu et al. 1997). Mutations of the polymerase gene"/>
   <result pre="Genomics20122224725322322242 AlterMJKruszon-MoranDNainanOVet al.The prevalence of hepatitis C virus infection in" exact="the United States," post="1988 through 1994N Engl J Med199934155656210451460 AltmanMDet al.HIV-1 protease"/>
   <result pre="AlterMJKruszon-MoranDNainanOVet al.The prevalence of hepatitis C virus infection in the" exact="United States," post="1988 through 1994N Engl J Med199934155656210451460 AltmanMDet al.HIV-1 protease"/>
   <result pre="type 1J Virol2001753291330011238855 Blum RA (2005) HIV resistance testing in" exact="the USA" post="– a model for the application of pharmacogenomics in"/>
   <result pre="HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART):" exact="Swiss" post="HIV Cohort StudyLancet19983517237249504519 KilbyJMEronJJNovel therapies based on mechanisms of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7120554/results/search/country/results.xml">
   <result pre="in its Phase I and II clinical trial stage in" exact="Japan" post="(Tan et al. 2002; Tomei et al. 2003). Currently,"/>
   <result pre="glabra has been in use for over 20 years in" exact="Japan" post="for treatment of hepatitis. Its dried and processed root"/>
   <result pre="HSV) (Chiang et al. 2003). On the other hand, in" exact="China" post="and Taiwan, Ocimum basilicum is widely used traditionally against"/>
   <result pre="15 Fenner FJ, Bachmann PA, Gibbs EPJ (2014) Veterinary virology." exact="Australia" post="Academic Press. eBook ISBN: 9781483257815 FilerCet al.Metabolic and pharmacokinetic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7120890/results/search/country/results.xml">
   <result pre="wide usage has been limited to China, India, Japan, Pakistan," exact="Sri Lanka," post="Thailand and a number of African countries. However, developed"/>
   <result pre="has been limited to China, India, Japan, Pakistan, Sri Lanka," exact="Thailand" post="and a number of African countries. However, developed countries"/>
   <result pre="England (Jiang 2005). Besides, the Natural Health Product Regulations of" exact="Canada" post="promulgated in 2004 and the performance of phase III"/>
   <result pre="III clinical trial of Chinese medicine Danshen dripping pills in" exact="America" post="in 2010 are also very important steps toward modernization"/>
   <result pre="isolated from Hypericum connatum (Guttiferae), which is used in southern" exact="Brazil" post="in the treatment of lesions in the mouth and"/>
   <result pre="Tibetan herb Potentilla anserina L. has been widely used in" exact="China" post="for many thousands of years to treat hepatitis-B. Bioassay-guided"/>
   <result pre="oil from Cedrus libani widely used as traditional medicine in" exact="Lebanon" post="for treatment of different infection diseases are mainly consist"/>
   <result pre="substances from Hypericum connatum Lam., a plant used in southern" exact="Brazil" post="to treat oral lesionsJ Ethnopharmacol200711351752017719731 FukudaMLongneckerREpstein–Barr virus (EBV) latent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7120914/results/search/country/results.xml">
   <result pre="in their raw form and the environment protection agency in" exact="the USA" post="classified as &quot;GRAS&quot; which mean Generally Regards as Safe"/>
   <result pre="in 2008 analyzed the essential oils of seven plants from" exact="Lebanon" post="for in vitro antiviral activity (Loizzo et al. 2008)."/>
   <result pre="major constituent (Jung et al. 2006). Medicinal plants of Oriental" exact="Morocco" post="were studied for their antidiabetic property in rats. The"/>
   <result pre="of Chinese medicinal products (based on traditional Chinese medicine) from" exact="China" post="to other developed nations. Plants used in traditional Chinese"/>
   <result pre="Carcinogen200981910.4103/1477-3163.51368 BnouhamMet al.Antidiabetic effect of some medicinal plants of oriental" exact="Morocco" post="in neonatal non-insulin-dependent diabetes mellitus ratsHum Exp Toxicol2010291086587110.1177/096032711036270420154101 BoundJet"/>
   <result pre="crude extracts and essential oils of Ocimum gratissimum Linn from" exact="Benin" post="and influence of vegetative stageJ Ethnopharmacol201415531417142310.1016/j.jep.2014.07.01425058875 LaakmannGet al.St. Johns"/>
   <result pre="in vitro antiviral activities of the essential oils of seven" exact="Lebanon" post="speciesChem Biodivers20085346147010.1002/cbdv.20089004518357554 LoprestiLSalvia (sage): a review of its potential"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7121504/results/search/country/results.xml">
   <result pre="played by risk perception during the 2009 H1N1 pandemic in" exact="Italy" post="is discussed. Evidence of Uncoordinated Behavioral Changes During an"/>
   <result pre="sneezes (27 %)&quot; to reduce the risk of infection [24]. In" exact="the USA," post="data collected on public response to H1N1 influenza from"/>
   <result pre="For instance, an 80 % reduction in travel to and from" exact="Hong Kong" post="has been reported during the 2003 SARS crisis [9]."/>
   <result pre="&quot;alert&quot; takes place too late. The 2009 H1N1 Pandemic in" exact="Italy" post="In March 2009, a new influenza virus emerged in"/>
   <result pre="Italy In March 2009, a new influenza virus emerged in" exact="Mexico" post="giving rise to a pandemic that spread worldwide [10]."/>
   <result pre="alter the dynamics of the epidemic? As most European countries," exact="Italy" post="experienced one single pandemic wave during fall-winter 2009 and"/>
   <result pre="by two distinct exponential growth rates, can be appreciated in" exact="Italy" post="(especially when data are plotted in logarithmic scale) by"/>
   <result pre="scale on the right axis) during the 2009 pandemic, in" exact="Italy" post="The observed pattern cannot be reproduced by a classic"/>
   <result pre="as the main determinant of the influenza dynamics reported in" exact="Italy" post="in the 2009. The same result is suggested by"/>
   <result pre="of July, despite no substantial ILI activity was detected in" exact="Italy" post="during the summer. The concern about the pandemic might"/>
   <result pre="of an emerging epidemic, as it might have happened in" exact="Italy" post="during the 2009 H1N1 pandemic. Acknowledgements This work has"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7121811/results/search/country/results.xml">
   <result pre="(2016). Administration of siRNA encapsulated in LNPs able to target" exact="Sudan" post="ebolavirus VP35 gene to rhesus monkeys receiving a lethal"/>
   <result pre="Microbiol Immunol201337013314622234411 BrownVRBevinsSNA review of virulent Newcastle disease viruses in" exact="the United States" post="and the role of wild birds in viral persistence"/>
   <result pre="Immunol201337013314622234411 BrownVRBevinsSNA review of virulent Newcastle disease viruses in the" exact="United States" post="and the role of wild birds in viral persistence"/>
   <result pre="powderJ Vet Med Sci2014761277128010.1292/jvms.14-015824871643 ThiEPLeeACHGeisbertJBUrsic-BedoyaRAgansKNRobbinsMDeerDJFentonKAKondratowiczASMacLachlanIGeisbertTWMireCERescue of non-human primates from advanced" exact="Sudan" post="ebolavirus infection with lipid encapsulated siRNANat Microbiol201611614210.1038/nmicrobiol.2016.14227670117 ThiEPMireCELeeACHGeisbertJBZhouJZAgansKNSneadNMDeerDJBarnardTRFentonKAMacLachlanIGeisbertTWLipid nanoparticle"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7121845/results/search/country/results.xml">
   <result pre="the nation’s security needs – both external and internal –" exact="India" post="has over 1.0 million paramilitary personnel. The military personnel"/>
   <result pre="prevalence of rich traditions of diverse systems of medicine in" exact="India" post="that have been tried, tested and proved over a"/>
   <result pre="a long period. Resurgence of Interest in Herbal Technologies in" exact="India" post="Affordable, accessible and acceptable healthcare for all sections of"/>
   <result pre="of years of medical practice with medicinal plants in humans." exact="India" post="is endowed with extremely rich biodiversity and is home"/>
   <result pre="and survival during operational conditions in diverse terrain (Fig. 8)." exact="India" post="is extremely rich in phytobiodiversity in view of the"/>
   <result pre="East are strategically important because of the international borders with" exact="China" post="and Pakistan. The Armed Forces, deployed in these regions,"/>
   <result pre="health and longevity in the Himalayan tracts of India, China," exact="Japan" post="and several other Asian countries has been used to"/>
   <result pre="regions/states and ultimately aim to destabilize and weaken the nation." exact="India" post="has witnessed several low-intensity conflicts of varying nature, degree"/>
   <result pre="the use of pellet guns to disperse mobs in North" exact="India" post="resulted in serious eye injuries to several people. Subsequently,"/>
   <result pre="eye injuries to several people. Subsequently, the Supreme Court of" exact="India" post="ruled that being a welfare state, it is the"/>
   <result pre="viz. Podophyllum montanum and Podophyllum peltatum, are found in Western" exact="China" post="and North America, respectively. The plant contains picropodophyllotoxin, podophyllotoxin,"/>
   <result pre="in mammals. In a 30-day survival study using strain ‘A’" exact="Swiss" post="Albino mice, our group showed that the crude extract"/>
   <result pre="Distribution ranges from the Himalayan region, India, Nepal, Bhutan, Pakistan," exact="Afghanistan" post="to China, Mongolia, Russia, Kazakhstan, Hungary, Romania, Switzerland, Germany,"/>
   <result pre="Afghanistan to China, Mongolia, Russia, Kazakhstan, Hungary, Romania, Switzerland, Germany," exact="France" post="and Britain to Scandinavian countries, including Finland, Sweden and"/>
   <result pre="Switzerland, Germany, France and Britain to Scandinavian countries, including Finland," exact="Sweden" post="and Norway. In India, it is found in North"/>
   <result pre="ranges from Leh, Ladakh, India. It is also found in" exact="Pakistan" post="and Nepal. The biologically active phyto-constituents present in different"/>
   <result pre="plant has been used in Russia, Mongolia, China, India, America," exact="Kazakhstan" post="and European countries. The therapeutic uses include application in"/>
   <result pre="30 min prior to 10 Gy exposure in strain ‘A’" exact="Swiss" post="albino mice model system, 1000 mg/Kg b.wt. indicating the"/>
   <result pre="vectors, mosquitoes are responsible for causing major vector-borne diseases in" exact="India" post="and other tropical countries. Use of repellents and insecticides"/>
   <result pre="mechanistic aspectsMol Cell Biochem20042661-2657710.1023/B:MCBI.0000049139.05337.4015646028 GuptaM.L.AgrawalaP.K.KumarPremDeviM.SoniN.L.TripathiR.P.Modulation of Gamma Radiation-Inflicted Damage in" exact="Swiss" post="Albino Mice by an Alcoholic Fraction ofPodophyllum hexandrumRhizomeJournal of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7122247/results/search/country/results.xml">
   <result pre="aerosol formulation of aprotinin has been developed and approved in" exact="Russia" post="for the treatment of mild-to-moderate influenza infections (Zhirnov et"/>
   <result pre="731 nM and 569 nM, respectively (Basak and Lotfipour 2005)." exact="Turkey" post="ovomucoid third domain (OMTKY3) belongs to the family of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7122610/results/search/country/results.xml">
   <result pre="of generic drug production in major developing countries, such as" exact="India" post="and China, as well as the roles of these"/>
   <result pre="response capability. In 1995, the TRIPS agreement was implemented in" exact="Uruguay" post="Round to join the protection of intellectual property rights"/>
   <result pre="taken, will significantly minimize these serious public health issues in" exact="China" post="as well as in other developing countries. The Implementation"/>
   <result pre="constitutes a national emergency. Some developing countries, including Thailand, Brazil," exact="South Africa," post="and a few others, have already made full use"/>
   <result pre="license in developing countries Country Type Type of drugs Asia" exact="India" post="Compulsory license All drugs prior to January 1st, 2005."/>
   <result pre="submitted between 1995 and 2005, including some second-line antiretroviral drugs" exact="Malaysia" post="Compulsory license AIDS drugs Indonesia Compulsory license AIDS drugs"/>
   <result pre="including some second-line antiretroviral drugs Malaysia Compulsory license AIDS drugs" exact="Indonesia" post="Compulsory license AIDS drugs Thailand Compulsory license AIDS drugs,"/>
   <result pre="Malaysia Compulsory license AIDS drugs Indonesia Compulsory license AIDS drugs" exact="Thailand" post="Compulsory license AIDS drugs, anticancer drugs, cardiovascular medicine Africa"/>
   <result pre="Thailand Compulsory license AIDS drugs, anticancer drugs, cardiovascular medicine Africa" exact="Zambia" post="Compulsory license AIDS drugs Mozambique Compulsory license AIDS drugs"/>
   <result pre="anticancer drugs, cardiovascular medicine Africa Zambia Compulsory license AIDS drugs" exact="Mozambique" post="Compulsory license AIDS drugs Zimbabwe Compulsory license AIDS drugs"/>
   <result pre="Zambia Compulsory license AIDS drugs Mozambique Compulsory license AIDS drugs" exact="Zimbabwe" post="Compulsory license AIDS drugs South Africa Extended the importation,"/>
   <result pre="Mozambique Compulsory license AIDS drugs Zimbabwe Compulsory license AIDS drugs" exact="South Africa" post="Extended the importation, manufacture, and voluntary licensing to other"/>
   <result pre="countries of antiretroviral drugs in four generic drug companies in" exact="South Africa" post="AIDS drugs Cameroon Granted public procurement agencies the right"/>
   <result pre="in four generic drug companies in South Africa AIDS drugs" exact="Cameroon" post="Granted public procurement agencies the right to purchase antiretroviral"/>
   <result pre="is lower than that of the patent owners AIDS drugs" exact="Ghana" post="Compulsory license AIDS drugs Eritrea Compulsory license AIDS drugs"/>
   <result pre="the patent owners AIDS drugs Ghana Compulsory license AIDS drugs" exact="Eritrea" post="Compulsory license AIDS drugs Guinea Compulsory license AIDS drugs"/>
   <result pre="Ghana Compulsory license AIDS drugs Eritrea Compulsory license AIDS drugs" exact="Guinea" post="Compulsory license AIDS drugs Latin America Peru Compulsory license"/>
   <result pre="Compulsory license AIDS drugs Guinea Compulsory license AIDS drugs Latin" exact="America" post="Peru Compulsory license AIDS drugs Brazil Compulsory license AIDS"/>
   <result pre="license AIDS drugs Guinea Compulsory license AIDS drugs Latin America" exact="Peru" post="Compulsory license AIDS drugs Brazil Compulsory license AIDS drugs"/>
   <result pre="license AIDS drugs Latin America Peru Compulsory license AIDS drugs" exact="Brazil" post="Compulsory license AIDS drugs China China Threaten to use"/>
   <result pre="Peru Compulsory license AIDS drugs Brazil Compulsory license AIDS drugs" exact="China" post="China Threaten to use compulsory license Oseltamivir phosphate Taiwan"/>
   <result pre="Compulsory license AIDS drugs Brazil Compulsory license AIDS drugs China" exact="China" post="Threaten to use compulsory license Oseltamivir phosphate Taiwan Compulsory"/>
   <result pre="drugs China China Threaten to use compulsory license Oseltamivir phosphate" exact="Taiwan" post="Compulsory license CD-R and oseltamivir phosphate Brazil In 2005,"/>
   <result pre="license Oseltamivir phosphate Taiwan Compulsory license CD-R and oseltamivir phosphate" exact="Brazil" post="In 2005, Brazil began negotiations to issue a compulsory"/>
   <result pre="Taiwan Compulsory license CD-R and oseltamivir phosphate Brazil In 2005," exact="Brazil" post="began negotiations to issue a compulsory license for kaletra"/>
   <result pre="is estimated that 75,000 of those receiving ARV treatment in" exact="Brazil" post="will be using efavirenz by the end of 2007."/>
   <result pre="2007. Efavirenz (in tablets of 600 mg) was sold in" exact="Brazil" post="at $580 per patient per year, which was 136%"/>
   <result pre="year, which was 136% higher than the price offered by" exact="Thailand" post="[9]. The Brazilian government attempted negotiations for a lower"/>
   <result pre="November 2006. They threatened Merck with a compulsory license unless" exact="Brazil" post="could sell efavirenz at a rate equal to or"/>
   <result pre="government issued their first compulsory license on May 4, 2007." exact="Brazil" post="reduced the price per day from $1.56 to $0.45"/>
   <result pre="other important health problems like diabetes, cancer, or heart disease.&quot;" exact="South Africa" post="The government of South Africa first issued a compulsory"/>
   <result pre="diabetes, cancer, or heart disease.&quot; South Africa The government of" exact="South Africa" post="first issued a compulsory license in 1998 after the"/>
   <result pre="in the world [11]. In response to the severe epidemic," exact="South Africa" post="passed the South Africa Medicines and Related Substances Act"/>
   <result pre="In response to the severe epidemic, South Africa passed the" exact="South Africa" post="Medicines and Related Substances Act in December 1997, authorizing"/>
   <result pre="who, together, filed a lawsuit on the claim that the" exact="South Africa" post="Medicines and Related Substances Act of 1997 is unconstitutional"/>
   <result pre="patent to establish a profitable monopoly over the industry [13]." exact="Thailand" post="Brief History Towards the end of 2006, The government"/>
   <result pre="Brief History Towards the end of 2006, The government of" exact="Thailand" post="granted compulsory licenses for two ARV drugs (efavirenz–lopinavir and"/>
   <result pre="2007. In September 2007, the National Drugs Protection Office in" exact="Thailand" post="announced its intention to grant compulsory licenses for four"/>
   <result pre="the Thai National Health Insurance Program [14]. Compulsory Licenses in" exact="Thailand" post="Thailand has a severe HIV/AIDS epidemic. According to (UNAIDS)"/>
   <result pre="Thai National Health Insurance Program [14]. Compulsory Licenses in Thailand" exact="Thailand" post="has a severe HIV/AIDS epidemic. According to (UNAIDS) 2010"/>
   <result pre="to $38.5 per month [20]. This was the first time" exact="Thailand" post="used a strategy permitted under both patent law and"/>
   <result pre="issuing compulsory licenses was consistent with International Law. In 2007," exact="Thailand" post="and other developing countries succeeded in reducing the price"/>
   <result pre="of Compulsory Licenses in Developed Countries Developed countries such as" exact="the USA" post="and Canada have also made full use of compulsory"/>
   <result pre="in Developed Countries Developed countries such as the USA and" exact="Canada" post="have also made full use of compulsory licenses in"/>
   <result pre="license for Cipro was a controversial act. In the end," exact="the US" post="government used the threat of a compulsory license to"/>
   <result pre="Amending the TRIPS agreement (James 2007). Unlike the decisions of" exact="the US" post="and Italian governments to use a compulsory license for"/>
   <result pre="Boehringer Ingelheim, for a voluntary license and with petition from" exact="Rwanda" post="to the World Trade Organization, Canada granted the Apotex"/>
   <result pre="and with petition from Rwanda to the World Trade Organization," exact="Canada" post="granted the Apotex company a compulsory license for TriAvir"/>
   <result pre="compulsory license for TriAvir in [25] to be exported to" exact="Rwanda" post="[26]. The Urgent Demand for Generic Drugs in Developing"/>
   <result pre="equivalent to 65% of the estimated number of incident cases." exact="India" post="and China accounted for 40% of the world’s reported"/>
   <result pre="65% of the estimated number of incident cases. India and" exact="China" post="accounted for 40% of the world’s reported TB cases,"/>
   <result pre="MDR-TB estimated to exist among reported TB patients in 2010." exact="China" post="is one of the 22 countries characterized as having"/>
   <result pre="which are from rural areas, especially the northwest part of" exact="China" post="where the economy is least developed [29]. The MDR-TB"/>
   <result pre="the economy is least developed [29]. The MDR-TB epidemic in" exact="China" post="is very severe and accounts for 1/4–1/3 of the"/>
   <result pre="HBV infection globally, 30–40% of which are chronic HBV patients." exact="China" post="is greatly affected by this epidemic, currently with 120"/>
   <result pre="demands are increasing each year, especially in countries such as" exact="China" post="and India with rapid development and improving living standards."/>
   <result pre="increasing each year, especially in countries such as China and" exact="India" post="with rapid development and improving living standards. In China,"/>
   <result pre="living standards. In China, Mr. Mingde Yu, President of the" exact="China" post="Pharmaceutical Enterprises Association disclosed that because of the recent"/>
   <result pre="RMB [33]. The annual growth of the pharmaceutical industry in" exact="China" post="is expected to be at 30%. It is estimated"/>
   <result pre="30%. It is estimated that the total pharmaceutical sales in" exact="China" post="will amount to US$46 billion in 2011 with China"/>
   <result pre="in China will amount to US$46 billion in 2011 with" exact="China" post="as the third largest pharmaceutical industry after the USA"/>
   <result pre="2011 with China as the third largest pharmaceutical industry after" exact="the USA" post="and Japan [34]. A survey conducted by CSPS Parma"/>
   <result pre="as the third largest pharmaceutical industry after the USA and" exact="Japan" post="[34]. A survey conducted by CSPS Parma in the"/>
   <result pre="medical coverage, generic drugs are invariably a better choice for" exact="China" post="and other developing countries. Generic Drug Production Capacity in"/>
   <result pre="Countries Generic Drug Factories and their Capability in Developing Countries" exact="China" post="and India are among the largest global producers of"/>
   <result pre="Drug Factories and their Capability in Developing Countries China and" exact="India" post="are among the largest global producers of generic drugs"/>
   <result pre="people, including more than one-third of the world’s total population." exact="China" post="is the largest producer and exporter of API (Active"/>
   <result pre="market share for many antiviral drugs. According to incomplete statistics," exact="the USA" post="is China’s largest purchaser of API. Most of the"/>
   <result pre="of the common antibiotics API in Europe also come from" exact="China" post="and India [37]. The four largest API manufacturers for"/>
   <result pre="common antibiotics API in Europe also come from China and" exact="India" post="[37]. The four largest API manufacturers for ARV drugs"/>
   <result pre="[37]. The four largest API manufacturers for ARV drugs in" exact="China" post="could supply almost all of the current ARV drugs"/>
   <result pre="production capacity is 7,690 tons, with 60–70% exported and with" exact="India" post="as the largest purchaser, followed by western pharmaceutical companies."/>
   <result pre="sale capacity was less than 1% of production capacity [38]." exact="China" post="has about 5,000 pharmaceutical companies and about 10% are"/>
   <result pre="could be reduced to one-tenth of the current price in" exact="China" post="and nevirapine to one-tenth of its international price. Trizivir"/>
   <result pre="industry has made it the leading industry in the country." exact="India" post="ranks fourth in the global pharmaceutical market [39]. The"/>
   <result pre="producing API for Ibuprofen and exporting API of Methyldopa to" exact="Germany" post="in 1986. Its API production passed SFDA (should be"/>
   <result pre="FDA?) certification in 1987–1990. Reddy set up distribution centers in" exact="America" post="and France in 1992 and 1993. By 2005, 56"/>
   <result pre="in 1987–1990. Reddy set up distribution centers in America and" exact="France" post="in 1992 and 1993. By 2005, 56 products passed"/>
   <result pre="France in 1992 and 1993. By 2005, 56 products passed" exact="the US" post="Food and Drug Administration (FDA) certification with a sales"/>
   <result pre="FDA certification. The company also owns many distribution sites in" exact="America" post="(with headquarters in New Jersey) and Europe (with headquarters"/>
   <result pre="Ranbaxy and Cipla, have gone through similar development paths [40]." exact="India" post="is arguably the largest generic product production country in"/>
   <result pre="20,000 pharmaceutical companies, around 260 of which are large-scale companies." exact="India" post="can produce nearly all popular domestic medicines and around"/>
   <result pre="increasing at the rate of 13.4% per year [39]. Meanwhile," exact="India" post="is the largest exporter of nonpatent drugs; 40% of"/>
   <result pre="and equity. After its entrance into the WTO in 1995," exact="India" post="was pressured by western countries to enter the TRIPS"/>
   <result pre="years to adapt their patent laws to the international standards." exact="India" post="issued the 2004 Patent (amendment) Bill on December 26,"/>
   <result pre="(amendment) Bill on December 26, 2004. This law mandates that" exact="India" post="must begin accepting medicine, agricultural chemicals, and food patent"/>
   <result pre="its approval process for generic drugs [44]. For example, if" exact="the US" post="FDA has approved a drug, a generic version can"/>
   <result pre="and the high quality and low price of their products." exact="India" post="has strategically entered foreign markets by buying up the"/>
   <result pre="products. India has strategically entered foreign markets by buying up" exact="the US" post="and European local pharmaceutical companies. Many Indians are trained"/>
   <result pre="form. Additionally, deliveries in Ethiopia, Haiti, Namibia, Rwanda, Tanzania, and" exact="Zimbabwe" post="were more than 99% generic. The officer in PEPFAR"/>
   <result pre="without hesitation to solve the crisis. A good example is" exact="the US" post="government forcing Bayer to reduce the price of Cipro"/>
   <result pre="numbers. Some developing countries such as Thailand, Brazil, Malaysia, and" exact="South Africa" post="took a bold move to provide generic drugs to"/>
   <result pre="with large emerging economies, such as India, China, Brazil, and" exact="South Africa," post="are not only faced with the public health challenges"/>
   <result pre="developed countries in Africa, to solve their public health crises." exact="China" post="is the world’s largest producer of APIs, including more"/>
   <result pre="half the global APIs used for ARV drugs and antibiotics." exact="India" post="is the world’s largest producer for generic drugs. Therefore,"/>
   <result pre="generic drugs. Through the PEPFAR and other global health programs," exact="the USA" post="is the largest founder and the major player in"/>
   <result pre="(2005) Amendment of the TRIPS agreement. http://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm 8.Alcorn K (2007)" exact="Brazil" post="issues compulsory license on efavirenz. Aidsmap News. http://www.aidsmap.com/Brazil-issues-compulsory-license-on-efavirenz/page/1427206/ 9.SUNS"/>
   <result pre="issues compulsory license on efavirenz. Aidsmap News. http://www.aidsmap.com/Brazil-issues-compulsory-license-on-efavirenz/page/1427206/ 9.SUNS (2007)" exact="Brazil" post="moves on compulsory license after failed talks with drug"/>
   <result pre="al.WHO must defend patients’ interests, not industryLancet2007369956697497510.1016/S0140-6736(07)60473-517382809 19.Gerhardsen TIS (2006)" exact="Thailand" post="compulsory license on aids drug prompts policy debate. http://www.ip-watch.org/weblog/index.php?p=499&amp;amp;res=1024_ff&amp;amp;print=0."/>
   <result pre="policy debate. http://www.ip-watch.org/weblog/index.php?p=499&amp;amp;res=1024_ff&amp;amp;print=0. Accessed 23 Dec 2006 20.Ling CY (2006)" exact="Thailand" post="uses compulsory license for cheaper AIDS drug 21.SteinbrookRThailand and"/>
   <result pre="access to antiretroviral therapy in the less-developed world: lessons from" exact="Brazil" post="and ThailandAIDS200721Suppl. 4S21S29 23.Sun H (2005) Analysis of the"/>
   <result pre="B prevention and treatment guidelines. Press conference speeches in China." exact="China" post="Foundation for Hepatitis Prevention and Control. http://www.cfhpc.org/detail.asp?ID=81&amp;amp;page=1 33.Zeng LM"/>
   <result pre="et al (2009) Chairman of the Pharmaceutical Society of China:" exact="China" post="is expected to be the third largest pharmaceutical market"/>
   <result pre="market in China. 26 Oct 2009 36.YangCheng Evening Paper (2010)" exact="China" post="has become the world’s largest raw material medicine producer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7122614/results/search/country/results.xml">
   <result pre="generated from groups actively monitoring the resistance among circulating strain—in" exact="the United States" post="this is actively done by the Centers for Diseases"/>
   <result pre="from groups actively monitoring the resistance among circulating strain—in the" exact="United States" post="this is actively done by the Centers for Diseases"/>
   <result pre="began to change when field isolates of A/H3N2 viruses from" exact="China" post="were noted to have a significant increase in the"/>
   <result pre="influenza season, approximately 70 % of the A/H3N2 isolates from" exact="China" post="and Hong Kong and nearly 15 % of those"/>
   <result pre="approximately 70 % of the A/H3N2 isolates from China and" exact="Hong Kong" post="and nearly 15 % of those from the United"/>
   <result pre="and Hong Kong and nearly 15 % of those from" exact="the United States" post="and Europe showed resistance due to a Ser31Asn mutation,"/>
   <result pre="Hong Kong and nearly 15 % of those from the" exact="United States" post="and Europe showed resistance due to a Ser31Asn mutation,"/>
   <result pre="mutation, and this frequency increased to over 90 % in" exact="the United States" post="during the 2005–2006 season [29, 38]. Since then, most"/>
   <result pre="and this frequency increased to over 90 % in the" exact="United States" post="during the 2005–2006 season [29, 38]. Since then, most"/>
   <result pre="tested by subtype No. (%) resistant Belshe et al. [24]" exact="United States" post="1978–1988 EIA, S 65 H1N1 0 181 H3N2 5"/>
   <result pre="0 181 H3N2 5 (2.0 %)a Valette et al. [202]" exact="France" post="1988–1990 EIA 28 H1N1 0 77 H3N2 0 Ziegler"/>
   <result pre="EIA, plaque 1813 28 (1.5 %) Suzuki et al. [205]" exact="Japan" post="1993–1998 Not stated 55 0 1999–2000 Not stated 179"/>
   <result pre="Not stated 179 6 (3.4 %) Shih et al. [206]" exact="Taiwan" post="1996–1998 Plaque, S 84 1(1.2 %) Bright et al."/>
   <result pre="1998–2004 589 H1N1 2 (0.3 %) Bright et al. [29]" exact="United States" post="2005 S 205 H3N2 193 (92.3 %) 8 H1N1"/>
   <result pre="%) 8 H1N1 2 (25 %) Saito et al. [207]" exact="Japan" post="2005–2006 S 354 H3N2 231 (65.3 %) 61 H1N1"/>
   <result pre="(65.3 %) 61 H1N1 0 Barr et al. [43] Australia," exact="New Zealand," post="Asia, South Africa 2005 S 102 H3N2 43 (42"/>
   <result pre="H1N1 0 Barr et al. [43] Australia, New Zealand, Asia," exact="South Africa" post="2005 S 102 H3N2 43 (42 %) 37 H1N1"/>
   <result pre="H3N2 viruses were 73.8 % in China, 69.6 % in" exact="Hong Kong," post="22.7 % in Taiwan, 15.1 % in South Korea,"/>
   <result pre="in Hong Kong, 22.7 % in Taiwan, 15.1 % in" exact="South Korea," post="4.3 % in Japan, 30.0 % in Canada, 19.2"/>
   <result pre="% in Canada, 19.2 % in Mexico, 14.5 % in" exact="United States," post="and 4.7 % in Europe The frequency of resistance"/>
   <result pre="initial human isolates of highly pathogenic avian A/H5N1 viruses in" exact="Hong Kong" post="in 1997 were M2 inhibitor susceptible, resistance to this"/>
   <result pre="since 1999, their use has been quite limited, except in" exact="Japan" post="and during the 2009 influenza A/H1N1 pandemic [88]. Clinical"/>
   <result pre="with an NA H275Y amino acid change emerged first in" exact="Norway" post="during the 2007–2008 season and was able to spread"/>
   <result pre="change in the low-pathogenic avian influenza A/H7N9 viruses circulating in" exact="China" post="since 2013 causes high NA inhibitor resistance to oseltamivir"/>
   <result pre="169 A/N2 0 128 B 0a Bovin and Goyette [217]" exact="Canada" post="1999–2000 NAI-CL 38 H3N2 0 40 H2N1 0 23"/>
   <result pre="B 2 (0.3 %) Asp198Glu, Ile222Thr Ferraris et al. [219]" exact="France" post="2002–2005 NAI-FA, S 788 H3N2 0b NISN WER [220]"/>
   <result pre="France 2002–2005 NAI-FA, S 788 H3N2 0b NISN WER [220]" exact="Japan" post="2003–2004 NAI-CL, S 1180 H3N2 3 (0.3 %) 2"/>
   <result pre="Glu119Val, 1 Arg292Lys 171 B 0 Hatakeyama et al. [221]" exact="Japan" post="2004–2005 NAI-FA, S 422 B 7 (1.7 %) 3"/>
   <result pre="%) 3 Asp198Asn, 3 Ile222Thr, 1 Ser250Gly NISN WER [222]" exact="Japan" post="2004–2005 NAI-CL, S 558 H3N2 0 4 His274Tyr 2005–2006"/>
   <result pre="understood at this point. The drug is currently licensed in" exact="Japan" post="for use selectively when approved by the Ministry of"/>
   <result pre="A20029921138495410.1073/pnas.21251969912368467 43.BarrIGet al.Increased adamantane resistance in influenza A(H3) viruses in" exact="Australia" post="and neighbouring countries in 2005Antiviral Res2007732112710.1016/j.antiviral.2006.08.00216963130 44.OhDYHurtACA review of"/>
   <result pre="porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in" exact="Germany" post="between 1981 and 2001Intervirology20064952869310.1159/00009424416809934 47.SleemanKet al.Antiviral susceptibility of variant"/>
   <result pre="47.SleemanKet al.Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in" exact="the United States" post="from 2011 to 2013Antimicrob Agents Chemother201458420455110.1128/AAC.02556-1324449767 48.JhungMAet al.Outbreak of"/>
   <result pre="al.Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the" exact="United States" post="from 2011 to 2013Antimicrob Agents Chemother201458420455110.1128/AAC.02556-1324449767 48.JhungMAet al.Outbreak of"/>
   <result pre="two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata," exact="Japan" post="and the clinical effectiveness of oseltamivir and zanamivirVirol J201075310.1186/1743-422X-7-5320202225"/>
   <result pre="influenza in AustraliaJ Infect Dis201220621485710.1093/infdis/jis33722561367 123.Okomo-AdhiamboMet al.Oseltamivir-resistant influenza A(H1N1)pdm09 viruses," exact="United States," post="2013–14Emerg Infect Dis20152111364110.3201/eid2101.14100625532050 124.TakashitaEet al.A community cluster of influenza"/>
   <result pre="experience with intravenous zanamivir under an Emergency IND program in" exact="the United States" post="(2011–2014)Antivir Ther2015205561410.3851/IMP294425667992 185.FraaijPLet al.Evaluation of the antiviral response to"/>
   <result pre="with intravenous zanamivir under an Emergency IND program in the" exact="United States" post="(2011–2014)Antivir Ther2015205561410.3851/IMP294425667992 185.FraaijPLet al.Evaluation of the antiviral response to"/>
   <result pre="hemagglutininsScience20113336044850610.1126/science.120566921798894 198.Okomo-AdhiamboMet al.Drug susceptibility surveillance of influenza viruses circulating in" exact="the United States" post="in 2011-2012: application of the WHO antiviral working group"/>
   <result pre="198.Okomo-AdhiamboMet al.Drug susceptibility surveillance of influenza viruses circulating in the" exact="United States" post="in 2011-2012: application of the WHO antiviral working group"/>
   <result pre="trialJAMA200128567485410.1001/jama.285.6.74811176912 212.GalbraithAWet al.Study of 1-adamantanamine hydrochloride used prophylactically during the" exact="Hong Kong" post="influenza epidemic in the family environmentBull World Health Organ1969413677824908342"/>
   <result pre="zanamivir and oseltamivir: a study performed on viruses circulating in" exact="France" post="prior to the introduction of neuraminidase inhibitors in clinical"/>
   <result pre="of neuraminidase inhibitor resistance among clinical influenza virus isolates in" exact="Japan" post="during the 2003-2006 influenza seasons. Wkly Epidemiol Rec, 2007."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7122828/results/search/country/results.xml">
   <result pre="the ships that brought the slaves to work mainly in" exact="Brazil" post="(Yalcindag et al. 2012). At the XVII century, as"/>
   <result pre="for the extraction of quinine from the bark of Cinchona," exact="the United States" post="started working in 1942 on an alternative synthetic drug,"/>
   <result pre="the extraction of quinine from the bark of Cinchona, the" exact="United States" post="started working in 1942 on an alternative synthetic drug,"/>
   <result pre="2001; Silva et al. 2005). During the Korean (1950–1953) and" exact="Vietnam" post="(1950–1957) wars, the US Army observed that some malaria"/>
   <result pre="al. 2005). During the Korean (1950–1953) and Vietnam (1950–1957) wars," exact="the US" post="Army observed that some malaria patients did not respond"/>
   <result pre="become increasingly necessary. Some emerging countries like Brazil, India, and" exact="China" post="have invested extensively in researches for the treatment of"/>
   <result pre="histórico da maláriaRevista Paraense de Medicina20062038182 Russel PF (1968) The" exact="United States" post="and malaria: debits and credits. Bulletin of the New"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7123656/results/search/country/results.xml">
   <result pre="in transformed cell lines Nakashima et al. (1993) α-defensins α-defensin" exact="Guinea" post="pig HIV-1 ssRNA Inhibits HIV infection in transformed cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7124147/results/search/country/results.xml">
   <result pre="Genetics and Crop Plant Research (IPK), [2], grid.463419.d0000000404040958US Salinity Laboratory," exact="United States" post="Department of Agriculture Agriculture Research Service, [3], grid.411340.30000000419370765Botany Department,"/>
   <result pre="prepared from the dried leaves continues to be used in" exact="China" post="and due to its apparent effectiveness has rapidly spread"/>
   <result pre="A 2011 survey completed by Willcox et al. (2011) in" exact="Kenya" post="and Uganda reported that 51 % (n = 20)"/>
   <result pre="survey completed by Willcox et al. (2011) in Kenya and" exact="Uganda" post="reported that 51 % (n = 20) of respondents"/>
   <result pre="Furthermore, a survey completed by Noumi and Manga (2011) in" exact="Cameroon" post="also noted that 13.8 % of respondents were using"/>
   <result pre="parts Artemisinin content Corrected IC50 low (μg/mL) Artemisia annua 1" exact="South Africa" post="1999 Leaves/flowers 0.36 1.0 2 South Africa 2002 Leaves/flowers"/>
   <result pre="Artemisia annua 1 South Africa 1999 Leaves/flowers 0.36 1.0 2" exact="South Africa" post="2002 Leaves/flowers 0.30 2.3 3 Tanzania 2005 Leaves 0.49"/>
   <result pre="0.36 1.0 2 South Africa 2002 Leaves/flowers 0.30 2.3 3" exact="Tanzania" post="2005 Leaves 0.49 1.4 4 South Africa 2006 Leaves"/>
   <result pre="Leaves/flowers 0.30 2.3 3 Tanzania 2005 Leaves 0.49 1.4 4" exact="South Africa" post="2006 Leaves 0.74 1.2 5 Tanzania 2006 Leaves 0.46"/>
   <result pre="0.49 1.4 4 South Africa 2006 Leaves 0.74 1.2 5" exact="Tanzania" post="2006 Leaves 0.46 1.3 6 Cameroon 2007 Leaves 0.56"/>
   <result pre="Leaves 0.74 1.2 5 Tanzania 2006 Leaves 0.46 1.3 6" exact="Cameroon" post="2007 Leaves 0.56 2.6 7 Germany 2007 Leaves 0.58"/>
   <result pre="Leaves 0.46 1.3 6 Cameroon 2007 Leaves 0.56 2.6 7" exact="Germany" post="2007 Leaves 0.58 4.5 8 Mozambique 2007 Leaves 0.40"/>
   <result pre="Leaves 0.56 2.6 7 Germany 2007 Leaves 0.58 4.5 8" exact="Mozambique" post="2007 Leaves 0.40 0.6 9 Germany 2009 Leaves 0.80"/>
   <result pre="Leaves 0.58 4.5 8 Mozambique 2007 Leaves 0.40 0.6 9" exact="Germany" post="2009 Leaves 0.80 3.7 Artemisia afra 10 South Africa"/>
   <result pre="0.6 9 Germany 2009 Leaves 0.80 3.7 Artemisia afra 10" exact="South Africa" post="&amp;gt;2008 Leaves nd 1.0 nd = not detected The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7124313/results/search/country/results.xml">
   <result pre="MD, Laboratory Medicine, Jai Prakash Narayan Apex Trauma Center, All" exact="India" post="Institute of Medical Sciences, Ansari Nagar, New Delhi 110029,"/>
   <result pre="has also affected many healthcare workers. A recent report from" exact="China" post="classified an overall 14.8% of confirmed cases among health"/>
   <result pre="of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020." exact="China" post="CDC Wkly [Internet]. Available at: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51. Accessed March 30,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7125728/results/search/country/results.xml">
   <result pre="Institutes of Health, 8200 Research Plaza, Fort Detrick, MD 21702," exact="United States." post="Tel.: +1 301 631 7221; fax: +1 301 619"/>
   <result pre="a gene encoding green fluorescent protein was introduced into Ebola" exact="Zaire" post="virus; although the modified agent replicated normally in cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7126206/results/search/country/results.xml">
   <result pre="mutant strain and its use in immunization studies in a" exact="Guinea" post="pig model of genital diseaseVirology23219971129185583 CuéllarM.J.GinerR.M.RecioM.C.MáñezS.RíosJ.L.Topical anti-inflammatory activity of"/>
   <result pre="was supported by the grants from Natural Science Foundation of" exact="China" post="(Nos. 81874483, 81473718, 81273787). We wish to acknowledge Professor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7126217/results/search/country/results.xml">
   <result pre="and Drug Control, No.2, Tiantan Xili, Dongcheng District, Beijing, 10050," exact="PR China." post="masc@nifdc.org.cn ∗∗Corresponding author. National Institutes for Food and Drug"/>
   <result pre="and Drug Control, No.2, Tiantan Xili, Dongcheng District, Beijing, 10050," exact="PR China." post="wyljoe@126.com pmc-release: 2020-1-1ppub: 2020-4-4epub: 2020-1-1251112550112550received: 2019-8-27rev-recd: 2019-10-24accepted: 2020-1-4(C) Elsevier"/>
   <result pre="competing interest None. References References Chinese Pharmacopoeia CommissionPharmacopoeia of People's" exact="Republic of" post="China2015China Medical Science PressBeijing CorreiaV.SantosL.A.GiriaM.Almeida-SantosM.M.Rebelo-de-AndradeH.Influenza A(H1N1)pdm09 resistance and cross-decreased"/>
   <result pre="work was supported by the National Natural Science Foundation of" exact="China" post="(grant No. 81303194) and the Academic Leader Foundation of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7127009/results/search/country/results.xml">
   <result pre="The Coronavirus-associated disease, that was first identified in 2019 in" exact="China" post="(CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus,"/>
   <result pre="homology with SARS and MERS-CoV, responsible for past outbreaks in" exact="China" post="and in Middle East. SARS-CoV2 spread from China where"/>
   <result pre="outbreaks in China and in Middle East. SARS-CoV2 spread from" exact="China" post="where the first infections were described in December 2019"/>
   <result pre="It was first reported in late December 2019 in Wuhan," exact="China" post="and the disease was officially named CoViD-19 by the"/>
   <result pre="many countries worldwide with a significant rate of infection in" exact="Italy" post="that currently accounts for more than 110,000 infected cases"/>
   <result pre="the Middle East Respiratory Syndrome (MERS)-CoV responsible for infections in" exact="Saudi Arabia" post="in 2012, respectively. Both these viruses had intermediate hosts"/>
   <result pre="hydroxychloroquine in CoViD-19 patients. Hydroxychloroquine is thus being used in" exact="Italy" post="for the treatment of CoViD-19 patients despite the absence"/>
   <result pre="uncomplicated SARS or MERS infection [10,11]. Recent preliminary data from" exact="China" post="reported high plasma levels of cytokines including IL-6, related"/>
   <result pre="single dose of tocilizumab was used in 21 patients in" exact="China" post="suffering from severe respiratory syndrome during CoViD-19 infection, at"/>
   <result pre="current measures. From the epidemiology of SARS-CoV and SARS-CoV2 in" exact="China" post="we have learned how fundamental are measures such as"/>
   <result pre="of a CoViD-19 infection. Furthermore, an international registry supported by" exact="America" post="College of Rheumatology, European League Against Rheumatism and other"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7127483/results/search/country/results.xml">
   <result pre="the National Key Plan for Scientific Research and Development of" exact="China" post="(2016YFD0500300), the Hunan Provincial Natural Science Foundation of China"/>
   <result pre="of China (2016YFD0500300), the Hunan Provincial Natural Science Foundation of" exact="China" post="(2018JJ3039), the National Natural Science Foundation of China (31500126"/>
   <result pre="Foundation of China (2018JJ3039), the National Natural Science Foundation of" exact="China" post="(31500126 and 31671371), the Chinese Academy of Medical Sciences"/>
   <result pre="more than 50 countries in Africa, Europe, Asia and South" exact="America" post="until now (Costard et al., 2013; Malogolovkin et al.,"/>
   <result pre="the virus has caused outbreaks in all provinces of mainland" exact="China" post="(Zhou et al., 2018). How to effectively control the"/>
   <result pre="al. (2016)BorcaMVO’DonnellVHolinkaLGRaiDKSanfordBAlfanoMCarlsonJAzzinaroPAAlonsoCGladueDPThe Ep152R ORF of African swine fever virus strain" exact="Georgia" post="encodes for an essential gene that interacts with host"/>
   <result pre="African swine fever virus isolates originating from outbreaks in the" exact="Russian Federation" post="betweenVeterinary Microbiology20121583–441541910.1016/j.vetmic.2012.03.00222445729 Miskin et al. (1998)MiskinJEAbramsCCGoatleyLCDixonLKA viral mechanism for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7127693/results/search/country/results.xml">
   <result pre="of influenza viruses, the re-emergence of West Nile virus in" exact="Italy" post="and the United States. Despite relatively long pauses, viruses"/>
   <result pre="viruses, the re-emergence of West Nile virus in Italy and" exact="the United States." post="Despite relatively long pauses, viruses such as influenza virus"/>
   <result pre="the re-emergence of West Nile virus in Italy and the" exact="United States." post="Despite relatively long pauses, viruses such as influenza virus"/>
   <result pre="hemagglutinin and neuraminidase isolated from A/Goose/Qinghai/59/05 (H5N1) influenza virus, Ebolavirus" exact="Zaire" post="envelope glycoprotein, and Lassa virus envelope glycoprotein, has been"/>
   <result pre="particle assembly in vitro by inositol phosphatesProc. Natl. Acad. Sci." exact="U. S." post="A.98192001108751087911526217 CampsteijnC.VietriM.StenmarkH.Novel ESCRT functions in cell biology: spiraling out"/>
   <result pre="studying the activity of a proteolytic enzymeProc. Natl. Acad. Sci." exact="U. S." post="A.8991992415941621570342 De ClercqE.Antiviral drugs in current clinical useJ. Clin."/>
   <result pre="that target multiple aspects of the infectionProc. Natl. Acad. Sci." exact="U. S." post="A.1071201029129619995961 GemeneK.L.MeyerhoffM.E.Detection of protease activities by flash chronopotentiometry using"/>
   <result pre="relationship between HIV-1 uncoating and reverse transcriptionProc. Natl. Acad. Sci." exact="U. S." post="A.1082420119975998021628558 HuloC.MassonP.de CastroE.AuchinclossA.H.FoulgerR.PouxS.LomaxJ.BougueleretL.XenariosI.Le MercierP.The ins and outs of eukaryotic"/>
   <result pre="is critically involved in coronavirus RNA synthesisProc. Natl. Acad. Sci." exact="U. S." post="A.1031320065108511316549795 MiyataY.ChangL.BainorA.McQuadeT.J.WalczakC.P.ZhangY.LarsenM.J.KirchhoffP.GestwickiJ.E.High-throughput screen for Escherichia coli heat shock protein"/>
   <result pre="wild-type and mutant Rous sarcoma virus integrasesProc. Natl. Acad. Sci." exact="U. S." post="A.9024199311633116378265600 MunjalA.KhandiaR.DhamaK.SachanS.KarthikK.TiwariR.MalikY.S.KumarD.SinghR.K.IqbalH.M.N.JoshiS.K.Advances in developing therapies to combat Zika virus:"/>
   <result pre="capsids and release of the viral genomeProc. Natl. Acad. Sci." exact="U. S." post="A.1001720039849985412909718 RaguramA.SasisekharanV.SasisekharanR.A chiral pentagonal polyhedral framework for characterizing virus"/>
   <result pre="of the &quot;speed limit&quot; of DNA polymeraseProc. Natl. Acad. Sci." exact="U. S." post="A.106482009202942029919906998 ScourfieldE.J.Martin-SerranoJ.Growing functions of the ESCRT machinery in cell"/>
   <result pre="transfected with cloned hepatitis B virus DNAProc. Natl. Acad. Sci." exact="U. S." post="A.8441987100510093029758 SeybertA.HegyiA.SiddellS.G.ZiebuhrJ.The human coronavirus 229E superfamily 1 helicase has"/>
   <result pre="retroviral capsids by the TRIM5alpha restriction factorProc. Natl. Acad. Sci." exact="U. S." post="A.1031420065514551916540544 SugrueR.J.BrownC.BrownG.AitkenJ.McL. Rixon, H.W.Furin cleavage of the respiratory syncytial"/>
   <result pre="in the YMDD region of reverse transcriptaseProc. Natl. Acad. Sci." exact="U. S." post="A.90121993565356567685907 TomarS.JohnstonM.L.St. JohnS.E.OsswaldH.L.NyalapatlaP.R.PaulL.N.GhoshA.K.DenisonM.R.MesecarA.D.Ligand-induced dimerization of middle east respiratory syndrome"/>
   <result pre="targeting signal accessibility to Tctex-1 of dyneinProc. Natl. Acad. Sci." exact="U. S." post="A.105302008105651057018647839 VogtP.K.Retroviral oncogenes: a historical primerNat. Rev. Cancer129201263964822898541 VolzT.AllweissL.ḾBarekM.B.WarlichM.LohseA.W.PollokJ.M.AlexandrovA.UrbanS.PetersenJ.LütgehetmannM.DandriM.The"/>
   <result pre="with phosphoproteomics for identifying direct kinase substratesProc. Natl. Acad. Sci." exact="U. S." post="A.1091520125615562022451900 YanH.ZhongG.XuG.HeW.JingZ.GaoZ.HuangY.QiY.PengB.WangH.FuL.SongM.ChenP.GaoW.RenB.SunY.CaiT.FengX.SuiJ.LiW.Sodium taurocholate cotransporting polypeptide is a functional receptor"/>
   <result pre="virus 1 is an ATP-dependent DNA helicaseProc. Natl. Acad. Sci." exact="U. S." post="A.90111993508650908389467 YangH.XieW.XueX.YangK.MaJ.LiangW.ZhaoQ.ZhouZ.PeiD.ZiebuhrJ.HilgenfeldR.YuenK.Y.WongL.GaoG.ChenS.ChenZ.MaD.BartlamM.RaoZ.Design of wide-spectrum inhibitors targeting coronavirus main proteasesPLoS"/>
   <result pre="ZhongJ.GastaminzaP.ChengG.KapadiaS.KatoT.BurtonD.R.WielandS.F.UprichardS.L.WakitaT.ChisariF.V.Robust hepatitis C virus infection in vitroProc. Natl. Acad. Sci." exact="U. S." post="A.1022620059294929915939869 ZhouY.AgudeloJ.LuK.GoetzD.H.HansellE.ChenY.T.RoushW.R.McKerrowJ.CraikC.S.AmbergS.M.SimmonsG.Inhibitors of SARS-CoV entry - identification using an"/>
   <result pre="and the Ministry of Education, Youth and Sport of the" exact="Czech Republic" post="(OPPC CZ.2.16/3.1.00/24503), through its &quot;National Program of Sustainability I&quot;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7128205/results/search/country/results.xml">
   <result pre="is associated with a cluster of cases of pneumonia in" exact="China" post="(Zhou et al., 2020). Coronaviruses (CoV) are a broad"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7128351/results/search/country/results.xml">
   <result pre="[1], many other TCM prescriptions used for COVID-19 patients in" exact="China" post="have been reported to be effective, including Lianhua Qingwen"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7128376/results/search/country/results.xml">
   <result pre="(Gomathi et al., 2020). Ayurveda and Siddha practices originated in" exact="India" post="and are still widely used among the Indian population."/>
   <result pre="This was closely followed by the emergence of MERS-CoV at" exact="Saudi Arabia" post="in 2012, which caused 858 deaths among the 2494"/>
   <result pre="With COVID-19 Sarilumab Recruiting Regeneron Study SiteNew York, New York," exact="United States" post="2. Study to Evaluate the Safety and Antiviral Activity"/>
   <result pre="California, United States3. Providence Regional Medical Center Everett, Everett, Washington," exact="United States" post="3. Study to Evaluate the Safety and Antiviral Activity"/>
   <result pre="California, United States3. Providence Regional Medical Center Everett, Everett, Washington," exact="United States" post="4. Fingolimod in COVID-19 Fingolimod 0.5 mg Recruiting Wan-Jin"/>
   <result pre="4. Fingolimod in COVID-19 Fingolimod 0.5 mg Recruiting Wan-Jin ChenFuzhou," exact="China" post="5. The Clinical Study of Carrimycin on Treatment Patients"/>
   <result pre="first people's HospitalYichang, Hubei, China3. Renmin Hospital of Wuhan UniversityWuhan," exact="China" post="7. Mild/Moderate 2019-nCoV Remdesivir RCT Remdesivir Recruiting Jin Yin-tan"/>
   <result pre="2019-nCoV Remdesivir RCT Remdesivir Recruiting Jin Yin-tan hospitalWu Han, Hubei," exact="China" post="8. Adaptive COVID-19 Treatment Trial Remdesivir Recruiting 1.National Institutes"/>
   <result pre="DiseaseGalveston, Texas, United States4. Providence Sacred Heart Medical CenterSpokane, Washington," exact="United States" post="9. Severe 2019-nCoV Remdesivir RCT Remdesivir Recruiting Bin CaoBeijing,"/>
   <result pre="9. Severe 2019-nCoV Remdesivir RCT Remdesivir Recruiting Bin CaoBeijing, Beijing," exact="China" post="10. Nitric Oxide Gas Inhalation for Severe Acute Respiratory"/>
   <result pre="Washington Health Research Institute - Vaccines and Infectious DiseasesSeattle, Washington," exact="United States" post="14. Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With"/>
   <result pre="Failure Methylprednisolone Recruiting Medical ICU,Peking Union Medical College HospitalBeijing, Beijing," exact="China" post="15. Lopinavir/Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment"/>
   <result pre="nCoV Treatment 1. Lopinavir/ritonavir2. Ribavirin3. Interferon Beta-1B Recruiting University of" exact="Hong Kong," post="Queen Mary HospitalHong Kong, Hong Kong 16. Efficacy of"/>
   <result pre="Beta-1B Recruiting University of Hong Kong, Queen Mary HospitalHong Kong," exact="Hong Kong" post="16. Efficacy of Chloroquine and Lopinavir/Ritonavir in mild/general novel"/>
   <result pre="citrate Recruiting Department and Institute of Infectious Disease, Wuhan, Hubei," exact="China" post="22. Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With"/>
   <result pre="Medical Center, University of Ulsan College of Medicine, Seoul, Korea," exact="Republic of" post="Korea 23. The Efficacy and Safety of Thalidomide Combined"/>
   <result pre="Randomized Control Trial Oral Not yet recruiting Subsai Kongsaengdao, Bangkok," exact="Thailand" post="25. Chloroquine Prevention of Coronavirus Disease (COVID-19) in the"/>
   <result pre="ChinaGuiqiang Wang, Beijing, Beijing, ChinaPeking University First Hospital, Beijing, Beijing," exact="China" post="27. Trial of Treatments for COVID-19 in Hospitalized Adults"/>
   <result pre="Medical Center, Minneapolis, Minnesota, United StatesUniversity of Minnesota, Minneapolis, Minnesota," exact="United States" post="29. Randomized Controlled Trial of Losartan for Patients With"/>
   <result pre="Medical Center, Minneapolis, Minnesota, United StatesUniversity of Minnesota, Minneapolis, Minnesota," exact="United States" post="30. Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in"/>
   <result pre="with ritonavir +/-Interferon Recruiting The Ninth Hospital of NanchangNanchang, Jiangxi," exact="China" post="31. Eculizumab (Soliris) in Covid-19 Infected Patients Eculizumab Initiated"/>
   <result pre="Prophylaxis for SARS-Coronavirus-2 Hydroxychloroquine Recruiting University of Minnesota, Minneapolis, Minnesota," exact="United States" post="35. The efficacy and safety of pirfenidone capsules in"/>
   <result pre="plants and its usage provided by the AYUSH, Government of" exact="India" post="as a therapeutic approach for COVID-19. Table 5 List"/>
   <result pre="(WHO, 2020a) as on 26th March 26, 2020 and in" exact="India" post="581 cases (ICMR, 2020) have been identified to be"/>
   <result pre="be positive for this COVID-19 and 11 death cases in" exact="India" post="as on 25th March 2020 (20:00 IST). More cases"/>
   <result pre="infection. 15 Recommendations The cases reported in many parts of" exact="China" post="and the outbreaks involve large numbers in Italy, USA,"/>
   <result pre="China and the outbreaks involve large numbers in Italy, USA," exact="Spain" post="and Germany; hence travel restrictions and quarantine measures have"/>
   <result pre="by the 10.13039/501100001843Science and Engineering Research Board (SERB), Government of" exact="India" post="[ECR/2016/001688]; 10.13039/501100001843The Science and Engineering Research Board (SERB), Government"/>
   <result pre="[ECR/2016/001688]; 10.13039/501100001843The Science and Engineering Research Board (SERB), Government of" exact="India" post="[ECR/2018/000718]; The Advanced Level State Biotech Hub (BT/04/NE/2009 Dt.29.082014),"/>
   <result pre="(BT/04/NE/2009 Dt.29.082014), India; the Expanding Excellence in England, Research England," exact="United Kingdom" post="(E3) scheme. Declaration of competing interest The authors declare"/>
   <result pre="drugs that may act on the novel coronavirus (2019-nCoV), Wuhan," exact="China" post="through a drug-target interaction deep learning modelbioRxiv202010.1101/2020.01.31.929547 BertramS.DijkmanR.HabjanM.HeurichA.GiererS.GlowackaI.WelschK.WinklerM.SchneiderH.Hofmann-WinklerH.TMPRSS2 activates"/>
   <result pre="3C-like proteases using luciferase-based biosensorsJ. Virol.872013119551196210.1128/JVI.02105-1323986593 KillerbyM.E.BiggsH.M.HaynesA.DahlR.M.MustaquimD.GerberS.I.WatsonJ.T.Human coronavirus circulation in" exact="the United States" post="2014–2017J. Clin. Virol.1012018525610.1016/j.jcv.2018.01.01929427907 KimI.LeeJ.E.KimK.H.LeeS.LeeK.MokJ.H.Successful treatment of suspected organizing pneumonia"/>
   <result pre="proteases using luciferase-based biosensorsJ. Virol.872013119551196210.1128/JVI.02105-1323986593 KillerbyM.E.BiggsH.M.HaynesA.DahlR.M.MustaquimD.GerberS.I.WatsonJ.T.Human coronavirus circulation in the" exact="United States" post="2014–2017J. Clin. Virol.1012018525610.1016/j.jcv.2018.01.01929427907 KimI.LeeJ.E.KimK.H.LeeS.LeeK.MokJ.H.Successful treatment of suspected organizing pneumonia"/>
   <result pre="of asc and asc-cm to treat ards, sars, and mers." exact="United States" post="patent application US 16/177,103. 2019 Apr 25. MarklandW.McQuaidT.JainJ.KwongA.Broad-spectrum antiviral"/>
   <result pre="by the Department of Biotechnology (DBT), New Delhi, Government of" exact="India" post="for providing the infrastructural support and facilities. P Pattanathu.K.S.M.Rahman"/>
   <result pre="thank Mr.T.Navaneethakrishnan (Indian Traditional Medicinal plant - based practitioner) Mettupalayam," exact="India" post="for providing valuable support for the preparation of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7128395/results/search/country/results.xml">
   <result pre="With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia," exact="Italy" post="AlbericiFedericofederico.alberici@unibs.it12∗DelbarbaElisa2ManentiChiara2EconimoLaura2ValerioFrancesca2PolaAlessandra2MaffeiCamilla2PossentiStefano2PivaSimone13LatronicoNicola13FocàEmanuele45CastelliFrancesco45GaggiaPaola2MovilliEzio2BoveSergio6MalbertiFabio7FarinaMarco8BracchiMartina9CostantinoEster Maria10BossiniNicola2GaggiottiMario2ScolariFrancesco12on behalf of the collab: Brescia Renal COVID"/>
   <result pre="are unique in view of their immunosuppressed status. Reports from" exact="China" post="suggest a less severe course of the disease in"/>
   <result pre="death in patients with coronavirus disease 2019 pneumonia in Wuhan," exact="China" post="[e-pub ahead of print]. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0994. Accessed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7128473/results/search/country/results.xml">
   <result pre="B virus infection for example, which is more prevalent in" exact="China" post="than Europe, does not appear to affect the outcome"/>
   <result pre="care for COVID-19. With regards to nosocomial-infections, recent observations from" exact="Spain" post="that compared patient characteristics between patients with community-acquired influenza"/>
   <result pre="analogue, RNA-dependent RNA polymerase (RdRp)- inhibitor, approved for influenza in" exact="Japan" post="•Preliminary results from a study with 80 COVID-19 patients31"/>
   <result pre="vitro which is required for S protein priming48 •Licensed in" exact="Japan" post="for treatment of chronic pancreatitis •Patients with chronic viral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7128742/results/search/country/results.xml">
   <result pre="COVID-19. Other initiative such as the &quot;Defense Production Act&quot; in" exact="the US" post="may be activated. Using post-exposure HCQ is in line"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7129043/results/search/country/results.xml">
   <result pre="[1], [2], [3], with more than 40,000 confirmed cases in" exact="China" post="and exportations to over 20 countries [4]. On January"/>
   <result pre="have potential use in the current outbreak [7]. Indeed, the" exact="China" post="government is advising doctors to consider combining Western antiviral"/>
   <result pre="and its traditional indications. TCM formulas have been used in" exact="China" post="over 2000 years. According to their effectiveness, TCM remedies"/>
   <result pre="This study was supported by 10.13039/501100001809National Natural Science Foundation of" exact="China" post="(No. 81430101). The funding source had no role in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7129111/results/search/country/results.xml">
   <result pre="economy and the society. As the forefront of the outbreak," exact="China" post="formulated and launched a series of emergency plans and"/>
   <result pre="effectively contained further spread of the pandemic. On March 19," exact="China" post="reported no domestic new case for the first time,"/>
   <result pre="mRNA-1273 (ClinicalTrials.gov, NO.NCT04283461) have entered phase 1 clinical trials in" exact="China" post="and the US respectively. Meanwhile, 52 candidate vaccines are"/>
   <result pre="NO.NCT04283461) have entered phase 1 clinical trials in China and" exact="the US" post="respectively. Meanwhile, 52 candidate vaccines are under pre-clinical research"/>
   <result pre="(COVID-19) situation report –70https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200330-sitrep-70-covid-19.pdf?sfvrsn=7e0fe3f8_22020 3National Health Commission of the People’s" exact="Republic of" post="ChinaWorking plan on prevention and control of novel coronavirus"/>
   <result pre="and the pharmacy workforcehttps://www.fip.org/files/content/priority-areas/coronavirus/Coronavirus-guidance-update-ENGLISH.pdf2020 7National Health Commission of the People’s" exact="Republic of" post="ChinaDiagnosis and treatment protocol for COVID-19 (trial version 7)https://www.chinadaily.com.cn/pdf/2020/1.Clinical.Protocols.for.the.Diagnosis.and.Treatment.of.COVID-19.V7.pdf2020"/>
   <result pre="guidance for providing pharmaceutical care services during COVID-19 pandemic: a" exact="China" post="perspectiveRes Soc Adm Pharm2020 12American Society of Health-System PharmacistsAssessment"/>
   <result pre="disordersChin J Hosp Pharm2020http://kns.cnki.net/kcms/detail/42.1204.R.20200222.1810.002.html 26National Health Commission of the People's" exact="Republic of" post="ChinaThe clinical guidance of convalescent plasma therapy (trial version"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7129535/results/search/country/results.xml">
   <result pre="Microbiology, Immunology, and Infection1684-11821995-9133Taiwan Society of Microbiology. Published by Elsevier" exact="Taiwan" post="LLC. pmcid: 7129535S1684-1182(20)30094-3 doi: 10.1016/j.jmii.2020.03.034 : Article Treatment options"/>
   <result pre="∗Corresponding author. Departments of Laboratory Medicine and Internal Medicine, National" exact="Taiwan" post="University Hospital, National Taiwan University College of Medicine, No."/>
   <result pre="Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National" exact="Taiwan" post="University College of Medicine, No. 7 Chung-Shan South Road,"/>
   <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan," exact="China" post="in December 2019. An extremely high potential for dissemination"/>
   <result pre="by the Centers for Disease Control (CDC) and Prevention of" exact="Taiwan" post="since February, 2020. According to an investigation by To"/>
   <result pre="in humans are available online.21 The first COVID-19 patient in" exact="the USA" post="was successfully treated with remdesivir for the progression of"/>
   <result pre="infection.28 Favipiravir was approved for the treatment of COVID-19 in" exact="China" post="in March, 2020. In addition, patients with COVID-19 infection"/>
   <result pre="serum level.31,33 A randomized, controlled open-label trial was launched in" exact="China" post="to evaluate the efficacy of LPV/RTV (200/50 mg twice"/>
   <result pre="advance) to chloroquine phosphate in inhibiting SARS-CoV-2 in vitro.41 The" exact="Taiwan" post="CDC declared hydroxychloroquine as an important anti-SARS-CoV-2 agent on"/>
   <result pre="of stem cells against COVID-19 has been under evaluation in" exact="China" post="recently. Additionally, tocilizumab (Roche Pharmaceuticals, Basel, Switzerland) is a"/>
   <result pre="absence of ARDS is advised. Additionally, despite conflicting advice from" exact="the US" post="Food and Drug Administration,65 the use of non-steroidal anti-inflammatory"/>
   <result pre="monitoring of persons exposed to patients with confirmed COVID-19 -" exact="United States," post="January-February 2020MMWR Morb Mortal Wkly Rep69202024524632134909 8LiuJ.LiuY.XiangP.PuL.XiongH.LiC.Neutrophil-to-lymphocyte ratio predicts"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7129715/results/search/country/results.xml">
   <result pre="pyrogenic cytokine and, and a trial involving 21 patients in" exact="China" post="[6] found that tocilizumab (an IL-6 receptor antagonist) quickly"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7130072/results/search/country/results.xml">
   <result pre="for medications. •Encourage and fund nonprofit generic drug manufacturing in" exact="the United States." post="•Prohibit deductibles and rebates for COVID-19–specific drugs. •Increase the"/>
   <result pre="medications. •Encourage and fund nonprofit generic drug manufacturing in the" exact="United States." post="•Prohibit deductibles and rebates for COVID-19–specific drugs. •Increase the"/>
   <result pre="only one or two FDA-approved versions available for sale in" exact="the United States." post="In contrast, in some countries in Europe and in"/>
   <result pre="one or two FDA-approved versions available for sale in the" exact="United States." post="In contrast, in some countries in Europe and in"/>
   <result pre="by an established manufacturer hitherto not authorized to sell in" exact="the United States." post="Second, the federal government must work with major brand"/>
   <result pre="an established manufacturer hitherto not authorized to sell in the" exact="United States." post="Second, the federal government must work with major brand"/>
   <result pre="we must encourage and fund nonprofit generic drug manufacturing in" exact="the United States." post="Civica Rx, for instance, was founded with the goal"/>
   <result pre="must encourage and fund nonprofit generic drug manufacturing in the" exact="United States." post="Civica Rx, for instance, was founded with the goal"/>
   <result pre="companies despite critical need. Fourth, in addition to negotiating with" exact="China" post="to increase supply, the United States must consider increasing"/>
   <result pre="Fourth, in addition to negotiating with China to increase supply," exact="the United States" post="must consider increasing the domestic manufacture of active pharmaceutical"/>
   <result pre="in addition to negotiating with China to increase supply, the" exact="United States" post="must consider increasing the domestic manufacture of active pharmaceutical"/>
   <result pre="of active pharmaceutical ingredients.10 Since factories closed in China, and" exact="India" post="shut down exports of medications, we have been under"/>
   <result pre="reminds us of the importance of having backup manufacturing within" exact="the United States," post="supported by taxpayer funds if needed. Finally, any state"/>
   <result pre="us of the importance of having backup manufacturing within the" exact="United States," post="supported by taxpayer funds if needed. Finally, any state"/>
   <result pre="that can increase the prices of COVID-19 related drugs in" exact="the United States" post="are pharmacy benefit managers (PBMs), who normally act as"/>
   <result pre="can increase the prices of COVID-19 related drugs in the" exact="United States" post="are pharmacy benefit managers (PBMs), who normally act as"/>
   <result pre="7ByrnesH.HarringtonJ.Prescription Unfilled? These 30 Drugs Are in Short Supply in" exact="the US" post="Right Now. 2020https://www.usatoday.com/story/money/2020/03/10/fda-shortage-30-drugs-currently-in-short-supply-in-the-us/111402408/ 8collab: US Food and Drug AdministrationGeneric"/>
   <result pre="Disrupt the U.S. Drug Supply. 2020https://www.cfr.org/in-brief/coronavirus-disrupt-us-drug-supply-shortages-fda 11PalmerE.Chinese APIs Flowing But" exact="India" post="Ban Hinders U.S. Approval of Hydroxychloroquine. 2020https://www.fiercepharma.com/manufacturing/chinese-apis-flowing-but-indian-ban-hinders-u-s-approval-hydroxychloroquine 12PalmerE.How Much"/>
   <result pre="Approval of Hydroxychloroquine. 2020https://www.fiercepharma.com/manufacturing/chinese-apis-flowing-but-indian-ban-hinders-u-s-approval-hydroxychloroquine 12PalmerE.How Much Does U.S. Rely on" exact="China" post="for Drugs? FDA Simply Doesn't Know. 2020https://www.fiercepharma.com/manufacturing/how-much-does-u-s-rely-china-for-drugs-fda-simply-doesn-t-know 13RajkumarS.V.The high"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7131061/results/search/country/results.xml">
   <result pre="use in treating the disease, according to a report in" exact="China" post="Daily. Marie-Paule Kieny of the WHO told a press"/>
   <result pre="conference in Geneva, Switzerland, on 12 February that doctors in" exact="China" post="have given a combination of two HIV drugs –"/>
   <result pre="few days or a few weeks&quot;, she said. Doctors in" exact="China" post="will also start testing remdesivir, a drug first developed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7131140/results/search/country/results.xml">
   <result pre="problem will be mass-producing them fast enough. A team in" exact="China" post="that tested antibodies against the coronavirus that caused the"/>
   <result pre="has already passed safety tests in people. A team in" exact="China" post="has identified four existing, approved drugs that might also"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7132016/results/search/country/results.xml">
   <result pre="supported by grants from the National Natural Science Foundation of" exact="China" post="(81500665), High Level Creative Talents from Department of Public"/>
   <result pre="growing in many parts of the world. The world and" exact="China" post="map showing the geographical distribution of coronavirus disease 2019"/>
   <result pre="Drugs Antibiotic drugs Antiviral drugs Antifungal drugs Zhang YH, 20206" exact="China" post="(Haikou) 3 months Female Normal Normal Non-severe No Azithromycin,"/>
   <result pre="Normal Non-severe No Azithromycin, Ceftazidime Paramivir NA Chen F, 20207" exact="China" post="(Wuhan) 1 Male Normal Normal Severe NA Meropenem, Linezolid,"/>
   <result pre="Severe NA Meropenem, Linezolid, Oseltamivir NA NA Cai JH, 20208" exact="China" post="(Shanghai) 7 Male 33 17 Non-severe No Levofloxacin NA"/>
   <result pre="33 17 Non-severe No Levofloxacin NA NA Holshue ML, 20209" exact="United States" post="35 Male 72 (16.4)* 124 (30.3)* Non-severe No NA"/>
   <result pre="124 (30.3)* Non-severe No NA NA NA Silverstein WK, 202010" exact="Canada" post="56 Male NA 29 Non-severe NA NA NA NA"/>
   <result pre="(%) Antiviral drugs (%) Antifungal drugs (%) Guan WJ 202011" exact="China" post="(Multi-center) 1099 168 (22.2) NA 158 (21.3) NA 640"/>
   <result pre="(2.1) 632 (57.5) 393 (35.8) 30 (2.7) Xu XW, 202012" exact="China" post="(Zhejiang) 62 10 (16.1) 26 (20–32) NA 22 (14–34)"/>
   <result pre="7 (11.3) 28 (45.2) 55 (88.7) NA Chen NS, 20205" exact="China" post="(Wuhan) 99 35 (35.3) 34 (26–48) 28 (28.2) 39"/>
   <result pre="(11.1) 70 (70.7) 75 (75.8) 15 (15.2) Chen L, 202013" exact="China" post="(Wuhan) 29 7 (24.1) NA 5 (17.2) NA 21"/>
   <result pre="(48.3) 15 (51.7) NA NA NA NA Wang DW, 202014" exact="China" post="(Wuhan) 138 NA 31 (24–51) NA 24 (16–40) 75"/>
   <result pre="4 (2.9) 89 (64.5) 124 (89.9) NA Pan F, 202015" exact="China" post="(Wuhan) 21 NA 32 ± 20 (15–95) NA 42"/>
   <result pre="(0.0) 21 (100.0) NA NA NA NA Liu C, 202016" exact="China" post="(Multi-center) 32 2 (6.2) 25 (19–32) 9 (28.1) 26"/>
   <result pre="28 (87.5) 1 (3.13) NA NA NA Huang C 202017" exact="China" post="(Wuhan) 41 15 (36.6) 34 (26–48) NA 32 (21–50)"/>
   <result pre="1 (2.4) 41 (100.0%) 38 (92.7%) NA Chen HJ 202018" exact="China" post="(Wuhan) 9 3 (33.3) 24 (21–119) 3 (33.3) 16"/>
   <result pre="200 mg/kg in children is likely to cause hepatotoxicity.24 Although" exact="the US" post="Food and Drug Administration Advisory Committee has proposed a"/>
   <result pre="Committee Meeting - what is the future of acetaminophen in" exact="the United States?" post="The perspective of a committee memberClin Toxicol (Phila)20094778478910.1080/1556365090323234519735211 26PrompetcharaEKetloyCPalagaTImmune"/>
   <result pre="Meeting - what is the future of acetaminophen in the" exact="United States?" post="The perspective of a committee memberClin Toxicol (Phila)20094778478910.1080/1556365090323234519735211 26PrompetcharaEKetloyCPalagaTImmune"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7132364/results/search/country/results.xml">
   <result pre="•The outcomes of some current clinical trials of chloroquine in" exact="China" post="have been announced, without access to the data. •Peer"/>
   <result pre="effect on dengue-infecteds patient in a randomized controlled trial in" exact="Vietnam" post="(Tricou et al., 2010). Chloroquine was also active ex"/>
   <result pre="clinical trial conducted during the chikungunya outbreak in 2006 in" exact="Réunion" post="Island showed that oral chloroquine treatment did not improve"/>
   <result pre="trial conducted during the chikungunya outbreak in 2006 in Réunion" exact="Island" post="showed that oral chloroquine treatment did not improve the"/>
   <result pre="scientists to report the interim trial results currently running in" exact="China" post="as soon as they are available. This should be"/>
   <result pre="to protect against infection and disease in the in vivo" exact="Guinea" post="pig modelJ. Gen. Virol.9620153484349226459826 FalzaranoD.SafronetzD.PrescottJ.MarziA.FeldmannF.FeldmannH.Lack of protection against ebola"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7134866/results/search/country/results.xml">
   <result pre="clear nor explained [11]. The novel coronavirus currently isolated in" exact="China" post="has been, with staggering speed, evaluated regarding its sensitivity"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7135139/results/search/country/results.xml">
   <result pre="azithromycin for Zika virus [2]. A response has come from" exact="China" post="to the respiratory disease caused by the new coronavirus"/>
   <result pre="absence of severe side effects [4,5]. This has led in" exact="China" post="to include chloroquine in the recommendations regarding the prevention"/>
   <result pre="use in viral infections lacking drugs. Following the discovery in" exact="China" post="of the in vitro activity of chloroquine against SARS-CoV-2,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7135364/results/search/country/results.xml">
   <result pre="Present address: Departments of Laboratory Medicine and Internal Medicine, National" exact="Taiwan" post="University Hospital, Number 7, Chung-Shan South Road, Taipei 100,"/>
   <result pre="reported in Wuhan, followed by other cities and provinces in" exact="China" post="and many other countries [1], [2], [3], [4], [5],"/>
   <result pre="more than 78 832 of these cases were reported from" exact="China" post="(https://www.worldometers.info/coronavirus/). In the view of virologists, human and zoonotic"/>
   <result pre="of parenteral remdesivir therapy in the treatment of COVID-19 in" exact="China" post="may open the window for effective antiviral therapy for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7136311/results/search/country/results.xml">
   <result pre="Research Group Project of the National Natural Science Foundation of" exact="China" post="81670537LiuJinfeng Funding http://dx.doi.org/10.13039/501100013317Shanxi Provincial Key Research and Development Project"/>
   <result pre="published. Most of the studies (74%, 26/35) were conducted in" exact="China" post="among pregnant female that started AVT across different trimesters"/>
   <result pre="work was supported by the National Natural Science Foundation of" exact="China" post="(Grant Nos. 81770594 and 81670537) Shaanxi Key Research and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7136878/results/search/country/results.xml">
   <result pre="of December 2019. The epidemic has affected various regions of" exact="China" post="in different degrees. As the situations evolve, the COVID-19"/>
   <result pre="COVID-19 diagnosis and treatment unit in Jilin Province in Northeast" exact="China" post="have established the management practices of drug supply and"/>
   <result pre="of coronavirus disease 2019 (COVID-19) began in Wuhan, Hubei Province," exact="China" post="in December 2019.1According to the Prevention and Control of"/>
   <result pre="The Third Hospital of Jilin University (THJU) is managed by" exact="China" post="National Health Commission (CNHC) which is a large-scale Grade"/>
   <result pre="but comprehensive reviewJ Infect202010.1016/j.jinf.2020.02.010 2National Health Commission of the People’s" exact="Republic of" post="ChinaAnnouncement No.1, 2020 of the National Health and Health"/>
   <result pre="of the National Health and Health Commission of the People's" exact="Republic of" post="China2020Accessed date: 1 April 2020http://www.nhc.gov.cn/xcs/zhengcwj/202001/44a3b8245e8049d2837a4f27529cd386.shtml 3Health commission of Jilin"/>
   <result pre="mapping and analysisSaf Sci702014918 7National Health Commission of the People’s" exact="Republic of" post="ChinaNotice on Strengthening the Prevention and Control of COVID-19"/>
   <result pre="date: 1 April 2020 9National Health Commission of the People’s" exact="Republic of" post="ChinaNotice on novel coronavirus infection prevention and control technical"/>
   <result pre="date: 1 April 2020 10National Health Commission of the People’s" exact="Republic of" post="ChinaDiagnosis and Treatment of COVID-19(version 3)2020Accessed date: 1 April"/>
   <result pre="date: 1 April 2020http://www.nhc.gov.cn/xcs/zhengcwj/202001/470b128513fe46f086d79667db9f76a5.shtml 11National Health Commission of the People’s" exact="Republic of" post="ChinaDiagnosis and treatment of COVID-19(version 5)20202020http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtmlAccessed date: 1 April"/>
   <result pre="Committee of the Ninth National People's CongressLaw of the people's" exact="Republic of" post="China on donation of public welfare undertakings (Order No."/>
   <result pre="the Ninth National People's CongressLaw of the people's Republic of" exact="China" post="on donation of public welfare undertakings (Order No. 19"/>
   <result pre="undertakings (Order No. 19 of the president of the people's" exact="Republic of" post="China)20082008http://www.npc.gov.cn/wxzl/wxzl/2008-12/15/content_1462090.htmAccessed date: 1 April 2020 13ZhengF.Y.WuY.YaoY.F.The adverse drug reaction"/>
   <result pre="Pneumonia(NCP)Chin J Hosp Pharm402020243249 16National Health Commission of the People’s" exact="Republic of" post="ChinaDiagnosis and treatment of COVID-19(version 7)2020Accessed date: 1 April"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7136885/results/search/country/results.xml">
   <result pre="muscle pain [54]. VEEV is confined to Central and South" exact="America" post="and can infect humans causing flu-like symptoms in healthy"/>
   <result pre="death in the immunosuppressed. This virus has been weaponised by" exact="the USA" post="and the Soviet Union [55]. SINV has a wide"/>
   <result pre="immunosuppressed. This virus has been weaponised by the USA and" exact="the Soviet Union" post="[55]. SINV has a wide geographic distribution and can"/>
   <result pre="This virus has been weaponised by the USA and the" exact="Soviet Union" post="[55]. SINV has a wide geographic distribution and can"/>
   <result pre="basic research and inhibitor discovery. The 2013–2016 EBOV outbreak in" exact="Sierra Leone," post="Liberia and Guinea, and the ongoing epidemic in the"/>
   <result pre="and inhibitor discovery. The 2013–2016 EBOV outbreak in Sierra Leone," exact="Liberia" post="and Guinea, and the ongoing epidemic in the Democratic"/>
   <result pre="Leone, Liberia and Guinea, and the ongoing epidemic in the" exact="Democratic Republic of Congo," post="led to a sharp increase in funding and efforts"/>
   <result pre="Liberia and Guinea, and the ongoing epidemic in the Democratic" exact="Republic of" post="Congo, led to a sharp increase in funding and"/>
   <result pre="alphavirus replicons by designing self-replicating subgenomic RNAsProc. Natl. Acad. Sci." exact="U. S." post="A.1112014107081071325002490 69ÖhlundP.DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7138017/results/search/country/results.xml">
   <result pre="affected city, Wuhan, and related regions in Hubei province of" exact="China" post="have reported 13 522 confirmed patients (66·16% of total cases)"/>
   <result pre="in 23 other countries beyond China, including Japan, Thailand, Singapore," exact="South Korea," post="Australia, the USA, Malaysia, and Germany. Because of the"/>
   <result pre="countries beyond China, including Japan, Thailand, Singapore, South Korea, Australia," exact="the USA," post="Malaysia, and Germany. Because of the seriousness of this"/>
   <result pre="emergency of international concern on Jan 30, 2020, followed by" exact="the USA" post="announcing a public health emergency on Jan 31, 2020."/>
   <result pre="protective equipment, and charitable funds from inside and outside of" exact="China" post="are transported to the epidemic area to support the"/>
   <result pre="protect the healthy population against viral infection not only in" exact="China" post="but also in the rest of the world. China"/>
   <result pre="in China but also in the rest of the world." exact="China" post="also faces other challenges, including asymptomatic carriers with 2019-nCoV"/>
   <result pre="areas of Hubei province. First-line medical staff and scientists in" exact="China" post="have had a leading role in fighting the outbreak"/>
   <result pre="modeling of its spike protein for risk of human transmissionSci" exact="China" post="Life Sci2020published online Jan 21.10.1007/s11427-020-1637-5 6LetkoMCMunsterVFunctional assessment of cell"/>
   <result pre="2020http://www.xinhuanet.com/english/2020-02/03/c_138752003.htm 19collab: Ministry of Science and Technology of the People's" exact="Republic of" post="ChinaEmergency scientific programs on prevention and control of the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7138187/results/search/country/results.xml">
   <result pre="diagnosis and treatment of 2019-nCoV pneumonia has been released in" exact="China" post="[1]. For the treatment of COVID-19, the guideline recommended"/>
   <result pre="know, since December 2019, the majority of COVID-19 patients in" exact="China" post="have been treated with integrated Chinese and Western medicine."/>
   <result pre="the occurrence of severe pneumonia [2].Recently, 4 provincial hospitals in" exact="China" post="used Qingfei Paidu decoction to treat 214 patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7138382/results/search/country/results.xml">
   <result pre="a human coronavirus causing the COVID-19 disease. It emerged in" exact="China" post="in December 2019 and rapidly propagated in numerous countries,"/>
   <result pre="and lopinavir/ritonavir is currently investigated in a clinical trial in" exact="Saudi Arabia" post="(Arabi et al., 2018). This is to our knowledge"/>
   <result pre="of COVID-19. The administration by vapor inhalation currently performed in" exact="China" post="offers the advantage of targeting specifically the respiratory tract;"/>
   <result pre="trials. Publications of data about IFN-based COVID-19 treatment performed in" exact="China" post="in early 2020, expected in a near future, should"/>
   <result pre="Principal Investigator: Florence Ader. Scientific coordinator: Yazdan Yazdanpanah. Chief methodologist:" exact="France" post="Mentre. Infectious diseases specialists: François-Xavier Lescure, Nathan Peiffer-Smadja. Intensivists:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7139247/results/search/country/results.xml">
   <result pre="In 2002, an outbreak of SARS was first reported in" exact="China" post="and then spread quickly worldwide, resulting in hundreds of"/>
   <result pre="11% mortality rate [3,4]. In 2012, MERS first emerged in" exact="Saudi Arabia" post="and subsequently spread to other countries, with a fatality"/>
   <result pre="human-to-human transmission. At present, the National Health Commission of the" exact="People's Republic of China" post="has recorded a total of 80 304 confirmed cases"/>
   <result pre="transmission. At present, the National Health Commission of the People's" exact="Republic of" post="China has recorded a total of 80 304 confirmed"/>
   <result pre="present, the National Health Commission of the People's Republic of" exact="China" post="has recorded a total of 80 304 confirmed cases"/>
   <result pre="observation. A total of 137 confirmed cases were reported from" exact="Macao" post="Special Administrative Region (SAR) (n = 10), Hong Kong"/>
   <result pre="reported from Macao Special Administrative Region (SAR) (n = 10)," exact="Hong Kong" post="SAR (n = 93) and Taiwan (Republic of China)"/>
   <result pre="(n = 10), Hong Kong SAR (n = 93) and" exact="Taiwan" post="(Republic of China) (n = 34). In addition to"/>
   <result pre="concomitant use of steroids during the outbreak of SARS in" exact="Hong Kong" post="[74], [75], [76]. Thus, ribavirin could be considered as"/>
   <result pre="antiviral drug against influenza infection that is widely used in" exact="Russia" post="and China. Arbidol and arbidol mesylate were shown to"/>
   <result pre="[79]. In addition, the first case of SARS-CoV-2 infection in" exact="the USA" post="was treated with intravenous remdesivir when the patient's condition"/>
   <result pre="been reported that a small number of SARS-CoV-infected patients in" exact="Taiwan" post="and Hong Kong received treatment with convalescent plasma during"/>
   <result pre="that a small number of SARS-CoV-infected patients in Taiwan and" exact="Hong Kong" post="received treatment with convalescent plasma during the early course"/>
   <result pre="of primary, household, and nosocomial transmissionLancet Infect Dis182018e217e22710.1016/S1473-3099(18)30127-029680581 7SuSWongGLiuYGaoGFLiSBiYMERS in" exact="South Korea" post="and China: a potential outbreak threat?Lancet38520152349235010.1016/S0140-6736(15)60859-526088634 8ReuskenCBHaagmansBLMüllerMAGutierrezCGodekeGJMeyerBMiddle East respiratory"/>
   <result pre="modeling of its spike protein for risk of human transmissionSci" exact="China" post="Life Sci63202045746010.1007/s11427-020-1637-532009228 12WongJELLeoYSTanCCCOVID-19 in Singapore—current experience: critical global issues"/>
   <result pre="fatal case of Middle East respiratory syndrome coronavirus infection in" exact="the United Arab Emirates," post="April 2014Am J Pathol186201665265810.1016/j.ajpath.2015.10.02426857507 58ChungMBernheimAMeiXZhangNHuangMZengXCT imaging features of 2019"/>
   <result pre="case of Middle East respiratory syndrome coronavirus infection in the" exact="United Arab Emirates," post="April 2014Am J Pathol186201665265810.1016/j.ajpath.2015.10.02426857507 58ChungMBernheimAMeiXZhangNHuangMZengXCT imaging features of 2019"/>
   <result pre="for severe acute respiratory syndrome among healthcare workers in a" exact="Taiwan" post="hospitalJ Antimicrob Chemother56200591992210.1093/jac/dki34616183666 103ter MeulenJBakkerABvan den BrinkENWeverlingGJMartinaBEHaagmansBLHuman monoclonal antibody"/>
   <result pre="This work was supported by the Natural Science Foundation of" exact="China" post="[nos. 81570408 and 81770461]. Competing interests: None declared. Ethical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugDebug/PMC7139252/results/search/country/results.xml">
   <result pre="reported as clinical manifestations of COVID-19 [18,19]. A study from" exact="China" post="also reported that the majority of patients (80.9%) were"/>
   <result pre="infection. The monitor of a cluster of COVID-19 cases in" exact="China" post="suggested the possibility of indirect viral transmission without a"/>
   <result pre="metabolic status determines the clinical course of COVID-19 Reports from" exact="China" post="and Italy suggested a high mortality rate of COVID-19"/>
   <result pre="determines the clinical course of COVID-19 Reports from China and" exact="Italy" post="suggested a high mortality rate of COVID-19 in older"/>
   <result pre="than an older woman [35,36]. The COVID-19 cases in both" exact="China" post="and Italy reported higher fatality in males than women"/>
   <result pre="older woman [35,36]. The COVID-19 cases in both China and" exact="Italy" post="reported higher fatality in males than women [19,27]. There"/>
   <result pre="coronavirus replication. There were case reports from China, Japan, and" exact="Thailand" post="for the effectiveness of the lopinavir-Ritonavir combination in COVID-19"/>
   <result pre="and Treatment Coronavirus (COVID-19), Updated 2020 Mar 8 ed2020StatPearls PublishingTreasure" exact="Island" post="(FL)https://www.ncbi.nlm.nih.gov/books/NBK554776/ 18AdhikariS.P.MengS.WuY.-J.MaoY.-P.YeR.-X.WangQ.-Z.SunC.SylviaS.RozelleS.RaatH.Epidemiology, causes, clinical manifestation and diagnosis, prevention and"/>
   <result pre="Rev. Allergy Immunol.56201930832128963611 37YangY.LiW.ZhangQ.ZhangL.CheungT.XiangY.-T.Mental health services for older adults in" exact="China" post="during the COVID-19 outbreakLancet Psychiatry72020e1910.1016/S2215-0366(20)30079-132085843 38HoffmanR.Micronutrient deficiencies in the"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
